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Major depressive disorder (MDD) is a mental condition characterized by a depressed mood and 
a loss of interest in otherwise enjoyable daily activities for more than two weeks. For the diag-
nosis of MDD according to the Diagnostic and Statistical Manual of Mental Disorders number 
5 (DSM-5), fi ve of the following symptoms need to be present: a depressed mood, anhedonia, 
insomnia or hypersomnia, psychomotor retardation or agitation, loss of energy or fatigue, 
worthlessness or guilt, change in weight or appetite, impaired concentration or indecisiveness, 
and thoughts of death or suicidal ideation or an attempt [1]. Globally, MDD is the leading cause 
of disability with a worldwide prevalence of 4.4 %, aff ecting 322 million people in 2015 (Fig. 
1). Almost half of the aff ected people live in South-East Asia or the Western Pacifi c region. A 
majority of MDD is seen in older adulthood, and females (5.1%) are aff ected more than males 
(3.6%) (Fig. 2). Its prevalence increased by 18.4% between the years of 2005 and 2015, indicating 
the relative growth of the age groups in which MDD mostly occurs [2, 3]. Because of its high and 
increasing prevalence, an appropriate treatment for MDD is important.
Th e treatment
MDD can be treated using antidepressant medication and psychological therapies [4]. However, 
approximately one-third of treated patients do not respond adequately to these treatments [5]. 
Th ese patients suff er from treatment-resistant depression (TRD), which is associated with more 
mental-health disorders, hospitalizations, past suicide attempts and consequently higher treat-
ment costs compared to non-TRD [6, 7]
figure 1.  Regional distribution of depressive disorder cases. Adopted from WHO, Depression and Other Com-
mon Disorders 2017 [2].
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For TRD, diff erent therapies modalities can be given, such as, electroconvulsive therapy 
(ECT), vagal nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and deep brain 
stimulation (DBS).
When immediate medical care for TRD is needed due to worsening of depressive symptoms, 
ECT can be given. In ECT, a small electrical current is passed through the brain under general 
anesthesia causing a series of seizures. Generally 70% of patients obtain a signifi cant release of 
symptoms aft er multiple sessions, however, the relapse rate aft er 6 to 12 months is around 50% 
[8, 9].Th erefore, ECT is not considered a cure, but rather a tool to overcome an acute phase of 
depression with severe symptoms. Its side-eff ects can include both short- and long-term memory 
loss.
VNS is the fi rst invasive neurostimulation technique used for the long-term treatment of TRD 
and was approved by the FDA in 2005. Research has shown that aft er two years of VNS stimu-
lation, 53.1% of TRD patients fulfi lled the response criteria of a 50% reduction in depression 
scores [10]. Furthermore, it has been shown that adjunctive VNS to antidepressant treatment 
can signifi cantly improve the quality of life in TRD [11]. Side-eff ects can include voice alteration, 
cough and pain [10].
A less invasive form of TRD therapy is repetitive transcranial magnetic stimulation (rTMS). 
In TMS, a magnetic fi eld is used to modulate mostly superfi cial neuronal cells in the brain [12]. 
Meta-analysis for rTMS randomized controlled trials (RCTs) showed a pooled remission and 
response rate of 16.0% and 25.1% for unilateral rTMS and 5.7% and 11.0% for sham treatment, 
respectively. Th e remission rate is ranged from depression scores of 7 or less to 10 or less, while 
the response rate is defi ned as a 50% or more reduction in depression scores. Th e pooled remis-
figure 2. Global prevalence of depressive disorder, by age and gender. Adopted from WHO, Depression and 




sion and response rates for bilateral rTMS were 16.6% and 25.4% for rTMS and 2.0% and 6.8% 
for sham treatment, respectively [13].
Both ECT and TMS generate wide disperse modulation signals, making the technique not 
circuit or cell group specific and mostly suitable for more superficial brain regions, although 
certain deep TMS coils for stimulation of deeper brain regions in TRD exist with a response- and 
remission rate of 38.4% and 32.6% for deep TMS and 21.4% and 14.6% for the sham group, 
respectively [14].
DBS is another stimulation method, evolved in parallel, not having the major limitation of 
such a wide disperse signal as evoked with ECT and TMS, with the additional possibility to reach 
deeper brain regions.
deep brain stimulation
DBS is an invasive treatment modality that is widely investigated for TRD. In DBS, an electric 
current is given through implanted electrodes in the brain using stereotaxis [15]. DBS has shown 
to be of great therapeutic value in Parkinson’s disease, refractory epilepsy, Tourette’s syndrome 
and obsessive compulsion disorder (OCD) [16-19]. Motivated by this success and since DBS 
in OCD patients consistently showed improvement in mood, DBS has been applied for TRD 
[19, 20]. Different brain regions for DBS for TRD have been targeted based on the imbalance of 
the limbic cortico-striatal-thalamic-cortico (CSTC) mood circuit and the involved brain regions 
[21, 22]. So far the subgenual cingulate cortex (SCC/SCG) which is showed to be hyperactive 
in untreated MDD patients [23], the nucleus accumbens (NAcc) which is involved in differ-
ent cognitive functions such motivation and reward [24], the ventral capsule/ventral striatum 
(VC/VS) which is also showed to be hyperactive in untreated MDD and OCD patients [25], 
the ventral part of the anterior limb of the internal capsule (vALIC) initially studied in OCD 
patients showed additional anti-depressant effects [26], the lateral habenula (LHb) which is 
negatively associated with reward and presumably hyperactive in untreated MDD patients, the 
inferior thalamic peduncle (ITP) which is thought to play a role in non-reward tractor theory 
of depression where the non-reward system is more easily triggered in depression leading to 
negative emotional states [27], the bed nucleus of the stria terminalis (BNST) responsible for 
integrating a proper response to environmental and social setting changes [28] and the medial 
forebrain bundle (MFB) important in reward-seeking behavior [29], have been stimulated with 
DBS in TRD[30-37](Fig. 3).
Although case reports and open-label trials have shown promising results for DBS in TRD, sev-
eral RCTs showed inconsistent results [38-42]. In summary, Dougherty et al. 2015 demonstrated 
that DBS in the VC/VS of thirty TRD patients did not significantly improve the response rate in 
depression rating scales compared to the control group after a 16-weeks trial period [38]. How-
ever, Bergfeld et al 2016 has shown that when stimulating the ventral anterior limb of the ventral 
capsule (vALIC), 10 out of 25 patients showed a significant decrease in depressive symptoms 
after a 12-week, double blind, cross-over study [39]. A third RCT named the BROADEN-trial has 
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been aborted preliminary due to a poor futility analysis. No signifi cant decrease in depression 
rating scales aft er a 6 months trial period was found [40]. A fourth DBS study, investigating VC/
VS stimulation in eight TRD patients was also discontinued due to a futility analysis showing no 
signifi cant diff erence between active versus sham stimulation aft er a 16 weeks trial period [41].
Altogether, these results imply that DBS of the VC/VS, SCC, or vALIC does not cure TRD in 
all patients, but showed to signifi cantly improve depression rating scales in certain subgroups of 
patients. Since the primary outcome of RCTs is an average decrease in depression rating scales 
for all patients, individual eff ects might be overshadowed which implicates that we are in need 
for a more personalized DBS approach.
depression; subdividing its heterogeneity into subgroups
Th e inconsistent results of open-label trials and RCTs raised discussions concerning the cor-
rect interpretation of trial results, patient selection criteria, optimal stimulation parameters, the 
indication of diff erent stimulation targets and the underlying pathological circuits modulated 
by DBS.
Recent research has revealed 4 connectivity-based biotypes of depression when analyzing 
resting-state connectivity. Th eir results show that the four biotypes are defi ned by either increased 
anxiety (biotype 1 and 4), increased anhedonia and psychomotor retardation (biotypes 3 and 4) 
figure 3. Deep brain stimulation targets for treatment resistant depression. Th e diff erent brain regions
research for DBS in TRD. SCG; subgenual cingulate cortex, NAcc; nucleus accumbens, VC/VS; ventral
capsule/ventral striatum, vALIC; ventral part of the anterior limb of the internal capsule, LHb; lateral





or increased anergia and fatigue (biotypes 1 and 2) (Fig. 4)[42]. Such complexity of TRD should 
be taken into account when evaluating the results of DBS treatment approaches and for future 
treatment of TRD. Study outcomes should be interpreted using subgroups of depression which 
creates the possibility to make future treatments more individualized proven to be benefi cial in 
other psychiatric diseases such as OCD [43].
Furthermore, we need to better understand the various underlying pathological circuits in 
TRD creating multiple subtypes of TRD and integrate them with our present diagnostic catego-
ries to reach a better nosology and treatment.
animal models of depression
To study depression, diff erent clinical and pre-clinical approaches are available. To investigate and 
modulate the neuronal microcircuits that underlie depression, animal models are valuable tools. 
To mimic depression, various animal models have been developed. Among those, the ‘Chronic 
Unpredictable Stress’ (CUS) model is a well-validated and widely used model for depression [44]. 
Th is CUS model is based on the loss of responsiveness to a reward when rodents are subjected to a 
schedule of minor stressors over a long period of time. It aims to model a chronic depressive-like 
state that develops gradually over time in response to stress and unfortunate events, mimicking 
the natural induction of depression, thereby improving its translational potential [45-46].
Since previous research done in our laboratory has shown anti-depressant eff ects when stimu-
lating the ventromedial prefrontal cortex (vmPFC), homologous to the SCG in humans, with 
DBS in rats exposed to CUS, I continued using this model [47].
figure 4. Functional connectivity biomarkers for diagnosing neurophysiological biotypes of depression. (c–f) 
Th e neuroanatomical locations of the nodes with the most discriminating connectivity features are illustrated 
for each biotype for the four-cluster solution, colored and scaled by summing the results of Wilcoxon rank–sum 
tests of patients as compared to controls across all connectivity features associated with that node. Red repre-




We need more information regarding the responsible circuits for depressive behavior in hu-
mans, therefore I will investigate if the depressive traits seen in depressive rats can be clustered 
as well, researching possible microcircuits for different depressive behavior. With this research, 
I hope to get a better understanding of the involved microcircuits in depression and possible 
confounding factors for results which are seen in human research thus far.
I hypothesize that different microcircuits are responsible for different modalities seen in the 
depressive-like behavior, and that stimulating these different microcircuits with DBS will alleviate 
different depressive-like behavior in modalities such as; anxiety, behavioral despair, motivation 
or (an)hedonia. This will help us further in identifying microcircuits responsible for different 
subtypes of depression and future DBS treatment for TRD.
exciting microcircuits
Standard electrical DBS works on a macro-scale and might not be precise enough to stimulate 
microcircuits, since the electrical currents spreads widely across multiple neurons. For this 
reason, we introduce a novel technique called ‘magnetothermal DBS’ (mDBS) in this thesis. This 
technique communicates with neurons in a more delicate way, on a nano-scale and wirelessly. 
MDBS works through magnetic nanoparticles (MNPs) which heat when exposed to an alternat-
ing magnetic field (AMF). This heat signal can activate heat-sensitive cation channels in close 
proximity which consecutively induce neural excitation. The AMF leaves the rest of the body 
unaffected which limits the occurrence of unwanted side-effects. MDBS allows for a wireless, 
remote control of neural activity [48]. In this thesis we investigated if this novel technique works 
in naïve mice, to be further explored for microcircuit activation and as treatment for disorders 
in the future.
personalized approach in treating trd
By combining the knowledge of subtypes in depression and possible microcircuits responsible 
for different behavioral traits in TRD, I hope to motivate a more personalized approach in the 
treatment of TRD with DBS. To my knowledge, this will improve DBS trial results and more 




aiM of the thesis
improving dBs for trd by investigating depression subtypes
The overall aim of this thesis is to study if depression with its various depressive-traits can be 
subdivided into different subtypes with different pathologically disturbed microcircuits. To study 
this, I focus on the prefrontal cortex and investigate if DBS of subregions of the prefrontal cortex 
alleviate particular symptoms of depression in the CUS animal model of depression. I have 
stimulated the infralimbic- (IL), prelimbic- (PreL) and dorsal peduncular (DP) cortex.
stimulating microcircuits and refining the interface of neuronal modulation
The second aim of this thesis is to explore the feasibility of modulating microcircuits with a more 
advanced wireless technique of neuromodulation called mDBS.
The following five research question are formulated and addressed in this thesis.
research questions of the thesis
- How can we further improve deep brain stimulation outcomes for treatment-resistant 
depression?
- Can we disentangle depression into multiple microcircuits responsible for different modali-
ties seen is this disorder using an animal model of depression?
- Can the current method of deep brain stimulation be improved with the usage of nanopar-
ticles, so that deep brain stimulation could potentially stimulate microcircuits and work 
wirelessly?
- Does magnetothermal deep brain stimulation, which operates with nanoparticles, work in 
animal models?
- Is it possible to apply magnetothermal deep brain stimulation in humans?
Chapter 1
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outline of the thesis
MDD is the leading cause of disability worldwide with a prevalence of 4.4 %, affecting 322 
million people in 2015 [2]. Approximately 30% of MDD patients do not responds adequately 
to treatment, causing TRD. For TRD, different treatment modalities such as DBS in various 
brain regions has been researched. In chapter 2, I will elaborate on the different brain regions 
stimulated in TRD, the results of open-label and placebo-controlled trials. Furthermore, I will 
go into detail about possible subtypes of depression and a personalized treatment approach for 
DBS in TRD in the future. In chapter 3, I research the possibility of subgroups in depression and 
depressive-traits in an animal model of depression. I dissected the anti-depressant effects of DBS 
in the vmPFC cortex in ‘depressed’ rats by subdividing the vmPFC into the PreL-, IL- and DP 
cortex. I investigated if high frequency (HF) DBS in these different subregions alleviated different 
depressive-like behavior in modalities such as; (an)hedonia, anxiety, behavioral despair and lack 
in motivation. This will pave the way to a better understanding of previous DBS trial results 
and a better understanding of a future personalized treatment. When investigating the different 
subregions of the prefrontal cortex, the DP cortex seemed non suitable for electrical stimulation 
and caused overt seizures in the stimulated animals. This unexpected side-effect is extensively 
described in chapter 4. To more precisely stimulate micro-circuitries on a nano-scale, I provide 
an overview of the established forms of advanced neuromodulation, and integrate the possible 
usage of MNPs to further advance their applications in chapter 5. I extensively describe the 
mechanism of optogenetics, designer receptors exclusively activated by designer drugs (DRE-
ADD), focused ultrasound and magnetic neuronal modulation with emphasis on mDBS. In 
chapter 6, we introduce a proof of principle of the new advanced technique mDBS. This research 
was done in collaboration with the department of Material Science and Engineering (DMSE) of 
the Massachusetts Institute of Technology (MIT, USA). We investigated mDBS in naïve mice and 
were able to control their rotation movements. We hope that future research incorporates this 
technique in other disease models such as our depression model in rats, so that it may pave the 
way to a non-invasive but highly specific method of neuromodulation. In chapter 7, I report on 
endogenously expressed TRPV1 in the human brain since this protein is needed for mDBS to 
function. Using endogenously expressed TRPV1 might overcome the disadvantage of lentiviral 
delivery, which to date is needed in rodents experiments, making the technique more clinically 
applicable. Finally, I provide a general discussion and conclusion in chapter 8, in which I answer 
the research questions formulated in this introduction, address the limitations of my studies and 
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Major depressive disorder (MDD) affects approximately 4.4% of the world’s population. One 
third of MDD patients do not respond to routine psychotherapeutic and pharmacotherapeutic 
treatment and are said to suffer from treatment-resistant depression (TRD). Deep brain stimula-
tion (DBS) is increasingly being investigated as a treatment modality for TRD. Although early 
case studies showed promising results of DBS, open-label trials and placebo-controlled studies 
have reported inconsistent outcomes. This has raised discussion about the correct interpretation 
of trial results as well as the criteria for patient selection, the choice of stimulation target, and 
the optimal stimulation parameters. In this narrative review, we summarize recent studies of the 
effectiveness of DBS in TRD and address the relation between the targeted brain structures and 
clinical outcomes. Elaborating upon that, we hypothesize that the effectiveness of DBS in TRD 
can be increased by a more personalized and symptom-based approach. This may be achieved 
by using resting-state connectivity mapping for neurophysiological subtyping of TRD, by using 
individualized tractography to help decisions about stimulation target and electrode placement, 
and by using a more detailed registration of symptomatic improvements during DBS, for instance 
by using ‘experience sampling’ methods (ESM).
Keywords: major depressive disorder; treatment resistant depression; deep brain stimulation; 
neuropsychological subtypes; personalized treatment approach
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1. introduction
Major depressive disorder (MDD) is a common mood disorder that affects one’s feelings, 
thoughts, and behavior. According to the Diagnostic and Statistical Manual of Mental Disorders 
number 5 (DSM-5), for a diagnosis of MDD, five of the following symptoms need to be present 
for at least two weeks: depressed mood, reduced interest or pleasure, weight loss or reduced 
appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of 
energy, worthlessness or excessive guilt, impaired concentration or indecisiveness, and recurrent 
thoughts of death or suicidal ideation or attempts. Either ‘depressed mood’ or ‘loss of interest or 
pleasure’ is essential for a diagnosis [1]. The total number of people suffering from MDD world-
wide was estimated to be 322 million in 2015 and its prevalence increased by 18.4% between 2005 
and 2015 [2]. Therefore, effective treatment of MDD merits intense consideration.
Whereas psychotherapy and antidepressant medication are effective in the majority of pa-
tients, approximately one third of patients do not respond to these therapies. In the Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) trial, the cumulative remission rate of 
MDD patients after four successive treatments was 67% [3]. In line with this, a meta-analysis 
of 92 studies of the effectiveness of psychotherapy showed that 62% of patients no longer met 
the criteria of depression after treatment [4]. Failure to respond to a treatment algorithm of 
several steps is commonly referred to as treatment resistance, although there is still discussion 
about the exact definition of treatment refractoriness [5]. Treatment-resistant depression (TRD) 
is associated with more (comorbid) mental health disorders, a higher number of hospitalizations, 
and more suicide attempts, leading to higher treatment costs compared to non-TRD [6]. In ad-
dition, patients with TRD show a higher demand of healthcare resources and costs of health care 
compared to non-TRD patients [7]. Various alternative treatment options for TRD are currently 
being investigated, including vagal nerve stimulation (VNS) [8], repetitive transcranial magnetic 
stimulation (rTMS) [9], and deep brain stimulation (DBS) [10].
The aim of this narrative review is to provide an overview of recent studies of the effectiveness 
of DBS in TRD with a special focus on the relationship between the targeted brain structures and 
clinical outcomes. Based on these findings, we discuss the importance of distinguishing between 
different clinical phenotypes of depression that would allow for more personalized symptom-
based treatment approaches, which may be a key factor in improving treatment outcomes.
2. recent insights on the pathophysiology of 
depression
It is hypothesized that in depression, there is an imbalance in the limbic cortico-striatal-thalamic-
cortico (CSTC) mood circuits [11,12], yet many aspects of circuitopathy in MDD remain largely 
unknown. Based on different models [11,12], three main components of the CSTC mood circuits 
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have been proposed (Fig. 1). First, the ventral component is essential for recognizing emotions 
and initiating an adequate emotional and behavioral response. In this circuit, the amygdala, 
ventral striatum, ventral part of the anterior cingulate cortex, orbitofrontal cortex, ventrolateral 
prefrontal cortex, and downstream structures such as the hypothalamus and locus coeruleus 
are involved. Second, the dorsal component that regulates the emotional responses and requires 
cognitive processing. Here, the dorsolateral and dorsomedial prefrontal cortex, the dorsal part 
of the anterior cingulate cortex, and the hippocampus are involved. Th ird, a modulating region 
is present, although no consensus has been made about its precise anatomical organization and 
function. Some have suggested that this component consists of the thalamus and the rostral part 
of the anterior cingulate cortex [11–13]. As implied by Mayberg et al., the model of depression 
indicates that depression is associated with a decreased activity in dorsal limbic and neocortical 
regions and a relative increase in ventral paralimbic regions. Treatment of depression therefore 
requires the inhibition of the overactive ventral regions, resulting in the disinhibition of the 
underactive dorsal regions. To mediate this process, proper functioning of the rostral cingulate 
cortex is required [12]. Th ese mood circuits overlap with the circuitry involved in compulsive 
traits; DBS of the ventral capsule/ventral striatum (VC/VS) in treatment resistant obsessive-
compulsive disorder (OCD) patients has led to improvements in mood which prompted studying 
the application of DBS in TRD patients [14,15].
figure 1. Schematic representation of emotional processing and its neurobiological base. Figure from Moonen 
et al. (2017) [82] with permission.
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expanding the cortico-striatal-Thalamic-cortico Mood circuits
One region that is not included in the CSTC mood circuits and yet has been a region of interest 
for DBS targeting in TRD for over a decade is the subgenual cingulate gyrus/cortex (SCG/SCC) 
[10]. This region has shown hyperactivity in untreated depressed patients [16], is part of the 
ventral component, and has projections to the amygdala, hippocampus, superior and medial 
temporal gyri, ventral striatum, mid- and posterior cingulate cortex, thalamus, hypothalamus, 
periaqueductal gray, and lateral habenula [17,18]. Furthermore, in recent years, it has become 
known that several other brain areas all belonging to the ventral component play a role in the 
pathophysiology of depression. Among these are the thalamic peduncles (THp) that intercon-
nects with the prefrontal cortex including the orbitofrontal cortex (OFC) [19], the medial 
forebrain bundle (MFB) that projects to the frontal cortex, the nucleus accumbens (NAcc) and 
ventral striatum [20], and the ventral part of the anterior limb of the internal capsule (vALIC) 
which forms a homeostatic system with the MFB and the bed nucleus of the stria terminalis 


























figure 2. Cortico-striatal-thalamic-cortico mood circuits divided in a dorsal, ventral, and modulating com-
partment based on Alexander et al. [11], Mayberg et al. [12], and Moonen et al. [82] expanded with regions 
researched with deep brain stimulation (DBS) for treatment-resistant depression (TRD). DLPFC; dorsolateral 
prefrontal cortex, DMPFC; dorsomedial prefrontal cortex, ACC; anterior cingulate cortex, THp; thalamic pe-
duncles, OFC; orbitofrontal cortex, VLPFC; ventrolateral prefrontal cortex, MFB; medial forebrain bundle, 
vALIC, ventral part of the anterior limb of the internal capsule, BNST; bed nucleus of the stria terminalis, SCG; 
subgenual cingulate gyrus, HPA axis; hypothalamic pituitary adrenal axis.
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3. deep Brain stiMulation for treatMent-resistant 
depression
DBS is an invasive neuromodulation technique that is effective in managing clinical symptoms of 
neurological and psychiatric disorders, such as Parkinson’s disease (PD) [22,23] and OCD [24]. 
At stimulation settings commonly used in clinical practice, DBS decreases the spontaneous firing 
of neuronal populations and activates axonal projections near the electrode [25]. This modulates 
pathological activity and replaces it with regular patterns of discharge with intervals of burst 
activity [26,27]. More recent theories suggest that DBS destabilizes abnormal synchronous 
oscillatory activity within the basal ganglia circuitry improving hyperkinetic symptomology 
[23]. However, the exact mechanism(s) by which DBS normalizes electrical activity in the basal 
ganglia and exerts beneficial effects on PD symptoms remain unknown. In DBS for TRD, target 
selection has mostly been based on either neuroimaging studies or clinical observations of mood 
improvement following DBS in OCD [10,15,28]. For these reasons, the underlying mechanisms 
of action are poorly studied. DBS studies for TRD (Table 1) and the outcomes for selected brain 
targets (Table 2) are described below.
3.1. subgenual cingulate gyrus/cortex
The first clinical trial of DBS of the SCG for TRD was performed in 2005 and included six patients 
with MDD [10]. The severity of depression was measured using the Hamilton Depression Rating 
Scale (HDRS) and the Montgomory Asberg Depression Rating Scale (MADRS). The HDRS has 
been the gold standard for the assessment of depression for years [29]. A clinical response is 
commonly defined as a decrease in the HDRS score of more than 50% compared to baseline, and 
clinical remission is defined as a decrease in the HDRS score to eight or less. After one month, 
two out of six patients met the criteria for response. At the end of the sixth month, a response 
was seen in four out of six patients, with three of the patients reaching remission or near remis-
sion. Preliminary observations with positron emission tomography (PET) showed a metabolic 
hyperactive SCG (Brodmann area 25, Cg25) during depressive states. It was speculated that 
DBS would reduce this hyperactivity [16] (Table 2). The improvement in depression scores after 
DBS was thought to be due to effectively disrupting focal pathological activity in limbic-cortical 
circuits. After 3 months of stimulation of the subgenual cingulate region (Cg25) in patients 
suffering from TRD, local cerebral blood flow (CBF) was decreased in Cg25 and the adjacent 
orbitofrontal cortex (Brodmann area 11). Moreover, after three and six months of stimulation, 
CBF was decreased in the hypothalamus, anterior insula, and medial frontal cortex of long-term 
responders, while CBF increased in the dorsolateral prefrontal cortex (dlPFC), dorsal anterior, 
posterior cingulate, and premotor and parietal regions (Table 2) [10]. In the different open-label 
trials, response rates varied from 20 to 57% after 1 month, 33.3 to 87.5% after 6 months, and 29 
to 62.5% after 12 months (Table 1) [10,30–41]. In a long term follow-up, Kennedy et al. (2011) 
reported response rates at 1, 2, and 3 years after DBS implantation in the SCC of TRD patients 
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of 62.5%, 46,2%, and 75%, respectively [30] (Table 1). In a case series of DBS of the SCG in five 
TRD patients, a decrease in the score of the depression rating scale was only found in one of 
the five TRD patients. This patient turned out to be stimulated in the posterior gyrus rectus 
(PGR) based on single subject tractography results rather than the initially targeted Cg25 [42]. 
A recent exploratory meta-analysis of four observational studies investigating DBS for TRD 
(Holtzheimer et al. 2012, Lozano et al. 2012, Puigdemont et al. 2012, and Kennedy et al. 2011) re-
ported relatively large response and remission rates following DBS treatment: the twelve-month 
response and remission rates were 39.9% (95% CI = 28.4% to 52.8%) and 26.3% (95% CI = 13% to 
45.9%). The included studies reported a significant decrease in depression scores between 3 and 6 
months (Hedges’ g = −0.27, p = 0.003), while no additional decrease was found between 6 and 12 
months, suggesting that maximal antidepressant effects occur mostly within the first 6 months of 
treatment [43]. However, adverse events can occur, including worsening of depression, suicidal 
ideation, and seizures (Table 1). A study consisting of a double-blind active vs. sham stimulation 
phase of four weeks, followed by an open-label stimulation for up to 24 months, reported no 
significant differences between the active and sham stimulation of the SCG and no reduction in 
HDRS scores in the first four weeks. In the open-label phase, response rates were 37.5%, 43% and 
23% after 6, 12 and 28 months, respectively. Remission rates were 12.5% and 14.2% at 6 and 12 
months, respectively, and 33.3% at 24 and 28 months [44].
A randomized controlled trial (RCT) investigating DBS of the subcallosal cingulate, known 
as the BROADEN trial, was aborted prematurely. The study lasted six months, during which 
all patients should have received SCC implantation surgery. After six months, blinding would 
have been uncovered and both groups would have been offered open-label DBS for another six 
months. At the end of the first six months, responses of the treatment group and control group 
were predicted to be 40% and 18.5%, respectively. In this trial, the response rate was defined 
as more than or equal to a 40% decrease in MADRS scores from baseline. However, after six 
months, only 20% of patients (n = 12) in the treatment group showed a response versus 17% of 
patients (n = 5) in the control group. At that time, a futility analysis predicted the probability of 
a successful study outcome to be 17% or less leading to the funding for DBS electrodes for this 
study to be discontinued. The actual study was never published, but results were published and 
mentioned in Morishita et al. (2014) [45,46]. It has been postulated that the patients enrolled 
in the BROADEN trial had extreme and chronic depression with a mean duration of the cur-
rent depressive episode of 12 years, nearly twice that of previous open-label studies. Therefore, 
these patients could have required a longer treatment period before significant results emerge. 
Long-term outcomes of SCG DBS in TRD patients for up to 8 years show that most patients have 
a sustained antidepressant response [40]. However, these results need to be interpreted care-
fully as the patient group consisted of both MDD and bipolar type-II disorder patients. Further 
comparison between high- and low frequency DBS in the SCG in TRD showed no significant 





Another brain region involved in MDD is the NAcc, part of the mesolimbic dopaminergic circuit 
involved in different cognitive functions such as motivation and reward [31] (Table 2). DBS of 
the NAcc exerts immediate and long-term positive clinical effects in TRD and has been shown 
to significantly improve depression scores within one week [31]. Visualized with PET–com-
puted tomography (PET-CT or PET/CT), NAcc-DBS increased metabolic activity in the ventral 
striatum, dlPFC, dorsomedial PFC (dmPFC), cingulate cortex, and the amygdala. Furthermore, 
metabolic activity in the vmPFC, ventrolateral prefrontal cortex (vlPFC), dorsal caudate nucleus, 
and part of the thalamus were decreased. Targeting the NAcc was essential for the effect of DBS 
on anhedonia (i.e., the inability to feel pleasure) in patients suffering from TRD. However, when 
Schlaepfer et al. (2008) looked at single items of depression rating scales, capturing aspects of 
anhedonia such as ‘work and activities’, ‘apparent sadness’, and the ‘inability to feel’, no significant 
improvements were found following NAcc-DBS. A follow-up study showed a 50% response rate 
in 10 patients suffering from TRD undergoing NAcc-DBS after 10 months [32]. In a more recent 
study reporting the long term effects of NAcc-DBS, 45% of TRD patients (n = 11) were classi-
fied as responders with a 50% reduction in HDRS scores after 12 months of stimulation, which 
remained until the last follow-up of 4 years [33] (Table 1). Several side effects were reported, such 
as seizure, agitation, and a transient increase in anxiety. In addition, one attempted suicide and 
one completed suicide were reported, for which the relation with the DBS treatment is uncertain.
3.3. Ventral capsule/Ventral striatum
The VC/VS is thought to be hyperactive in MDD [48] (Table 2). Capsulotomy (i.e., lesioning) of 
the VC/VS improved not only OCD symptoms but also depressive symptoms, inspiring stimula-
tion of the VC/VS for TRD [15]. In an open-label trial that stimulated the VC/VS in 15 TRD 
patients, responder rates at three months, six months, and 12 months were 53.3%, 46.7%, and 
53.3%, respectively, using the MADRS as an outcome measure, and were 46.7%, 40%, and 53.3%, 
respectively, using the HDRS as an outcome measure [34]. Adverse events ranged from pain or 
discomfort at the incision site, to hypomania, mixed bipolar state, and increased depression due 
to battery depletion.
The first RCT of DBS of the VC/VS for TRD was performed by Dougherty et al. (2015) who 
stimulated 30 patients for 16 weeks. There were no significant differences in response rates 
between the intervention and sham group in the double-blind phase [49,50]. Another RCT of 
VC/VS DBS in eight TRD patients was discontinued after an interim futility analysis of active vs. 
sham stimulation showed no difference in effects between the two groups after 16 weeks. These 
results were never published but were discussed by Rezai et al. [51].
3.4. The Ventral part of the anterior limb of the internal capsule
The anterior limb of the internal capsule (ALIC) is another brain region that was initially studied 
for DBS in OCD. One study aimed at stimulating the NAcc and discovered that most treated 
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OCD patients (9 out of 16) actually received DBS in the ventral part of the ALIC (vALIC), 
which improved obsessive compulsive scale scores, showed anti-depressive effects, and led to the 
clinical implementation of vALIC-DBS in TRD [28]. DBS of the vALIC has also been associated 
with a decreased metabolism in the OFC, subgenual anterior cingulate cortex, and right dlPFC 
[52–54] (Table 2).
The first RCT of DBS of the vALIC for TRD was conducted by Bergfeld et al. (2016), investigat-
ing 25 TRD patients during a 52 week open-label trial, which resulted in a significant decrease in 
HDRS scores in the whole group during the optimization phase, although overall HDRS scores 
were still in the depression range (22.2 at baseline vs. 15.9 after optimization phase). Ten of the 25 
patients could be classified as responders, with a more than 50% decrease on the HDRS. After the 
optimization phase, a RCT with a cross-over design including nine responders and seven non-
responders ensued and showed a significantly lower score in the active DBS phase compared with 
the sham DBS phase (mean HDRS score of 13.6 (95% CI; 9.8–17.4 vs. 23.1 (95% CI; 20.6–25.6)) 
(HDRS < 0.001). However, the scores on the HDRS in the active treatment group were still within 
the mild to moderate depression range [55]. Both crossover phases lasted approximately 21 and 
18 days, respectively.
3.5. lateral habenula
The activity of the LHb is negatively associated with reward, meaning its neurons increase their 
firing rate in a non-reward situation or in the omission of a reward. LHb hyperactivity could 
therefore explain the lower reward-seeking behavior in TRD [56] (Table 2). Speculation that 
DBS of the LHb could lead to the inhibition of hyperactivity prompted the first case study of 
LHb-DBS in TRD, which notably led to full remission of the patients’ depressive symptoms [57]. 
A clinical non-randomized study in six patients suffering from TRD is currently being held, 
investigating the safety, tolerability, and benefit of LHb DBS in TRD. Patients that respond at 12 
months of stimulation will enter a randomized, staggered withdrawal phase. During this phase, a 
double-blind discontinuation will be attempted at month 12 or 13, decreasing the stimulation by 
50% and then completely discontinuing it during the following two weeks. Evaluation will take 
place at 15 months, where, in the meantime, escape criteria are included, and if met, will stop the 
blinded phase and will be continued with an open treatment [58].
3.6. Thalamic peduncles
The inferior thalamic peduncle (ITP) is a bundle of fibers connecting the OFC to the thalamus. 
The OFC is thought to play a role in the non-reward attractor theory of depression, where the or-
bitofrontal non-reward system is more easily triggered in depression, causing negative emotional 
states [59] (Table 2). Stimulating the ITP could disrupt this enhanced triggering and lead to less 
depressive symptoms. ITP stimulation for OCD has already shown improvements of the score on 
the Yale-Brown Obsessive-Compulsive scale in five OCD patients [60]. A case study in one TRD 
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patient reported that DBS of the ITP decreased depressive symptoms [61]. However, within this 
study, two brain regions were investigated, the second being the BNST.
3.7. Bed nucleus of the stria terminalis
The BNST is involved in a range of behaviors, such as stress response, social behavior, and ex-
tended duration of fear states. This nucleus assesses sensory information from the environment, 
coupled together with the subjects current mood and arousal, integrating a proper response to 
environmental and social setting changes [21] (Table 2). Raymaekers et al. (2017) indicated that 
both BNST and ITP stimulation could alleviate depressive symptoms; however, due to a small 
sample size, no statistical analyses were conducted [61].
3.8. Medial forebrain Bundle
The MFB is a fiber tract connected to various parts of the limbic system thought to play a role in 
reward-seeking systems [20] (Table 2). In one trial, DBS of the superolateral branch of the MFB 
resulted in more than a 50% decrease in depressive symptoms in six out of seven TRD patients 
within seven days [62]. An additional interim analysis of MFB-DBS in TRD confirmed these 
findings, showing more than a 50% decrease in depressive symptoms in three out of four patients 
within seven days of stimulation. At 26 weeks follow-up, two patients showed more than an 80% 
decrease in depression rating scales [35] (Table 1).
Taken together, the results of the aforementioned studies of DBS for TRD imply that stimulation 
at a number of different brain areas can alleviate depressive symptoms, which is in line with the 
view that MDD is a circuitopathy involving various brain regions and networks mainly within 
the limbic CSTC mood circuits [12,63]. However, how DBS of those targets improves the depres-
sive symptoms is not completely clear. Moreover, stimulation parameters vary between studies 
due to a need to adjust and balance therapeutic effects to side effects.
MDD is a circuitopathy that involves a wide range of brain structures and exhibits diverse 
clinical manifestations. Therefore, a one-size-fits-all approach to the DBS targeting may not be 
beneficial in all patients, whereas a patient-centric selection based on individually disrupted 
neurocircuits could improve therapeutic outcomes. In evaluating the effects of DBS, one needs 
to focus on overall improvement on depression rating scales as well as individual scores and 
symptom-specific improvements. This will enhance the understanding of the effects of DBS and 
eventually contribute to the development of more personalized treatment approaches. Seemingly, 
this also applies in other psychiatric disorders such as OCD, where personalized approaches with 
content-specific DBS targets have already proven to be beneficial [64].
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table 2. Targets for DBS in treatment resistant depression (TRD), functions, pathophysiology and the effect of DBS.
Brain
region
function pathological activity in Mdd hf-dBs effect
scg
Contains three white matter bundles; 
forceps minor + uncinate fasciculus 
connecting to the medial frontal cortex, 
cingulum connecting to the rostral and 
dorsal ACC and fronto-striatal fibers 
connecting to the NAcc, CN, Pt and 
anterior Th
Connects higher ‘top-down’ cortical regions 
with subcortical modulatory regions
Involvement in brain DMN [83]
Increased activity [84]
Reduced volume in familial depression [85]
Projections to:
(1) NAcc may play a role in lack of 
interest, disruption in reward and underlie 
anhedonia
(2) Hth and brainstem may play a role in 
circadian and sleep disturbances, problems 
with appetite and an abnormal stress 
responds and cortisol metabolism [84].
Disruption of pathological 
activity
Modulation of multiple 
regions connected to the 
SCG [84]
nacc
Receives projections from VTA, AG, OFC, 
mPFC, dCN, GP and Hip and projects to 
Cg25, mPFC, VP, Th, AG and Hth.
Transmits information from emotion 
centers to motor control regions, causing 
motivational behavior to obtain rewards 
[31]
Processes reward and pleasure information
In severe anhedonia; smaller size and less 
activation to reward [86]
Acute: Increase in exploratory 
motivation
Chronic: reduction in 
anhedonia
PET Imaging:
↑ activity in VS, bilateral 
dlPFC and dmPFC, cingulate 
cortex and bilateral AG.
↓ activity in vmPFC and 
vlPFC, dCN and Th [31]
Vc/Vs
Contains fibers connecting the dPFC, 
dACC, OFC and vmPFC with THAL, AG, 
Hth and brainstem (SN, VTA, RN and 
PTN) [87]
Increased activity [48]
Activation of the connection from left vs. 
to left caudate has been associated with 
anhedonia
Increased connectivity of vs. to DMN is 
positively correlated to higher depression 
scores in the CES-D score [88]
-
valic
Contains two fiber bundles: the anterior 
thalamic radiation and the supero-lateral 
branch of the MFB connecting the PFC to 
different subcortical structures such as the 
Th, NAcc, VTA and VS.
Decreased integrity of the right vALIC in 
depressed patients [89]
-
Decreased metabolism in 
OFC, subgenual ACC and 
right DLPFC in patients with 
OCD [90]
lhb
Activity corresponds negatively to 
anticipation and reception of a reward [91]
Increased activity [92]
Possible down regulation of serotonergic, 
noradrenergic and dopaminergic systems 
[93], volume reduction [94]
Localized metabolic increase 
in one patient with FDG-
PET, presumably due to 
functional inhibition [57]
itp
Interconnects the intralaminar nucleus and 
TRN with the OFC [60,83]
Hyperactivation in both TRN and OFC 
[95]
Cortical desynchronization
Disruption of adrenergic and 
serotonergic malfunction [95]
MfB
Interconnects the Nacc, VTA, vmHth, lHth 
and AG ventromedial and lateral nuclei of 
the Hth and AG with convergence onto the 
PFC [62,96]
Plays a crucial role in the reward pathway;
Dysfunctional reward system.
Responders showed a strong connectivity 
between the active electrode contact and 
the mPFC pre-operatively using individual 
DTI [35]
Insignificant changes in 
metabolism in 3 patients 
with PET measurements pre-
operatively, 6 and 12 months 
post-operatively [35]
Bnst
Mayor output pathway of the AG
Regulates stress response
Integrates information from multiple brain 
areas to perform ‘valence surveillance’ 
[21,83]
Oscillatory activity with high a-power [97] -
“-”: not known.
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4. toWards a More personalized dBs treatMent 
approach for treatMent-resistant depression
Since open-label trials and RCT data on DBS in TRD show inconsistent results, this gives rise 
to discussion about the chosen study designs, the correct interpretation of results, and the best 
target(s) for neuromodulation. Depression entails different clinical subtypes and looking at ho-
mogenous subgroups of depressed patients may lead to a personalized DBS approach. This would 
be superior to looking at primary outcomes across all participants. Importantly, a prerequisite 
to this approach is the ability to determine pathoanatomical substrates of specific subtypes. How 
to implement such a more personalized approach to DBS treatment for TRD is discussed below.
4.1. clinical and neurophysiological subtypes of depression
Most response rates in depression treatments to date have been measured with changes in aver-
age levels among all patients treated. However, depressive symptomatology varies highly among 
individuals, making the standardization of positive outcomes challenging. Mood, sleep rhythm, 
concentration, psychomotor, and cognitive domains can all be disturbed in depression, while 
treating one selected brain structure within the mood circuit may not have an effect on all afore-
mentioned symptoms nor have an effect on the main symptomatology of all depressed patients.
Subdividing TRD into different subtypes, involving distinct clinical symptoms as well as 
distinct patterns of dysfunctional connectivity in limbic and frontal striatal networks, may reveal 
different subtype-related outcomes for each investigated brain region, and if so, patient selec-
tion for a given brain target could enhance treatment effectiveness [65]. Analysis of resting-state 
connectivity biomarkers previously revealed four connectivity-based biotypes of depression 
characterized by either anxiety, increased anhedonia, psychomotor retardation, and/or increased 
anergia and fatigue. Moreover, patients could not be differentiated into a particular subtype 
based on clinical features alone and clustering them based on functional connectivity was 
needed [66]. Therefore, imaging procedures as well as featured symptoms should be taken into 
account when treating TRD with DBS. It is conceivable that subdividing TRD patients according 
to connectivity-based biotypes will shed new light on the interpretation of previous DBS study 
results, and that the integration of functional connectivity in future DBS studies will reveal clini-
cally relevant subgroups that might respond to DBS of a specific target within the mood circuit. 
Altogether, it can be suggested that better assessment of therapeutic outcomes at symptom level 
might be accomplished when TRD patients with dominant anergia/fatigue symptoms (biotype 
2) are stimulated within the Cg25; and patients characterized by more anxiety (biotype 4) are 
stimulated within the thalamic region, as suggested by Drysdale and coworkers [66]. Likewise, 





Another way in which DBS efficiency can be improved is to ameliorate the implantation of elec-
trodes with the usage of individualized, patient-specific, deterministic tractography targeting. 
Riva-Posse et al. (2018) used individualized patient-specific tractography targeting for SCC-DBS 
surgeries in TRD patients, aiming at the convergence of the four white matter bundles: the for-
ceps minor, uncinate fasciculus, cingulum, and fronto-striatal fibers. This resulted in a response 
rate of 81.8% and a remission rate of 54% after a one year trial period, which proved greater than 
the previous open-label trials [67]. In a recent study, diffusion tensor imaging (DTI) tractogra-
phy was used to target SCC-DBS more optimally, and the authors examined the impact of tract 
activation on clinical response at 6 and 12 months. Stimulation of vmPFC pathways by SCC-DBS 
was associated with a positive response and stimulation of the cingulum was associated with 
a 6 month, but not a 12 month DBS response. Monopolar stimulation of 130 Hz was applied 
with either pulse width (90–450 µs) or amplitude (4–8 V) progressively increased every month, 
based on response status. Patients were changed to bipolar settings if monopolar stimulation 
caused adverse effects. It was speculated that targeting more ventral, rather than the dorsal mPFC 
projections, might improve the response [68].
4.3. combining deep Brain stimulation with cognitive-Behavioral Therapy
It is plausible that better therapeutic outcomes could be achieved if DBS is applied in combina-
tion with concurrent treatments, such as pharmacotherapy with antidepressants or cognitive-
behavioral therapy (CBT) in TRD. Studies focusing on the added effect of concurrent treatments 
to DBS have not been conducted in patients with TRD. The results from studies in OCD patients 
treated with DBS show that adding CBT to DBS has added beneficial effects [69]. Studies targeted 
at revealing the added effects of concomitant treatments after DBS in TRD would also provide 
information that may facilitate establishing a treatment algorithm to determine the place of these 
treatments in TRD patients.
4.4. Biomarkers
Biomarkers are quantifiable characteristics of biological processes, which could prove helpful in 
improving diagnostic objectivity of MDD and TRD as well as help in personalizing its treatment. 
For MDD, no specific biomarkers have yet been found, though several markers have been shown 
to be potential candidates, such as brain-derived neurotrophic factor (BDNF), interleukins 
(IL) 1 and 6, tumor necrosis factor (TNF), malondialdehyde (MDA), hypothalamic-pituitary-
adrenal (HPA) activity, and cortisol responses [70,71]. Every biomarker as a standalone shows 
a low sensitivity and specificity, partly explained by the heterogeneity of MDD. To overcome 
this shortcoming, either examining a biological panel of several markers [72] or phenotyping 
MDD and TRD into distinct subtypes could be considered. However, a recent meta-analysis 
showed that only cortisol has a predictive effect on onset/relapse and recurrence of MDD making 
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the integration of biomarkers for personalizing TRD treatment a futuristic milestone yet to be 
discovered [73].
4.5. insights into symptomatic improvement after deep Brain stimulation
For TRD, different regions in the mood circuit can be stimulated with DBS (Table 2), although 
it is still unclear which depressive-symptoms respond to the stimulation of a specific target. 
More research into the mood circuit is needed to untangle which emotions arise from specific 
brain regions. This may vary from basic animal research, disentangling neuronal function per 
brain region, and ultra-high field MR studies in humans, all of which could shed light on the 
dysfunctional brain circuits in TRD. In contrast to the motor system that is studied thoroughly 
[74,75], emotional circuitry is far less understood. One reason for this is that animal research 
into mood circuitry remains complicated as there is considerable heterogeneity between species 
[76]. Modeling depression in animals is complex as there are several depressive-like behavior 
models, such as the chronic unpredictable stress paradigm (CUS), which give insight into 
depression pathology [77]. DBS is investigated within these models to unravel behavioral and 
cellular changes following DBS [78].
Alongside the standard clinical rating scales, the use of momentary assessment techniques, 
such as the experience sampling method (ESM), could enhance the documentation of the mo-
mentary mood states [79]. The ESM includes short repeated assessments of experiences and 
behaviors, as well as moment-to-moment changes in mental states in the context of daily life. 
Research has shown that depressed patients can improve their depressive symptomology while 
using weekly ESM for six weeks, and add-on ESM derived feedback resulted in a significant 
decrease in HDRS scores compared to controls (p < 0.01; −5.5 point reduction in HDRS at 6 
months) [80]. In add-on-derived feedback, a psychologist or psychiatrist gives feedback on the 
association between the participants momentary affective states and specific daily life contexts 
[81]. ESM-derived feedback could further improve treatment by showing within-subject changes 
in a heterogeneous TRD population and contribute to clinical decision-making [81]. In the case 
of DBS, the use of ESM may reveal specific response patterns depending on the brain region 
that is stimulated, which can provide valuable information about emotional circuitry. This can 
be done using well-evaluated day-to-day scores, including questionnaires that go into detail on 
current mood and adaptive functioning.
5. conclusions
More personalized treatment approaches hold the potential to increase the overall efficacy of DBS 
in TRD. Precise evaluations of symptoms, biomarkers, and resting-state connectivity patterns are 
essential when distinguishing clinical subtypes of TRD. Moreover, subtyping may provide more 
insight into the working mechanisms of DBS and help in selecting optimal targets in patients. 
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Monitoring of biomarkers at multiple time points during treatment along with evaluation of ESM 
data, in parallel with clinical assessments of mood using standardized depression-rating scales, 
will lead to a better understanding of symptom changes when stimulating specific brain regions. 
Such considerations could further lead to optimal adjustments of stimulation parameters as 
long-term effects of DBS on mood occur.
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3 Deep brain stimulation of the prelimbic prefrontal cortex alleviates anhedonia-like 
symptoms in rats





Background: Major depressive disorder (MDD) is estimated to affect 4.4% of the population. 
Despite available therapies, approximately 30% of patients remain treatment resistant. Deep 
brain stimulation (DBS) has shown to be effective in treating depressive symptoms. Nevertheless, 
the outcomes have been contradictory. It has been postulated that depression might consist of 
different connectivity-based subtypes, which requires a tailored targeting. Herein, we addressed 
whether DBS in specific subregions of the prefrontal cortex could alleviate distinct symptom 
domains of experimental depression, aiming to improve the effectiveness of DBS for MDD.
Method: rats were implanted with DBS electrodes in either the prelimbic (PreL) or infralimbic 
(IL) subregion of the prefrontal cortex. They were assigned to chronic mild stress or non-stressed 
control groups. After four weeks, all animals underwent behavioral testing for different behav-
ioral domains including anhedonia, anxiety and helplessness. Rats were stimulated using high 
frequency, monophasic and bipolar pulses for 15 minutes before and during the behavioral tasks.
results: High frequency (HF) DBS in the PreL cortex but not the IL cortex alleviated anhedo-
nia and behavioral despair revealed by the sucrose preference and forced swim tests, respectively. 
No differences were found for the home cage emergence test, food intake test and elevated zero 
maze.
conclusion: these data suggest that modulation of specific sub-regions in the prefrontal cortex 
might be a potential approach towards providing tailored DBS therapy for different subtypes of 
depression.
Keywords: Deep brain stimulation; depression; anhedonia; symptom specific
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1. introduction
Major depressive disorder (MDD) is a psychiatric disorder characterize by a depressed mood 
and a loss of interest in otherwise enjoyable daily activities for more than two weeks. For the di-
agnosis of MDD, as stated in the Diagnostic and Statistical Manual of Mental Disorders number 
5 (DSM-5), five of the following symptoms need to be present: a depressed mood, anhedonia, 
change in weight or appetite, insomnia or hypersomnia, psychomotor retardation or agitation, 
loss of energy or fatigue, worthlessness or guilt, impaired concentration or indecisiveness and 
thoughts of death or suicidal ideation or attempt (1). Worldwide over 300 million people suffer 
from the disease in 2015, equivalent to 4.4% of the world’s population (2). The treatment of 
MDD consists of pharmacotherapy, psychological therapies such as cognitive behavioral therapy 
and interpersonal psychotherapy and electroconvulsive therapy (3-5). However, roughly 30% of 
treated patients do not respond adequately to these treatments. For treatment-resistant depres-
sion (TRD), non-pharmacological therapies such as transcranial magnetic stimulation (6) and 
deep brain stimulation (DBS) are proposed (7).
In depression, various cortical and subcortical brain areas have been indicated to play a role in 
its pathology (8, 9). These cortical areas involve the orbital frontal cortex (OFC) and the medial 
prefrontal cortices (MPFC) forming the orbital and medial networks (10, 11). In the orbital net-
work, Brodmann area 13 and parts of area 12 form an associative network that processes visual, 
auditory, somatosensory, gustatory, and olfactory information. This information is projected to 
multiple nuclei within the amygdala, entorhinal, perirhinal and temporal cortices, the dorsal 
striatum and portions of the mediodorsal thalamic nuclei (MD). In these brain regions, sensory 
information is integrated, and reward and aversion values are provided to these experiences that 
guide behavior (10, 11). The medial prefrontal network consist of Brodmann areas 25, 32 and 
part of area 24, 14, 10 and 11. These areas, project to the amygdala, entorhinal, perirhinal and 
temporal cortices as well as the subiculum, hippocampal CA1, striatum, the medial part of the 
MD, the hypothalamus and periaqueductal grey. This network mainly plays a role in mood and 
emotion, and modulating visceral reactions to emotional stimuli. It is not directly related to a 
sensory modality, but resemble a ‘default’ system that is active in a resting state as determined 
by fMRI (10, 11).
Targets for DBS studies therefore, are mainly parts of the orbital or medial prefrontal networks. 
For example the subcallosal cingulate gyrus (SCG), which includes Brodmann area 25, parts of 
area 24, and 32 (12).
For TRD, DBS has shown promising results in open-label trials when stimulating the SCG, 
ventral capsule/ventral striatum, (VC/VS), nucleus accumbens, the inferior thalamic peduncle, 
lateral habenula and more, reviewed in detail elsewhere (13). However, randomized controlled 
trials stimulating the SCG, anterior limb of the internal capsule or VC/VS have revealed contra-
dictory results (14-17). In this regard multiple questions have been raised; i) what is the optimal 
target for the DBS electrode? ii) what are the precise underlying brain circuits modulated by 
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stimulation? and iii) are certain targeted brain regions only effective for a subgroup of patients 
with specific symptoms?
There is growing agreement on subtypes of depression, reflecting the dysfunction of particular 
large scale neural circuits, rather than seeing the disorder as one unitary (18). In a resting state 
fMRI study, four different biotypes of depression has been reported (19). In this study all MDD 
patients shared a neuroanatomical core of pathology, consisting of the insula, orbitofrontal cor-
tex, ventromedial prefrontal cortex (vmPFC) and multiple subcortical areas. These brain regions 
represent three symptoms of depression, namely; mood (feeling of sadness, hopelessness, and 
helplessness), anhedonia and fatigue. Beside this pathological core, distinct patterns of abnormal 
functional connectivity differentiated four biotypes associated with specific clinical-symptom 
profiles. A severe reduced connectivity was found in fronto-amygdala networks, which is re-
sponsible for fear-regulated behavior, in biotypes 1 and 4, characterized by increased anxiety. 
Hyperconnectivity in thalamic and fronto-striatal networks, which supports reward processing, 
adaptive motor control and action initiation, was found in biotypes 3 and 4, showing increased 
anhedonia and psychomotor retardation. Furthermore, a reduced connectivity in anterior 
cingulate and orbitofrontal areas, which supports motivation and incentive-salience evaluation, 
was most severe in biotype 1 and 2, characterized partly by anergia and fatigue. Seemingly, DBS 
in one specific brain region might not be an effective treatment for all depressed patients with 
heterogeneous symptoms.
To unravel if DBS in different cortical (sub)regions ameliorate particular depressive symptoms, 
animal research can be useful. In this research DBS was chosen and not TMS since DBS can be 
applied more regionally and within deep brain regions, additionally more stimulation settings 
can be explored. In rodents, the prefrontal cortex is homologous to the SCG in humans (20).
Our research group has previously showed that high frequency (HF) DBS of the vmPFC 
induced anti-depressive effects, however subdivisions of the vmPFC were not studied in detail 
(21). Likewise, other groups have found similar effects when stimulating the vmPFC (22). The 
vmPFC can be subdivided into the infralimbic (IL) prelimbic (PreL) and dorsal peduncular (DP) 
cortices. In rodents the IL cortex mainly plays a role in stress, autonomic responses and the 
extinction of conditioned responses, while the PreL cortex is involved in cognitive processes 
such as memory, delayed variable responses, the integration of behavioral sequences, planning 
of behavioral responses and the attention and behavioral flexibility (23). The IL cortex is most 
homologous to Brodmann area 25, where the PreL cortex is most homologous to Brodmann 
area 32 (24). Herein, we aimed to investigate if different microcircuits within the vmPFC are 
responsible for particular domains and symptoms of depression by applying HF DBS in the IL 
or PreL subregion of the vmPFC and test for different anti-depressive effects in a rat model of 
depression.
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2. Materials and Methods
2.1. subjects
Fifty-one male rats (300–400 g; Sprague Dawley, Envigo) were used in this study. All animals 
were housed in standard individual ventilated cages (IVC) in a controlled environment (tem-
perature 22 °C, humidity 59 (rH)) in a reversed 12:12 h light-dark cycle. After DBS surgery, all 
animals were housed individually. Water and rat chow was available ad libitum, except during the 
CUS period when the given stressor related to food or water intake. All animal procedures were 
carried out in accordance with the Netherlands Central Committee on Animal Testing (CCD).
2.2. surgical procedure
A detailed description of the electrodes used for DBS and the surgical procedure for electrode 
implantation appeared in our earlier publications (25, 26). In summary, under isoflurane induc-
tion anesthesia, all animals were placed in a stereotactic frame. Bur wholes were made in the 
skull and bilateral electrodes were implanted in either the IL (anteroposterior (AP): + 3.00 mm. 
mediolateral (ML): ± 0.60 mm dorsoventral (DV): 5.00 mm), or PreL (anteroposterior (AP): 
+ 3.00 mm. mediolateral (ML): ± 0.60 mm dorsoventral (DV): 3.50 mm), area of the vmPFC, 
according to the brain atlas of Paxinos and Watson 6th edition (27). All animals were given two 
weeks postoperative recovery before being introduced to the stress protocol.
2.3. experimental groups
After the postoperative recovery period, all rats were randomly assigned to undergo either the 
chronic unpredictable stress (CUS) paradigm or no stress. The animals undergoing the CUS 
paradigm with DBS implants into the IL brain area were randomly assigned to the group re-
ceiving DBS during behavioral testing, i.e. IL-HF DBS (n=12) or the sham group not receiving 
stimulation. i.e. IL sham (n=5). The animals undergoing the CUS paradigm with DBS implants 
into the PreL brain area were randomly assigned to the group receiving DBS during behavioral 
testing, i.e. PreL-HF DBS (n=16) or the sham group not receiving stimulation. i.e. PreL sham 
(n=7). The stressed sham animals were pooled together as one group (n=12). The non-stressed 
sham animals implanted into the IL (n=4) or PreL (n=7), were also pooled together as one 
non-stressed sham group (n=11). Due to electrode loss, the number of IL and PreL implanted 
animals in stressed and non-stressed sham groups differ. Notably, for the sake of animal ethics 
we implanted fewer animals in sham groups to reduce the number of animals used in this study 
similar to our earlier studies. It has been shown that there were no significant differences in the 
behaviors with respect to the implantation site (21).
The DP cortex within the prefrontal cortex has not been researched within this paper, since our 
previous research showed severe seizure induction upon stimulation of this brain region (26).
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2.4. The cus model
To induce experimental depression, the CUS protocol was executed as described before (21, 26). 
The stressors consisted of; soiled-cage bedding with 300 ml of cold water (4 °C), intermittent 
illumination every 2 h during their dark cycle, stroboscopic light (2.5 Hz), food or water depriva-
tion, housing in mouse cages, and paired-housing where the rat alternatingly was the intruder or 
resident. Also a condition with no stressors was given. Each stressor was given at a unpredictable 
time in a random order in both the morning and evening and lasted 10-14 h. Stressors were given 
for 4 consecutive weeks.
2.5. deep brain stimulation
A digital stimulator (A-M systems 3800, USA) and stimulus isolator (A-M systems 3820, USA) 
were used to apply monophasic, bipolar DBS for 15 minutes before and during the behavioral 
tasks at a frequency of 100 Hz, an amplitude of 100 μA and a 100 μs pulse width. Sham rats were 
connected; but did not receive stimulation. An acute stimulation paradigm was chosen, since 
previous results done in our research group has shown antidepressant effects upon acute DBS in 
the PFC in this model of experimental depression (21).
2.6. Behavioral testing
Stimulated animals received HF DBS 15 minutes before and during the entire behavioral task. All 
animals, CUS-susceptible, CUS-resilient, sham and non-stressed animals underwent the behav-
ioral paradigm including the sucrose preference test, home cage emergence test, food intake test, 
elevated zero maze and the forced swim test, each described below.
2.6.1. Sucrose preference test
One day before testing, all animals were exposed to a 1% sucrose solution instead of water for 1 h 
in a custom-made freely-moving stimulation setup without stimulation. The custom-made freely 
moving stimulation set-up consisted of a wooden square (50 by 50 cm) with high walls (100 cm) 
in which the home cage could be inserted and two drinking bottles in opposite direction could 
be placed. The sucrose 1% bottles were randomly placed in one of the two bottle holders. This 
was followed by a 14 h long period of food and water deprivation starting at the beginning of 
their dark cycle. After the deprivation, the actual sucrose preference test took 1 h. The sucrose 
1% bottle was randomly placed in one of the two bottle holders and normal drinking water was 
placed in the other bottle holder. Both drinking bottles were weighted before and after the 1 hour 
testing. Sucrose preference index (SPI, %) was determined using the equitation SPI = (sucrose 
intake/ total liquid intake) x 100.
2.6.2. Home cage emergence test
In the Home cage emergence (HCE) test, the home-cage of the animal was opened and placed in 
the middle of an open field, which consisted of a Plexiglas square arena covered with cardboard 
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(100 x 100 cm with 40 cm high walls), and a dark floor. A custom-made iron grid was placed 
over the edge of the home-cage to ease leaving the home-cage. The latency to leave the home-cage 
onto the iron grid was recorded. The session lasted for 10 min. If the rat did not escape its home-
cage within these 10 min, a score of 600 seconds was given.
2.6.3. Food Intake test
The food Intake test took place in the same custom made freely-moving stimulation setup as the 
STP. Prior to the test, the animals were food and water deprived for 24 h starting at the beginning 
of their dark cycle. During the test, all rats had access to a limited amount of food on a petri-dish. 
After 2h of testing, the total food intake was measured and corrected for their body weight. Food 
that was hidden by the animal in their home-cage, was taken into account.
2.6.4. Elevated zero maze
The elevated zero maze (EZM) was performed using a black circular arena (100 cm in diameter, 
10 cm path width, 70 cm above floor level) with an integrated infrared light powered via an 
external adaptor. A long stimulation cable was attached next to the camera above the center 
of the circular arena, with a long enough reach so rats could move freely during stimulation. 
Each rat was placed in the middle of an open arm facing one of the closed arms, and was al-
lowed to explore the maze for a period of 5 min. Rat’s movement was recorded using an infrared 
video tracking system (EthoVision version 8.5, Noldus, The Netherlands). The arena was cleaned 
after every rat. Scoring of behavior was done manually by three blinded observers. As outcome 
measures, the percentage of time spend in closed arm was noted and corrected for the time the 
rat entered a closed arm for the first time. Also the latency to go into a closed arm for the first 
time was measured.
2.6.5. Forced swim test
The Forced Swim test (FST) was performed using a transparent Perspex cylinder (50 x 20 cm). 
The cylinder was filled with tap water (25 °C) to a depth of 30 cm. Testing was performed over 
two consecutive days. On day one, a pretest session was given in which the rat was placed in 
the water for 15 minutes. The following day, rats were tested in the water for 10 minutes. The 
test sessions were video-taped using a digital camera. The immobility time was measured using 
EthoVision tracking software (EthoVision version 8.5, Noldus, The Netherlands).
2.7. electrode localization
The localization of electrodes was verified in sections containing the electrode trajectory from 




All data were represented as mean ± standard error of the mean (SEM). Analysis were performed 
using IBM SPSS Statistics 25. Normality and homogeneity of variance of the data were checked 
using the Shapiro-Wilk test and levene’s test. Th e data were analyzed using either a one-way 
analysis of variance (ANOVA) or a Kruskal–Wallis H test, as appropriate. Multiple comparison 
correction was done using the Tukey HSD post hoc test.
3. results
3.1.1. Sucrose preference test
Th e sucrose preference test signifi cantly diff ered between the four animal groups, (one-way 
ANOVA, 614.871(6.595)=0.001, P<0.05). Th e Tukey HSD was used for multiple comparison and 
showed that HF DBS in the PreL cortex signifi cantly enhanced the sucrose preference compared 
to sham animals (p=0.049). It showed a signifi cant diff erence between the IL-HF DBS and PreL-
HF DBS group (p=0.002), where the PreL-HF DBS animals consumed more sucrose water. Fur-
thermore a signifi cant diff erence was observed between the IL-HF DBS and non-stressed control 
animals (p=0.013), where the non-stressed animals consumed more sucrose water (Fig. 1).
figure 1. Sucrose preference test (SPT) following high frequency deep brain stimulation (HF-DBS); graph 
shows the quantitative sucrose preference index data obtained by SPT during HF-DBS in the prelimbic or 
infralimbic prefrontal cortices (PreL and IL, respectively) compared to sham and control groups. Data are rep-
resented as the mean sucrose preference index per group ± SEM; * p=<0.05.
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3.1.2. Forced swim test
Th e immobility of the forced swim test signifi cantly diff ered between the four animal groups, 
(one-way ANOVA, 198.399(6.223)=0.001, P<0.05). Th e Tukey HSD was used for multiple com-
parison and showed that HF DBS in the PreL cortex signifi cantly decreased the immobility time 
in the FST compared to the sham group (P=0.034). Furthermore, a signifi cant diff erence between 
PreL-HF DBS and IL-HF DBS (p=0.004) or non-stressed controls (p=0.005) was found (Fig. 2).
figure 2. Forced swim test (FST) aft er 4 weeks of chronic unpredictable stress (CUS); graph shows the quantita-
tive immobility time data obtained during 10 minutes of FST following HF-DBS in the prelimbic or infralimbic 
prefrontal cortices (PreL and IL, respectively) compared to sham and control groups. Data are represented as 
the mean immobility time per group ± SEM; * p=<0.05.
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3.1.3 Home cage emergence test
HF DBS in the IL or PreL subregion did not have any signifi cant eff ect on escape latencies in the 
HCE test compared to the sham animals (one-way ANOVA, 1473.615(0.399)=0.755) (Fig. 3).
3.1.4 Food Intake test
HF DBS in the IL or PreL subregion did not have any signifi cant eff ect on food consumption in 
stimulated groups compared to the sham animals (one-way ANOVA, 0.000(2.077)=0.117) (Fig. 4).
figure 4. Food intake test following high frequency deep brain stimulation (HF-DBS); graph shows the quan-
titative food intake data obtained by food intake test during HF-DBS in the prelimbic or infralimbic prefrontal 
cortices (PreL and IL, respectively) compared to sham and control groups. No signifi cant eff ect was observed 
for DBS. Data are represented as the mean food intake per group ± SEM.
figure 3. Home cage emergence test (HCE) following high frequency deep brain stimulation (HF-DBS); graph 
shows the quantitative escape latency data obtained by HCE test during HF-DBS in the prelimbic or infralimbic 
prefrontal cortices (PreL and IL, respectively) compared to sham and control groups. No signifi cant eff ect was 
observed for DBS. Data are represented as the mean escape latency per group ± SEM.
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3.1.5 Elevated Zero Maze
HF DBS in the IL or PreL subregion did not change the total time spend in open arms or escape 
latency to the fi rst closed arm in the EZM compared to the sham group (one-way ANOVA, 
3711.108(2.599)=0.065, Kruskal-Wallis 6.865(3)=0.76) (Figs. 5-6).
figure 5. Elevated Zero Maze (EMZ) test; total time spent in open arms following high frequency deep brain 
stimulation (HF-DBS); graph shows the quantitative time data obtained by EZM test during HF-DBS in the 
prelimbic or infralimbic prefrontal cortices (PreL and IL, respectively) compared to sham and control groups. 
No signifi cant eff ect was observed for DBS. Data are represented as the mean time spend in open arms per 
group ± SEM.
figure 6. Elevated Zero Maze (EMZ) test; escape latency to the fi rst closed arm following high frequency deep 
brain stimulation (HF-DBS); graph shows the quantitative escape latency obtained by EZM test during HF-DBS 
in the prelimbic or infralimbic prefrontal cortices (PreL and IL, respectively) compared to sham and control 
groups. No signifi cant eff ect was observed for DBS. Data are represented as the average escape latency to the 
fi rst closed arm per group ± SEM.
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3.2. Verifi cation of electrode placement
Th e DBS electrodes in stimulated, sham and non-stressed animals were placed correctly in 49 out 
of 51 animals in either the IL or PreL cortex as it was indicated in postmortem histology (Fig. 7). 
Th e two animals with incorrect electrode placement were excluded from analysis. 
figure 7. Electrode localization; fi gures show electrode tip localizations in the prelimbic and infralimbic pre-
frontal cortices (PreL and IL, respectively) in four experimental groups.
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4. discussion
Our results showed that PreL-HF DBS alleviates anhedonia, indicated by an increase in sucrose 
preference and reduced behavioral despair in forced swim test. This implicates that two major 
symptom domains seen in depression, namely the anhedonia and helplessness, are regulated 
within a circuitry involving the PreL cortex and not the IL cortex in rats.
The IL cortex has been studied earlier in a rodent DBS study, where the authors showed no 
effect of IL-HF DBS on immobility in forced swim test in rats (28). However, as this study was 
conducted on naïve rats, the outcomes cannot be compared to our study. Nevertheless, these 
contradicting outcomes implies the importance of using relevant disease model when the thera-
peutics outcomes of DBS are desired.
In rats, the IL and PreL cortices receive projections from the orbitofrontal cortex, agranular 
insular, perirhinal and entorhinal cortices, hippocampus, subiculum, claustrum, basal forebrain 
structures, amygdala, midline thalamus and monoaminergic brainstem nuclei (29). However, 
projection patterns from the IL and PreL cortices are somewhat different. The IL cortex projects 
mainly to forebrain structures, amygdala, hypothalamus and parabrachial and solitary nuclei of 
the brainstem, while the PreL cortex projects to the agranular insular cortex, claustrum, nucleus 
accumbens, olfactory tubercle, thalamus, amygdala, and the dorsal and medial raphe nucleus of 
the brainstem (23). Although, both structures innervate parts of the orbitofrontal cortex, olfac-
tory forebrain and midline thalamus (23). The IL cortex is mainly involved in stress regulation 
and autonomic responses functioning as a visceromotor region, while the PreL cortex not only 
has visceromotor activities but is also involved in ‘higher-order’ functions like memory and the 
integration of behavioral sequences and planning of behavioral responses (20, 23). These thereby 
explain why DBS of the PreL- and not the IL cortex alters states of anhedonia and helplessness.
Research from McKlveen et al. 2016 suggests that chronic stress increases synaptic inhibition 
onto prefrontal glutamatergic output neurons. In their research they used patch clamping of 
pyramidal neurons from layer V in the IL cortex of SD rats. To induce chronic stress they have 
used a two weeks CVS protocol using stressors such as cold room exposure (1 hour, 4 °C) and hy-
poxia (30 min of 8% oxygen), which slightly differs from our CUS protocol. Their results showed 
that chronic stressed rats had i) an increase of iPSCs frequency with no effect on the amplitude 
suggesting an increased GABA release in the ILPFC , ii) increased inhibitory appositions and 
terminals onto glutamatergic cells in all layers of the ilPFC and iii) GR downregulation in the 
ILPFC especially in PV+ interneurons(30) compared to controls.
Czéh et al. 2018, however, have shown opposite results of GABAergic disturbances in neu-
rotransmission and a reduced number of GABAergic neurons in the medial PFC in anhedonic 
whistar rats. Their rats underwent a nine weeks CUS paradigm, after which a sucrose prefer-
ence test was performed, subdividing the stressed animals into a CUS susceptible, hence the 
anhedonic animals, and a CUS-resilient group. Their results showed that anhedonic rats had i) a 
37% reduction of spontaneous inhibitory postsynaptic currents (sIPSC’s) frequency in the mPFC 
Chapter 3
62
(infralimbic and prelimbic region) and a reduced amplitude, ii) a decrease in release probability 
and thus GABA release in the mPFC and iii) a down regulation of GABAbR-GIRK currents, 
indicating a reduced GABAb receptor mediated inhibition in the mPFC and iiii) less GABAergic 
cells in the MPFC compared to controls. No subdivision between the PreL- and IL cortex was 
made except in there histopathological analysis of GABAergic neurons in which both the IL- and 
PreL-cortex of anhedonic rats showed less CKK+ neurons, but only the IL cortex also showed 
less PV+ and CR+ neurons (31).
Their differences in outcome can be due to the different amount of stress given, two versus nine 
weeks, different forms of stress, CVS versus CUS paradigm, but can also be strain related, SD 
versus whistar rats. Furthermore, McKlveen et al. 2016 only measured the IL cortex, while Czéh 
et al 2018 measured in the prelimbic-infralimbic region.
In our research we stressed our SD rats for four consecutive weeks. Therefore, our research is 
mostly comparable with the work done by McKlveen et al. 2016, keeping in mind we investigated 
both the IL- and PreL cortex. We believe that when chronic stress increases synaptic inhibi-
tion onto prefrontal glutamatergic output neurons (30), DBS restores this imbalance between 
excitatory and inhibitory neurotransmission possibly by diminishing the elevated GABA release. 
Furthermore, it is known that gamma-oscillations in the mPFC, tightly controlled by PV neu-
rons, are disrupted in MDD (32, 33). McKlveen et al. 2016 has shown that after two weeks of 
chronic stress, PV+ neurons are less expressed in the IL cortex not the PreL cortex, possibly 
disabling information outflow out of the mPFC. DBS could thereby restore these impaired 
gamma-oscillations, enhancing the information flow out of the mPFC. Research by Parthoens et 
al 2014 has shown that 60HZ DBS in the PreL cortex causes hypermetabolism in glucose using 
[(18)F]FDG microPET indicating cellular changes upon DBS (34).
We, however, found that HF DBS of the PreL cortex and not the IL cortex alleviates particular 
depressive-like symptoms, a region which according to McKleev et al. 2016 does not show less 
PV+ neurons. Nonetheless, we must highlight our differences in chronic stress time, therefore 
more abundant changes in the PreL cortex after four weeks of CUS could underlie our findings. 
Why HF DBS in the PreL- and not the IL cortex alleviates anhedonia and learned helplessness 
still remains unclear. Since these depressive domains are not directly anxiety related, a different 
pathway not including the basolateral amygdala (BLA) but higher order regions could be altered 
with HF DBS. Including electrophysiology and microdialysis in both the IL- and PreL cortex 
together with regions such as the DRN, amygdala and lateral habenula in future experiments 
might elucidate their different outcome.
Interestingly, we did not find any significant effects of HF DBS on other symptom domains of 
depression, such as anxiety, neophobia or motivation for food consumption. In the HCE test, we 
would have expected that non-stressed control rats tend to explore more and escape the home 
cage faster compared to stressed animals (21). However, the non-stressed control group was not 
handled as much as the stressed animals, as the various stressors require a lot of handling, which 
might have influenced behavioral outcomes. It has been shown that stressed rats emerge quicker 
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from their home cage because of increased behavioral agitation (35). Nonetheless, it should be 
noted that CUS is a challenging model to reproduce and that stress outcome vary greatly among 
trials and laboratories (36).
As mentioned above, the vmPFC is homologous to the human SCG. The SCG has shown to be 
hyperactive in MDD patients and DBS in this region elicited a significant reduction in depression 
rating scales in open-label studies while a RCT could not replicate this finding (12, 16, 37). In our 
rat model, HF DBS of the PreL (Brodmann are 32) but not the IL (Brodmann area 25) cortices 
within the vmPFC alleviated anhedonia and helplessness, suggesting that also in the human 
SCG subdivisions and microcircuits are responsible for different domains of depression showing 
contradictory results when SCG subdivisions are not taken into consideration in DBS trials.
5. conclusion
Taken together, our findings suggest that circuits emerging from distinct subregions in the pre-
frontal cortex of rats are responsible for different depressive symptoms such as anhedonia and 
behavioral despair. This means that our study support the concept of targeting selective brain 
areas for specific subtypes of depression. These data might partially explain the contradictory 
outcomes of SCG DBS in depression, emphasizing that a DBS approach for TRD needs to be 
more individualized with a focus on microcircuits.
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4 Severe seizures as a side eff ect of deep brain stimulation in the dorsal peduncular region of 
the prefrontal cortex in a rat model of depression
Milaine Roet, Sylvana Pol, Ali Jahanshahi, Fred Schaper and Yasin 
Temel




Deep brain stimulation (DBS) has shown to have antidepressant effects in both human trials and 
animal studies. However, it remains to be determined what the best target is, and which mecha-
nisms underlie therapeutic effects. In this study, we investigated if DBS in the dorsal peduncular 
(DP) subregion of the ventromedial prefrontal cortex (vmPFC) could alleviate depressive-like 
behavior in an experimental model of depression. Surprisingly, DBS in the DP cortex caused 
acute induction of seizures in ~40% of stimulated animals. Clinically relevant stimulation pa-
rameters were applied, and a bipolar stimulation approach was chosen to keep the current spread 
to a minimum. We therefore conclude that the DP subregion of the vmPFC is not a suitable target 
to conduct DBS in mood disorders but could be a potential model for seizure induction.
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1. introduction
Major depression is a common mental disorder affecting more than 300 million people 
worldwide [1]. Despite advances in antidepressant treatment, 10-30% of the patients show an 
inadequate respond to therapy. This treatment-resistant depression (TRD) is diagnosed when a 
patient shows a poor or unsatisfactory response to two to four medication and psychotherapy 
treatment sessions [2]. For these patients, alternative treatments are widely investigated. Deep 
brain stimulation (DBS) is one of these treatment options initially showing promising results 
in different open labelled trials. Nevertheless, more recent randomized controlled trials could 
not replicate these positive findings [3]. Factors that contribute to these varying results include 
differences in study design, stimulation settings, patient selection and targets for DBS. Regarding 
the latter, there is no consensus about the best target for TRD. To get a better insight into the 
neurobiology of depression and to study potentially better targets for DBS, we need to further 
investigate the different neuronal circuits of mood. Previous animal research done in our labora-
tory showed that DBS in the ventromedial prefrontal cortex (vmPFC) caused anti-depressant 
effects in behavior in a rat model of depression [4]. The vmPFC is part of the prefrontal cortex 
(PFC) and consist of multiple interconnected regions fulfilling numerous functions such as the 
regulation of emotion, decision making, the process of extinction and fear conditioning, and 
self-directed cognition [5]. In rodents, the mPFC can be subdivided into different subregions 
including the prelimbic cortex (PreL), the infralimbic cortex (IL) and the dorsal peduncular (DP) 
cortex, each fulfilling different functions [6, 7]. Further dissection of the pathways causing the 
anti-depressive effects may give important insights into the neurobiology of this behavior. In this 
study, we used an experimental model of depression induced by ‘chronic unpredictable stress’ 
(CUS). This model mimics the pathway to depression by chronic exposure to various unpredict-
able stressors inducing a range of behavioral and physiological changes parallel to symptoms of 
depression. Our aim was to electrically stimulate the DP cortex with DBS which has not been 
studied much. We expected to see different anti-depressive behavioral effects when stimulating 
the DP subregion then what is seen with stimulating the IL and PreL subregions. We believe 
that multiple small microcircuits are responsible for different traits seen in depression and that 
stimulating the DP cortex would alleviate particular traits. Our hypothesis was that the different 
subregions of the vmPFC are responsible for different modalities of mood related behavior such 
as anhedonia, anxiety, behavioral despair and motivation. This could be critically important for 
the treatment of various mood related disorders such as depression and will give the opportunity 
to integrate a symptom-based treatment.
abbreviations; AcbC; midrostrocaudal level of the nucleus accumbens core, AcbS; dorsal caudo-
medial shell of the nucleus accumbens, BDA; biotinylated dextranamine, BLA; basolateral nucleus 
of the amygdala, BST; bed nucleus of stria terminalis, CeA; central nucleus of the amygdala, DBS; 
deep brain stimulation, CUS; chronic unpredictable stress, dlPAG; dorsolateral periaqueductal 
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gray, DP; dorsal peduncular, EEG; electroencephalographic, IL; infralimbic, mPFC; medial pre-
frontal cortex, NAcc; nucleus accumbens, PFC; prefrontal cortex, PreL; prelimbic, SIT; sucrose 
intake test, SPC; sulcal prefrontal cortex, STN; subthalamic nucleus, TRD; treatment-resistant 
depression, VMH; ventromedial hypothalamus, vmPFC; ventromedial prefrontal cortex, VS; 
ventral striatum
2. Material and Methods
2.1. subjects
We used male rats (300-400 g; Sprague Dawley, n=29, Envigo), housed in standard individual 
ventilated cages (IVC) in a controlled environment (temperature 22°C, humidity 59 (rH)) using 
a 12/12-h reversed dark/light cycle (light on 07AM-07PM). After DBS surgery, all animals were 
housed individually. Food and water were given ad libitum, except during the CUS model when 
the given stressor related to food or water intake. All the experiments were carried out in ac-
cordance with the Animal Experiments and Ethics Committee of Maastricht University.
2.2. electrode construct
All stimulations electrodes were custom made by the engineering department (IDEE) of Maas-
tricht University [8]. A DBS electrode consist of a bilateral construct of two concentric bipolar 
coaxial gold-coated stimulation electrodes containing a platinum-iridium inner wire; shaft 
diameter 0.3 mm, tip (core) diameter 0.08 mm, with an interelectrode distance of 1.2 mm.
2.3. electrode implantation
Following an induction of isoflurane anesthesia, rats were placed into a stereotactic frame and 
their body temperature was kept a 37°C using a thermo-regulated heating pad. Throughout the 
whole surgical procedure, rats were sedated with 2,5% isoflurane inhalation anesthesia. Initially 
a bur whole in the skull was made and the DBS electrode construct was implanted into the DP 
subregion of the vmPFC (AP: + 3.00 mm. ML: +/- 0.60 mm DV: 5.00 mm), according to the brain 
atlas of Paxinos and Watson 6th edition [9]. After surgery, all animals were given a post-operative 
recovery period before introducing the stress protocol.
2.4. The chronic unpredictable stress (cus) model
The CUS protocol was executed as described before [4]. The stressors given consisted of soiled-
cage bedding with 300 ml of cold water (4°C), intermittent illumination every 2 hours during 
their dark cycle, stroboscopic light (2.5 Hz), food or water deprivation, housing in mouse cages, 
paired-housing where the rat alternatingly was the intruder or resident and a condition with no 
stressor. Each stressor lasted between 10-14 hours and was given in a random order at an unpre-
dictable time during both the morning and evening. Stressors were given for 3 consecutive weeks.
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2.5. dBs stimulation parameters
We used clinically relevant stimulation parameters with a biphasic and monophasic, bipolar high 
frequency stimulus (100 Hz) with a stimulation amplitude of 100 μA and a pulse width of 100 μs. 
For a precise delivery of the stimulus we used an A-M systems model 3800 8 channel stimulator 
connected to stimulus isolation units’ model 3820.
2.6. Behavioral testing
During behavioral testing, animals received either stimulation or sham stimulation. For sham 
stimulation the animals were attached to a DBS cable without attachment to the stimulator. In all 
our experiments, animals were stimulated 15 minutes before behavioral testing und during the 
entire behavioral test.
Sucrose Intake Test (SIT): The day before testing, all animals were habituated to a 1% sucrose 
solution instead of water for 1h. This was followed by a period of 14h of food and water depriva-
tion, starting at the beginning of their dark phase. After the 14h fasting period all animals were 
offered a 1% sucrose solution for 1h. The sucrose intake was calculated from the total amount of 
1% sucrose solution consumed divided by the bodyweight of the animal (g/kg).
Home-cage emergence test (HCE): In this test, the home-cage of the animal was opened and 
placed in an open field. An iron grid was placed over the edge of the home-cage to ease leaving 
the home-cage. The total amount of time it takes for the animal to get out of their home-cage 
onto the iron grid was measured. The session lasted for 10 minutes. If the rat did not escape its 
home cage within these 10 minutes, the rat was given a score of 600 sec.
2.7. statistical analysis
All the data are represented as mean ± standard error of the mean (SEM) and the analyses were 
performed with IBM SPSS Statistics 24. Normality and homogeneity of variance was performed 
using the Kolmogorov–Smirnov test and normality plots. The data of our behavioral tests were 
analyzed using either an independent sample t-test or a nonparametric Mann–Whitney U-test, 
as appropriate. All P-values <0.05 were considered significant.
3. results
3.1. cus model
To test for CUS susceptibility, we performed a sucrose intake test (SIT) right before the onset of 
CUS and 3 weeks after the onset of CUS. Rats exposed to the CUS model, showed less increase in 
1% sucrose solution consumption over time compared to the non-stressed control animals. This 





Aft er 3 weeks of CUS we started behavioral testing for all animals. Part of the stressed animals 
(n=18) underwent DBS and part of the stressed animals (n=6) served as sham controls (CUS+ 
sham) being coupled to a DBS cable but not to the stimulator. For DBS, biphasic bipolar stimula-
tion with a frequency of a 100 Hz an amplitude of a 100 μA and a pulse width of a 100 μs was 
given. Th e animals not undergoing CUS (n=6) served as a non-stressed control group and 
therefore were also not stimulated.
Th e HCE test showed an eff ect between the CUS+ and CUS- group aft er the second day of 
testing, where the stressed group undergoing DBS remained in their cage for a longer period than 
the non-stressed controls. (HCE1: 1.844(2) = 0.398 and HCE2: 6.064(2) =0.048, P<0.05, post hoc 
Bonferroni correction showed that the signifi cant diff erence was seen between the CUS+ and 
CUS- group, p=0.025 (Fig. 2). Since no diff erences between the CUS+ and CUS+ sham was found 
we cannot speak of a neophobia eff ect of DBS in the DP region of the vmPFC, but a certain trend 
might be seen when the number of animals in the CUS+ sham and CUS- groups are increased 
(p=0.122).
SIT with DBS in the DP was executed in which surprisingly, 5 out of the 18 stimulated animals 
showed involuntary movements and seizure-like behavior upon start of DBS in the 15 minutes 
of pre-stimulation. A signifi cant diff erence between the diff erent groups was found (One-way 
ANOVA, 4.934(3,25) = 0.008, p<0.05) in which the signifi cant eff ect was seen between the CUS+ 
animals experiencing seizures and the CUS- group (p=0.005) (Fig. 3). A trend towards less 1% 
sucrose intake between the animals experiencing involuntary movements upon DBS and the 
CUS+ sham control group was seen (p=0.077).
figure 1. sucrose intake test before and aft er 3 weeks of cus. Results of the sucrose intake test at t=0 baseline 
and aft er 3 weeks of CUS. Data are represented as means ± SEM (CUS+ n=18, CUS+ sham n=6, CUS- n=6). 
*p<0.05. CUS+ Chronic unpredictable stress, CUS- non-stressed controls.
At baseline (t=0), no signifi cant diff erence between the group of stressed (CUS+) and non-stressed (CUS-) 
animals was found (Mann-Whitney U, U=65.50, z=-.338, p=0.736). Aft er 3 weeks of CUS, the 1% sucrose 
consumption levels showed a signifi cant diff erence between the CUS+ and CUS- animals (Mann-Whitney U, 
U=14.500, z=-2.953, p=0.003).
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During further behavioral testing we observed that even more CUS+ animals receiving DBS 
began to show seizure like behavior upon stimulation (~40%, n=7 out of n=18). Th is seizure like 
behavior was not seen in the non-stimulated animals confi rming that the observed involuntary 
movements were due to stimulation. Due to severe seizure like behavior, we stopped further 
behavioral testing and decided to acquire electroencephalographic (EEG) recordings upon DBS 
in the aff ected animals to investigate if indeed this seizure like behavior could be classifi ed as 
seizures.
seizure induction
To classify the observed seizure like behavior, EEG recordings were made during both biphasic 
and monophasic DBS. During baseline measurements, the rats were not stimulated but EEG 
recordings were made to record background EEG activity. Before DBS, the rats showed no signs 
figure 2. home cage emergence test with dBs. Results of the HCE test during DBS on two consecutive days. 
Data are represented as means ± SEM (CUS+ n=17, CUS+ sham n=6, CUS- n=6). *p<0.05. CUS+ Chronic 
unpredictable stress, CUS- non-stressed controls.
figure 3. sucrose intake test with dBs. Results of the SIT during DBS. Data are represented as means ± SEM 
(CUS+ seizure n=5, CUS+ non-seizure n=12, CUS+ sham n=6, CUS- n=6). *p<0.05. CUS+ Chronic unpredict-
able stress, CUS- non-stressed controls.
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of discomfort with normal explorative and washing behavior. When starting DBS, the rats im-
mediately froze and subsequently showed facials movements (Racine stage I) and head nodding 
(Racine stage II), quickly followed by a left forelimb clonus (Racine stage III) with rearing (Racine 
stage IV) and a full generalized clonus with falling (Racine stage IV-V). EEG recordings showed 
typical spike and wave discharges characteristic for seizures. Approximately 1 minute after the 
DBS is turned off, the rats still showed some automatism comprised of facial movements and 
post ictal behavior while the EEG signal normalized. Full recovery in which the rats were fully 
conscious and showing exploring behavior appeared roughly two to four minutes after cessation 
of DBS.
3.3. electrode localization
Electrodes were traced in the DP of the vmPFC in 88% of the rats undergoing DBS, with a 100% 
accuracy in the rats experiencing seizures upon stimulation (n=7) (Fig. 5). Two animals were 
excluded from analysis due to misplacement or detachment of the electrode construct.
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4. discussion
4.1. dorsal peduncular region stimulation induced seizures
The present study showed that DBS in the DP region of the vmPFC can induce seizures while 
using clinically relevant stimulation parameters with both biphasic and monophasic stimulation 
paradigms. Due to this disabling side-effect, we can conclude that the DP cortex in the rat is not 
a feasible brain structure to conduct DBS experiments for mood disorders but can potentially be 
used as a model for seizure induction.
Seizure induction following cortical stimulation has been seen before in literature [10], how-
ever previous research stimulating the vmPFC in rats did not show this finding [4]. Experienc-
ing seizure behavior upon cortical stimulation in our experimental model of depression was 
therefore unexpected and is extensively described in this paper to broaden our knowledge of this 
unforeseen finding and to prevent cases like this in the future.
The DP cortex has not been widely investigated so far, therefore we chose the stimulation 
parameters based on our previous experience with DBS experiments and stimulation in the PFC 
[4, 8]. The DP subregion seems to be far more sensitive to electrical current than the IL and PreL 
regions, therefore conventional DBS parameters do not seem to be appropriate for this region. 
However, the parameters used are clinically relevant and we have not experiences seizures so 
far in any of the regions used such as the subthalamic nucleus (STN), the nucleus accumbens 
(NAcc), the dorsolateral periaqueductal gray (dlPAG) and the ventromedial hypothalamus 
(VMH) [11-13]. In contrast, similar parameters used for DBS in the anterior nucleus of the 
thalamus have shown to be effective in animal models of epilepsy [14] and drug refractory epi-
lepsy patients [15]. Nevertheless, our findings show that when given into the DP subregion of the 
vmPFC, these stimulation parameters are potent seizure inducers. These findings can be used as 
a new rat model of seizure induction in the PFC as opposed to stimulating temporal structures as 
performed in the amygdala kindling and post-status epilepticus models [16]. This model might 
have the advantage that classical structures involved in seizure induction remain undamaged 
by chemical or electrical lesioning and therefore its action during seizures can be accurately 
investigated using histological, imaging or electrophysiological measures. In addition, this model 
represents more a frontal seizure-model than the widely applied models of temporal seizures.
4.2. other reports of stimulation induced seizures
The mechanism behind seizure induction when stimulating the DP cortex remains unclear. 
Previous research has shown that partial kindling of the PFC in rats with +/-11 after discharges 
of 5s stimulus train of 60 Hz frequency, a pulse duration of 0.5 ms and a 600-800 μA intensity, 
propagated into the hippocampus and Nacc, where postictal activity lasted for > 5 minutes [17]. 
However, the stimulation intensity used in their experiments was far greater than the intensity 
used in our experiments. Furthermore, current spread in this experiment was larger given that 
monopolar electrodes were used, while we stimulated with a bipolar electrode construct.
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Nakamura-Palacois et al. have shown convulsion induction and behavioral responses such 
as head shaking upon bilaterally electrical activation (ten 30-sec trains, 60 Hz, 80-100μA) of 
the mPFC using monopolar electrodes, influenced by both diazepam and haloperidol [10]. Low 
frequency pulse stimulation in the cortex (2 ms monophasic, square wave pulses, frequency 
9 Hz, intensity 400-800 μA) with monopolar constructs has been used as a procedure for in-
ducing seizures by a different group [18]. Other researchers observed seizures during cortex 
self-stimulation acquisition in the sulcal prefrontal cortex (SPC) and medial prefrontal cortex 
(mPFC), but these seizures were not seen below currents of 100 μA [19].
Unlike other studies, we used a bipolar electrode constructs where the distance between the 
cathode and anode is approximately 50 micrometers. Therefore, the current spread should be 
significantly less in our experiments. Nevertheless, we do see overt seizures induced by direct 
stimulation in the PFC, possibly caused by its connections to the limbic system.
4.3. anatomical connections of the dorsal peduncular region of the vmpfc
Since we lack a precise description of the DP cortex, tissue properties may differ substantially 
from those of the IL and PreL vmPFC subregions. Previous research has shown direct projec-
tions from the DP subregion of the vmPFC to the trigeminal brainstem sensory nuclear complex 
and other brain stem nuclei; where retrograde tracing by Fluorogold showed labeling of the 
rostrocaudal middle level of DP when injected into the rostro-dorsomedial part of the laminae 
I/II of the trigeminal subnucleus caudalis (rdm-I/II-Vc). Anterograde labeling with biotinylated 
dextranamine (BDA) into the mid-PD showed bilaterally labeling in the rdm-I/II-Vc, periaque-
ductal gray and solitary tract nucleus, and ipsilaterally in the parabrachial nucleus and trigeminal 
mesencephalic nucleus. Also, BDA-labeled axons and terminals were found reciprocally between 
the mid-PD and ipsilateral most caudal level of the granular and dysgranular insular  cortex. 
These projections indicate a role for intraoral and perioral sensory processing, including noci-
ceptive processing [20].
Retrograde labeling from the ventral striatum (VS), dorsal caudomedial shell of the nucleus 
accumbens (AcbS) the midrostrocaudal level of the nucleus accumbens core (AcbC), the para-
brachial nuclei, the medial lateral septum, the bed nucleus of stria terminalis (BST), the lateral 
hypothalamus, the mediodorsal thalamus and the basolateral and central nucleus of the amygdala 
nucleus accumbens (BLA, CeA) to the dorsal peduncular cortex has been shown [21, 22].
The NAcc is part of the ventral striatum and a widely researched brain structure receiving 
dopaminergic input onto its GABAergic medium spiny neurons involved in functions such as 
motivation, reward and positive behavioral reinforcement. The parabrachial nuclei as discussed 
earlier mediate both ascending and descending nociceptive signaling. The medial lateral septum 
covers multiple nuclei receiving reciprocal information from regions such as the olfactory bulb, 
hippocampus, amygdala, hypothalamus, cingulate gyrus, habenula, thalamus and midbrain. This 
region mainly plays a role in reward and reinforcement [23]. The BST consist of multiple nuclei 
mainly containing GABAergic neurons that can express a variety of peptides and to some extent 
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glutamatergic cells [24]. It functions as a relay center where descending cortical information meets 
ascending interoceptive and exteroceptive information regarding homeostatic states or potential 
changes in homeostasis [25]. The lateral hypothalamus is involved in homeostasis, feeding behav-
ior, arousal and reward and even receives input of the BST [26, 27]. The mediodorsal thalamus 
has a function in memory and cognition and mainly uses glutamate to communicate with the 
cortex [28, 29]. The amygdala consists of heterogenous nuclei where the BLA receives sensory 
input directly from the temporal lobes. The CeA processes this information serving as the major 
output nucleus of the amygdala. Mostly, GABA receptors are found in the BLA and CeA [30, 31].
Knowing that there are retrograde connections to the limbic system and in particular the 
amygdala, a region also known for kindling, the assumption that the current density upon stimu-
lation in the PFC spreads into and activates the limbic system causing overt seizures becomes 
more plausible.
4.4. functional connections of the dorsal peduncular region of the vmpfc
Despite the IL and PreL subregions of the vmPFC, the DP subregion is relatively unexplored [32]. 
Up to now, no actual functional connectivity studies of the DP subregion have been executed. A 
functional connection between the vmPFC and the basolateral nucleus of the amygdala (BLA) 
was shown in rats using optogenetics and electrophysiological recordings [33]. However, no clear 
distinction of the DP subregion has been made. Functional differences for dorsal and ventral 
subregions of the mPFC in controlling attention has been shown [34]. In their research, lesioning 
either the ventral (dorsal peduncular cortex and tenia tecta) or dorsal (prelimbic and infralimbic 
cortices) subregion resulted in differences in five-choice serial reaction time performance.
4.5. The synchronized parallel forebrain hypothesis
Another possible explanation for seizure induction following DBS in the DP region can be found 
in Penfield’s prediction which describes the synchronized parallel forebrain hypothesis. In this 
hypothesis, the forebrain provides the neural apparatus necessary for temporal synchronization 
of multiple independent streams of processed information necessary for parallel processing [35]. 
Due to this property, stimulation in the cortex might be risky and cause uncontrolled propaga-
tion of the signal leading to seizures. It might be speculated that the cortex is more sensitive to 
stimulation than is thought before and therefore caution has to be taken when suggesting DBS 
for depression in cortical areas.
5. conclusions
In summary, current results show that DBS in the DP subregion of the vmPFC in rats has a high 
incidence of inducing seizures up to Racine stage IV-V. The stimulation paradigms used are 




 1. WHO, Depression. 2018.
 2. Limandri, B.J., Treatment-Resistant Depression: Identification and Treatment Strategies. J Psychosoc 
Nurs Ment Health Serv, 2018. 56(9): p. 11-15.
 3. Dougherty, D.D., Deep Brain Stimulation: Clinical Applications. Psychiatr Clin North Am, 2018. 
41(3): p. 385-394.
 4. Lim, L.W., et al., Electrical stimulation alleviates depressive-like behaviors of rats: investigation of brain 
targets and potential mechanisms. Transl Psychiatry, 2015. 5: p. e535.
 5. Roy, M., D. Shohamy, and T.D. Wager, Ventromedial prefrontal-subcortical systems and the generation 
of affective meaning. Trends Cogn Sci, 2012. 16(3): p. 147-56.
 6. Peters, J., P.W. Kalivas, and G.J. Quirk, Extinction circuits for fear and addiction overlap in prefrontal 
cortex. Learn Mem, 2009. 16(5): p. 279-88.
 7. Suzuki, S., et al., The infralimbic and prelimbic medial prefrontal cortices have differential functions in 
the expression of anxiety-like behaviors in mice. Behav Brain Res, 2016. 304: p. 120-4.
 8. Tan, S., et al., Experimental deep brain stimulation in animal models. Neurosurgery, 2010. 67(4): p. 
1073-9; discussion1080.
 9. Paxinos, G.W.C., The Rat Brain in Stereotaxic Coordinates 6th edition. 2007: p. 1-456.
 10. Nakamura-Palacios, E.M., R.W. de Oliveira, and C.F. Gomes, Effects of diazepam or haloperidol on 
convulsion and behavioral responses induced by bilateral electrical stimulation in the medial prefrontal 
cortex. Prog Neuropsychopharmacol Biol Psychiatry, 1999. 23(8): p. 1369-88.
 11. Temel, Y., et al., Acute and separate modulation of motor and cognitive performance in parkinsonian 
rats by bilateral stimulation of the subthalamic nucleus. Exp Neurol, 2005. 193(1): p. 43-52.
 12. Sesia, T., et al., Deep brain stimulation of the nucleus accumbens shell increases impulsive behavior and 
tissue levels of dopamine and serotonin. Exp Neurol, 2010. 225(2): p. 302-9.
 13. Lim, L.W., et al., High-frequency stimulation of the dorsolateral periaqueductal gray and ventromedial 
hypothalamus fails to inhibit panic-like behaviour. Behav Brain Res, 2008. 193(2): p. 197-203.
 14. Hamani, C., et al., Deep brain stimulation of the anterior nucleus of the thalamus: effects of electrical 
stimulation on pilocarpine-induced seizures and status epilepticus. Epilepsy Res, 2008. 78(2-3): p. 117-
23.
 15. Salanova, V., et al., Long-term efficacy and safety of thalamic stimulation for drug-resistant partial 
epilepsy. Neurology, 2015. 84(10): p. 1017-25.
 16. Gorter, J.A., E.A. van Vliet, and F.H. Lopes da Silva, Which insights have we gained from the kindling 
and post-status epilepticus models? J Neurosci Methods, 2016. 260: p. 96-108.
 17. Ma, J. and L.S. Leung, Kindled seizure in the prefrontal cortex activated behavioral hyperactivity and 
increase in accumbens gamma oscillations through the hippocampus. Behav Brain Res, 2010. 206(1): p. 
68-77.
 18. Applegate, C.D. and G.M. Samoriski, Mechanisms of kindling: an evaluation of single trial seizure 
induction procedures for use as controls. Epilepsy Res, 1993. 15(3): p. 201-5.
 19. McGregor, I.S., Determinants of the slow acquisition of medical and sulcal prefrontal cortex self-
stimulation: an individual differences approach. Physiol Behav, 1992. 51(6): p. 1219-25.
 20. Akhter, F., et al., Projections from the dorsal peduncular cortex to the trigeminal subnucleus caudalis 
(medullary dorsal horn) and other lower brainstem areas in rats. Neuroscience, 2014. 266: p. 23-37.
 21. Reynolds, S.M. and D.S. Zahm, Specificity in the projections of prefrontal and insular cortex to ventral 
striatopallidum and the extended amygdala. J Neurosci, 2005. 25(50): p. 11757-67.
81
Severe seizures as a side effect of deep brain stimulation in the dorsal peduncular cortex in a rat model of depression
4
 22. Gabbott, P.L., et al., Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic 
centers. J Comp Neurol, 2005. 492(2): p. 145-77.
 23. Olds, J. and P. Milner, Positive reinforcement produced by electrical stimulation of septal area and other 
regions of rat brain. J Comp Physiol Psychol, 1954. 47(6): p. 419-27.
 24. Gungor, N.Z. and D. Pare, Functional Heterogeneity in the Bed Nucleus of the Stria Terminalis. J 
Neurosci, 2016. 36(31): p. 8038-49.
 25. Dumont, E.C., What is the bed nucleus of the stria terminalis? Prog Neuropsychopharmacol Biol 
Psychiatry, 2009. 33(8): p. 1289-90.
 26. Giardino, W.J., et al., Parallel circuits from the bed nuclei of stria terminalis to the lateral hypothalamus 
drive opposing emotional states. Nat Neurosci, 2018. 21(8): p. 1084-1095.
 27. Brown, J., et al., Lateral Hypothalamic Area Neurotensin Neurons Are Required for Control of Orexin 
Neurons and Energy Balance. Endocrinology, 2018. 159(9): p. 3158-3176.
 28. Mitchell, A.S. and S. Chakraborty, What does the mediodorsal thalamus do? Front Syst Neurosci, 
2013. 7: p. 37.
 29. Sherman, S.M., The function of metabotropic glutamate receptors in thalamus and cortex. Neuroscien-
tist, 2014. 20(2): p. 136-49.
 30. Hasanein, P., N. Mirazi, and K. Javanmardi, GABAA receptors in the central nucleus of amygdala 
(CeA) affect on pain modulation. Brain Res, 2008. 1241: p. 36-41.
 31. Capogna, M., GABAergic cell type diversity in the basolateral amygdala. Curr Opin Neurobiol, 2014. 
26: p. 110-6.
 32. Heidbreder, C.A. and H.J. Groenewegen, The medial prefrontal cortex in the rat: evidence for a dorso-
ventral distinction based upon functional and anatomical characteristics. Neurosci Biobehav Rev, 
2003. 27(6): p. 555-79.
 33. Cho, J.H., K. Deisseroth, and V.Y. Bolshakov, Synaptic encoding of fear extinction in mPFC-amygdala 
circuits. Neuron, 2013. 80(6): p. 1491-507.
 34. Maddux, J.M. and P.C. Holland, Effects of dorsal or ventral medial prefrontal cortical lesions on five-
choice serial reaction time performance in rats. Behav Brain Res, 2011. 221(1): p. 63-74.
 35. Murrow, R.W., Penfield’s Prediction: A Mechanism for Deep Brain Stimulation. Front Neurol, 2014. 5: 
p. 213.

5 Progress in neuromodulation of the brain; a role for magnetic nanoparticles?
Milaine Roet, Sarah-Anna Hescham, Ali Jahanshahi, Bart P.F. Rutten, 
Polina O. Anikeeva and Yasin Temel




The field of neuromodulation is developing rapidly. Current techniques, however, are still limited 
as they i) either depend on permanent implants, ii) require invasive procedures, iii) are not cell-
type specific, iv) involve slow pharmacokinetics or v) have a restricted penetration depth making 
it difficult to stimulate regions deep within the brain. Refinements into the different fields of 
neuromodulation are thus needed. In this review, we will provide background information on 
the different techniques of neuromodulation discussing their latest refinements and future po-
tentials including the implementation of nanoparticles (NPs). In particular we will highlight the 
usage of magnetic nanoparticles (MNPs) as transducers in advanced neuromodulation. When 
exposed to an alternating magnetic field (AMF), certain MNPs can generate heat through hyster-
esis. This MNP heating has been promising in the field of cancer therapy and has recently been 
introduced as a method for remote and wireless neuromodulation. This indicates that MNPs may 
aid in the exploration of brain functions via neuromodulation and may eventually be applied 
for treatment of neuropsychiatric disorders. We will address the materials chemistry of MNPs, 
their biomedical applications, their delivery into the brain, their mechanisms of stimulation with 
emphasis on MNP heating and their remote control in living tissue. The final section compares 
and discusses the parameters used for MNP heating in brain cancer treatment and neuromodula-
tion. Concluding, using MNPs for nanomaterial-mediated neuromodulation seem promising in 
a variety of techniques and could be applied for different neuropsychiatric disorders when more 
extensively investigated.
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1. introduction
Neurological disorders are of huge impact in society. More than 90.000 disability adjusted life 
years (DALYs) are estimated for neurological disorders in the year 2015 increasing to a number 
of 100.000 DALYs in 2030 (WHO 2017). A larger part of these disorders includes both mental 
as well as neurodegenerative disorders. One example is Parkinson’s disease (PD), increasing in 
incidence mainly due to the increase in human life expectancy (Schrag, Ben-Shlomo et al. 2000, 
van de Vijver, Stricker et al. 2001, Totaro, Marini et al. 2005, Havulinna, Tienari et al. 2008, 
Hirsch, Jette et al. 2016). The prevalence and thus disability due to PD has more than doubled 
from 1990 to 2015, with an estimation of 6.2 million people currently having PD worldwide. This 
number is expected to grow exponentially in the next decades (Dorsey and Bloem 2018) causing 
a substantial socio-economic burden for our society. For management of these disorders, we are 
in need of adequate treatment options. Unfortunately, up to now, preventive and drug-based 
therapies have shown limited progress and are not delivering the breakthroughs that the medical 
field needs to confront the challenges associated with population ageing (Temel and Jahanshahi 
2015). Mainly improving the blood-brain barrier (BBB) permeability remains a challenge for 
drug-based therapies.
Contrary to this, the field of neuromodulation is progressing rapidly to continuously improve 
existing treatment strategies and to deliver new ones. In recent years, the application of transcra-
nial magnetic stimulation (TMS), electric acoustic stimulation (EAS) and deep brain stimulation 
(DBS) have increased substantially in the clinics with focused ultrasound (FUS) as a newly 
emerging approach.
The clinical efficacy of DBS has been demonstrated in a number of disorders involving the 
basal ganglia and several neuropsychiatric disorders. The therapeutic concept of DBS is based 
on electrical stimulation through chronically implanted unilateral or bilateral electrodes into a 
specific subcortical structure in the brain. For PD, dystonia, Tourette’s Syndrome and partial and 
generalized seizures, DBS has proven to be effective (Ackermans, Duits et al. 2011, Odekerken, 
van Laar et al. 2013, Schuepbach, Rau et al. 2013, Janssen, Duits et al. 2014, Dowd, Pourfar et 
al. 2017). Recently, new indications for DBS have emerged such as Alzheimer disease (AD) and 
intractable obesity (Whiting, Tomycz et al. 2013), needing greater follow up to show their effects.
Despite the proven clinical efficacy of DBS in the aforementioned indications, we lack a com-
prehensive understanding of the underlying mechanisms mediating these effects nor have we 
identified the exact distinct neural circuits underlying mental and behavioral sign and symptoms 
expressed in people diagnosed with the most prevalent mental and neurodegenerative disorders 
including depression, OCD, psychosis, dementia etc.
Current hypotheses about the key mechanisms involved in the effect of DBS are diverse. The 
‘inhibition hypothesis’ suggests that local neuronal elements are inhibited upon stimulation 
showing similar effects as lesion therapy. This hypothesis fits well into the ‘firing rate model’ 
of movements disorders in which stimulating an overactive brain region inhibits the firing rate 
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(Lafreniere-Roula, Kim et al. 2010). The ‘excitation hypothesis’ suggest that DBS can also excite 
local neuronal elements, mainly axons, antidromically. This causes the activation of regions along 
efferent pathways (Deniau JM 2010, Reese, Leblois et al. 2011). Another hypothesis is ‘the disrup-
tion hypothesis’, proposing that the information flowing through the stimulated brain region is 
blocked upon DBS and thereby pathological activity is interrupted (Chiken and Nambu 2013). 
This can both be inhibitory or excitatory depending on the stimulated neural elements.
Although the underlying mechanisms of electrical DBS remain to be elucidated it is known to 
operate on a macroscale, lacking cell-type specificity. For this reason, its therapeutic effect will 
depend on the composition of neural elements in the targeted region causing interference with 
both pathological and physiological neural activities. This occasionally gives rise to side effects 
in a number of patients receiving DBS. For example, PD patients treated with DBS have reported 
speech deterioration as well as changes in mood, sleep and behavior which in turn range from 
new onset to worsening of pre-existing syndromes (Tan, Hartung et al. 2011, Kurtis, Rajah et al. 
2017, Mucke, Hermes et al. 2018).
Another drawback of the current technique of DBS is that it requires the implantation of a 
relatively large, wired system which entails the risk of bleeding and infection peri- and postop-
erative. As a result, many patients are reluctant to undergo DBS when surgery is warranted (Kim, 
Yun et al. 2016). The first challenge thus addresses clinician and patient demands to develop new, 
wireless avenues for DBS technology. A second challenge addresses the continuous stimulation 
paradigm of current DBS which need improvements. New advancements are made introducing 
intermittent or adaptive DBS (aDBS) working with a closed-loop system (Herron, Thompson et 
al. 2017). This closed-loop system is created to measure and analyze biomarkers reflecting the 
patient’s condition and to adapt its stimulation parameters accordingly improving treatment ef-
ficacy. Furthermore, this closed-loop systems benefit from less power consumption and therefore 
have a longer battery life. For PD, recent research has shown positive results when using aDBS 
of the subthalamic nucleus (STN) with LFPs in PD patients (Arlotti, Marceglia et al. 2018). A 
commercially available closed-loop system called responsive neuromodulation (RNS) has shown 
good results in patients suffering from refractory epilepsy (Sun and Morrell 2014). RNS includes 
an implanted neurostimulator that continuously records the electrocardiogram at the seizure 
focus and delivers brief pulses when abnormal electrographic activity is detected.
Another refinement for continuous stimulation is called coordinated reset (CR) DBS. In this 
method, brief high-frequency pulse trains are given through the different contacts of the stimula-
tion electrode in treatment blocks for a few consecutive days resulting in desynchronizing effects 
lasting beyond cessation of the stimulus. In a non-human primate model of parkinsonism, CR 
DBS of the STN for 5 consecutive days resulted in acute motor improvements and, in contrast 
to traditional DBS, showed benefits persisting up to two weeks after stimulation (Wang, Nebeck 
et al. 2016). Moreover, the usage of rechargeable implantable pulse generators (rIPG) has made 
its entrance into the field and has been proven effective and applicable in OCD patients. These 
rlPGs have a longevity of nine years in contrast to the non-rechargeable IPGs showing a mean 
87
Progress in neuromodulation of the brain; a role for magnetic nanoparticles?
5
longevity of 9 months (De Vloo, Raymaekers et al. 2017). Evaluation of the recharging process 
has been done with patients receiving CR DBS for PD, essential tremor (ET) and dystonia and 
was experienced as feasible with a low number of adverse events even in the elderly patients 
(Jakobs, Kloss et al. 2018).
Despite these recent refinements, there remains a need for new advanced neuromodulation 
techniques in which the information transfer between the neuromodulation technique and 
the evoked neuronal signals can be performed more delicately. This ideally will only cause the 
modulation of pathological neural activity, leaving physiological neural activity in close vicinity 
unaltered, thereby minimalizing the possibility of side-effects. Here, we will discuss different 
advanced neuromodulation techniques of the brain and analyse their clinical potential. In par-
ticular, we will review relevant preclinical and clinical literature and evaluate the progress of our 
current understanding.
2. search strategy
To describe and evaluate advanced techniques of neuromodulation of the brain and their 
latest refinements, we performed an extensive literature search. The literature for this review 
was identified by a PubMed search where the following keywords were queried either individu-
ally or combined: ‘deep brain stimulation’, ‘adaptive deep brain stimulation (aDBS), closed-loop 
deep brain stimulation (closed-loop DBS), coordinated reset (CR) DBS, ‘neuromodulation’, 
‘optogenetics’, ‘DREADD’, ‘focused ultrasound’ ‘neuropsychiatric disorders’, ‘neurodegenera-
tive disorders’ and ‘neurosensory disorders’ with an additional search on ‘ nanoparticles (NP)’, 
‘magnetic nanoparticles (MNP), ‘iron oxide nanoparticles’, ‘alternating magnetic field’, ‘magnetic 
hyperthermia’, ‘hysteresis’, ‘MNP heating’ and ‘magnetothermal deep brain stimulation’. Relevant 
articles were chosen from review papers, original research articles and book chapters. Articles of 
interest within the reference lists of selected articles were also considered. The search was limited 
to studies published in English.
3. neuroModulation of the Brain, neW insights
There are several advanced neuromodulation techniques besides electrical stimulation, such as 
optogenetics, Designer Receptors Exclusively Activated by Designer Drugs (DREADD), ultra-
sonic neuromodulation and magnetic neuronal control (Fig. 1). Each of these techniques has its 
own unique method of modulation and has broaden our insight into general neuronal function, 
numerous neural circuits underlying specific behavioral and pathological firing patterns respon-
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more refined, clinically applicable technique of neuromodulation. Each technique, and its latest 
insights, is described in more detail below.
3.1. optogenetics
In optogenetics, neurons are genetically modified to express microbial light-sensitive proteins 
termed ‘opsins’, which can be activated by visible light causing neuronal excitation or inhibition 
depending on the specific opsin. There are three classes of opsins, namely: the bacteriorhodop-
sins, the halorhodopsins and the channel-rhodopsins. Bacteriorhodopsins pump protons out 
of the cell causing hyperpolarization when inserted into a neuron and subsequently lead to 
neuronal inhibition. Inserted halorhodopsins cause hyperpolarization of neurons and neuronal 
inhibition by pumping negatively charged chloride ions into the cell. Channel-rhodopsins can 
either excite or inhibit neural systems when inserted into a neuron by allowing positively charged 
ions to flow into the cell or by chloride conduction, respectively (Deisseroth 2015). Early in its 
development, this groundbreaking method of neuromodulation has already demonstrated its 
ability to control the activity of specific mammalian neuronal populations with these engineered 
light switches (Boyden, Zhang et al. 2005). Shortly after, the modulation of a defined group of 
neurons in the hypothalamus, a structure deep in the brain, has been shown in freely moving 
mice (Adamantidis, Zhang et al. 2007). This research succeeded to show a causal relationship 
between frequent-dependent activity of these defined neurons and changes in the sleep-wake 
cycle as a behavioral outcome. Neuromodulation through optogenetics has continued to make 
remarkable progress over the past decade in animal models, illuminating the role of defined 
neural cell populations and their connectivity in healthy and disease-related states (Deisseroth 
2015). Recently, implantable wireless optogenetic devices have been developed, allowing for 
untethered complex behavioral research in rodents. For instance, wireless optogenetic activation 
experiments in mice demonstrated both central and peripheral neural activation. One research 
group was able to design fully internal miniature light-emitting implants with a minimum 
size of 10 mm^3. These implants are wirelessly powered through a resonant cavity, activating 
a micro-LED embedded in the construct with electromagnetic energy coupling (Montgomery, 
Yeh et al. 2015). Other research demonstrated fully implantable soft optoelectronic devices. For 
peripheral nerves, a soft stretchable film with an incorporated LED was used and for stimulation 
of the spinal cord stretchable filaments which are able to be inserted into the epidural space were 
designed. Their research states that in order to minimize the constructs, a dynamically moving 
antenna coupling radio-frequency (RF) radiation is needed (Park, Brenner et al. 2015).
However, scaling up wireless optogenetic stimulation for the use in larger rodents or poten-
tially even humans will remain a challenge since the amount of power required for RF-powered 
wireless optogenetic interfaces is considerably large. The need for an implanted light delivery 
device and the viral introduction of invertebrate genes, however, remain as the major challenges 
for clinical application of optogenetics. Furthermore, visible light needed to drive the inserted 
opsins is scattered and absorbed by neural tissue, thereby impeding its penetration into deep 
Chapter 5
90
brain regions in the absence of an invasive probe. These features hinder clinical application of 
optogenetics for neuromodulation in movement and neuropsychiatric disorders although recent 
translational efforts are underway. A recent study investigated a different approach of wireless 
optogenetics using NPs to serve as optogenetic actuators of transcranial near-infrared (NIR) 
light to stimulate neurons. In their experiments, upconversion NPs (UCNPs) were able to con-
vert NIR light into blue or green light with enough intensity to activate corresponding opsins in 
the surroundings of these UCNPs. Their results show that in transgenic mice expressing ChR2 
in the ventral tegmental area (VTA), in vivo neuronal activation is possible after the injection 
of UNCPs into the VTA and placing a NIR light probe 2 mm above the skull 4 weeks later. 
Furthermore, they demonstrated that neuronal silencing is also possible when using UCNPs that 
emit green light upon NIR light emission in transgenic mice expressing Arch in the hippocampus 
(Chen, Weitemier et al. 2018). These findings might be another different step towards wireless 
optogenetics, keeping in mind that the emission intensity of these particles decreased with an 
increase of the distance between the NIR light and UNCPs. Long distances might therefore pose 
a challenge. In non-human primates (NHP), the first optogenetics study showed the activation of 
neurons in the primary motor cortex upon optical stimulation (Han, Qian et al. 2009). Successive 
studies showed that optogenetics in NHP can also serve as a tool to modulate specific behavior, 
such as choice behavior when modulating dopamine activity and inducing saccadic dysmetria 
when stimulating cerebellar Purkinje cells (Stauffer, Lak et al. 2016, El-Shamayleh, Kojima et al. 
2017). In recent years, different disease models in transgenic primates have been added, which 
create opportunities to explore new optogenetic therapies (Liu, Li et al. 2016). In the field of 
ophthalmology, optogenetics is taking its first step into the clinics with a clinical trial in which 
researchers try to restore vision in completely blind patients by placing channelrhodopsin-2 into 
retinal ganglion cells (Schmidt 2017).
3.2. chemogenetics with dreadd
In chemogenetics, specific neurons are virally transduced to express DREADDs-genetically 
engineered G-protein coupled receptors (GPCRs) with high affinity to designer drugs, allowing 
for modulation of cellular functions through systemic administration of the drug. Clozapine 
N-oxide (CNO), is the most commonly used designer drug and is a pharmacologically inert 
metabolite of the antipsychotic drug clozapine (Armbruster, Li et al. 2007, Roth 2016). Following 
initial discovery in yeast, both excitatory and inhibitory DREADDs have been demonstrated. 
For enhancing neuronal firing, the Gq-DREADDs hM1Dq, hM3Dq and hM5Dq have been 
developed of which hM1Dq has been used the most. These DREADDs enhance neuronal activity 
by increasing intracellular calcium concentrations. The first study investigating the modula-
tion of neurons via hM1Dq demonstrated the activation of hippocampal neurons after CNO 
administration in hM1Dq-expressing mice (Alexander, Rogan et al. 2009). To inhibited neuronal 
activity, Gi-DREADDs hM2Di, hM4Di, and KORD are being used. Both hM4Di and KORD 
inhibited neuronal activity via hyperpolarization of the cell and synaptic silencing. HM4Di 
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is the mostly used inhibitory DREADD and the first study investigating its property showed 
neuronal silencing when incorporated into hippocampal neurons (Armbruster, Li et al. 2007). 
Furthermore, the DREADD GsD has been used to modulate plasticity via an increase in cAMP 
and the DREADD Rq(R165L) is used to enhance β-arrestin specific signaling (Roth 2016). Che-
mogenetics enables genetically-precise control of cellular activity in both superficial and deep 
brain regions and is less invasive compared to optogenetics. Its temporal precision, however, is 
limited by the pharmacokinetics of the designer drugs (Guettier, Gautam et al. 2009, Gomez, 
Bonaventura et al. 2017). Nevertheless, this promising approach has led to the discovery of sev-
eral behavioral circuits in rodents, including associative learning, memory and reward guided 
behavior. Moreover, it has been applied to various animal models of human disease, thereby 
enhancing its translational application (Urban and Roth 2015, Roth 2016, Whissell, Tohyama et 
al. 2016). In a chronic model of focal neocortical epilepsy in rats, it has been shown that virally 
introduced hM4Di into the seizure focus attenuates seizure frequency upon intraperitoneal CNO 
application. These results are promising as a possible intervention for intractable focal epilepsy 
(Katzel, Nicholson et al. 2014). Akin to opsins, DREADDs have recently been expressed in NHPs. 
Research done in rhesus monkeys demonstrated a repeatable disruption in relative reward value 
when the functional connection between two different brain regions, namely the orbitofrontal 
and rhinal cortices, was temporarily disrupted by inhibitory DREADD modulation (Eldridge, 
Lerchner et al. 2016).
Just recently, however, researchers have shown that not CNO but clozapine binds to DRE-
ADD. This finding might have implications for the interpretation of observed effects in previous 
research that used this technique. Based on the previous findings, it has been suggested that 
DREADD is an inaccurate name since the receptors are not activated by a designer drug nor 
are they exclusive. For future research, it has been proposed that scientists may simply apply 
clozapine as the actuator of this technique, keeping in mind to use proper controls. Clozapine 
is already an approved drug; nonetheless, due to its high affinity to various other receptors, 
scientists should use it at a low dose and carefully evaluate possible off-target effects (Gomez, 
Bonaventura et al. 2017).
Altogether, this technique seems promising, but still requires either the use of viral DREADD 
introduction or genetically engineered animals and its temporal precision is limited by slow 
pharmacokinetics. One advancement for DREADD could be the implementation of NPs as a 
safer alternative for gene delivery than viruses. Previous research has already shown cellular 
siRNA delivery with gold NPs and nanocarriers (Kakizawa, Furukawa et al. 2006, Elbakry, Zaky 
et al. 2009). This approach could simplify DREADD for clinical applications since now lentiviral 
delivery is one of its drawbacks.
3.3. ultrasonic neuromodulation
Ultrasound (US) is acoustic energy in the form of sound pressure waves at very high frequencies 
not audible to the human ear. It has been shown that these sound pressure waves can interact 
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with biological tissue, making US a well-known biomedical imaging modality. US can penetrate 
through the skull and be focused at specific regions deep within the brain without losing its 
signal. Focused ultrasound (FUS) can produce thermal and non-thermal effects depending 
on various parameters such as its frequency, intensity and exposure time. High-intensity FUS 
(HIFU) produces thermal effects on targeted tissue resulting in tissue ablation. A recently 
conducted randomized controlled clinical trial amongst patients suffering from ET showed that 
MRI-guided FUS lesioning of the thalamus resulted in an improvement in hand-tremor scores 
(Elias, Lipsman et al. 2016). HIFU has also been widely investigated as a form of cancer therapy 
including prostate, breast, liver, kidney, pancreatic cancer and bone malignancies showing mixed 
results (Hsiao, Kuo et al. 2016). Recently a study investigated whether adding MNPs to HIFU 
could enhance the thermal effects showing promising results (Devarakonda, Myers et al. 2017). 
In contrary to HIFU, low-intensity FUS has shown to be able to stimulate neuronal circuits by 
non-thermal (mechanical) effects without causing any neuronal damage. The first in vivo ex-
periments demonstrated that transcranial pulsed US to the motor cortex in anaesthetized mice 
could evoke motor behavior (Tufail, Matyushov et al. 2010). The following years, different brain 
circuits in various species have been modulated using transcranial FUS (tFUS), as reviewed in 
more detail elsewhere (Fini and Tyler 2017). In NHP, low-intensity FUS was able to modulate 
visuomotor behavior due to the disruption of information processing across the frontal eye fields 
(Deffieux, Younan et al. 2013). Also human applications of ultrasonic neuromodulation have 
already been investigated. In healthy volunteers it is shown that tFUS is able to produce changes 
in sensory-evoked brain activity. In these experiments, healthy volunteers were given median 
nerve stimulation while recording these sensory evoked brain oscillations. Subsequently tFUS 
was given, which caused suppression of the evoked somatosensory potentials (Legon, Sato et 
al. 2014). Other research showed that when stimulating the primary somatosensory cortex (S1) 
in healthy volunteers, a transient tactile sensation on the contralateral side of the stimulated 
hemisphere could be observed. Simultaneously EEG recordings showed sonication specific po-
tentials in the S1 (Lee, Kim et al. 2015). When stimulating the visual cortex with tFUS in healthy 
volunteers, a visual sensation could be evoked. Furthermore their results show that not only 
the sonicated brain area, but also other regions involved in visual processing were activated, 
demonstrated by simultaneously acquisition of blood-oxygenation-level-dependent functional 
MRI (Lee, Kim et al. 2016).
Ultrasonic neuromodulation is a promising technique since its application does not require the 
use of exogenous agents. However, the underlying mechanisms of FUS induced neuromodulation 
are still unclear. One hypothesis is that the mechanical force of FUS activates mechanosensitive 
ion channels embedded within cell membranes (Tyler 2012). The applied pressure waves may 
stretch or deform the cellular membrane altering the state of mechanosensitive ion channels 
embedded within these membranes leading to transmembrane currents and consecutive neural 
activity. Recent research elucidated that FUS is indeed capable of modulating sodium and potas-
sium mechanosensitive ion channels expressed in Xenopus oocytes resulting in transmembrane 
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currents (Kubanek 2016). Another research group introducing a technique called ‘sonogenetics’ 
showed that low pressure US is capable of inducing specific behavior in the Caenorhabditis el-
egans (c. elegans) by misexpressing a pore-forming subunit of the mechanotransduction channel 
TRP-4 (Ibsen, Tong et al. 2015). All these observations together make ultrasonic neuromodula-
tion an interesting non-invasive technique for future clinical application and we believe this 
field of neuromodulation will grow rapidly within the upcoming years. Future advancements in 
spatial resolution is expected to further improve this technique. One interesting finding is the 
combination of FUS with drug carrying NPs as is recently investigated in rats. In this research, 
ultrasound-gated NPs that encapsulated propofol were given intravascular and released their 
drug due to a conformation change of the NPs by FUS (Airan, Meyer et al. 2017). This enables 
a more targeting drug release. Additionally, FUS seems to be a promising method of delivering 
NPs to brain targets due to the possibility of BBB disruption on its own (Liu, Chen et al. 2011, 
Chu, Chai et al. 2016). Combining these two modalities could make the delivery of MNPs into 
the brain less invasive.
3.4. Magnetic neuronal control
Magnetic neuronal control is a recently discovered technique, which may hold promise as a clini-
cal neuronal activation approach since it does not require implantation of invasive electrodes or 
optical devices, it can penetrate into the brain and has a lower response latency than that achieved 
with drug delivery. Magnetic fields with magnitudes in millitesla range are able to penetrate into 
the brain without attenuation of the signal or given side effects because of the negligible magnetic 
susceptibility and low conductivity of biological tissue (Young 1980). Several research groups are 
investigating magnetic neuronal control by activating ion channels on membranes using purely 
the magnetic field itself or by the usage of transducers responding to this magnetic field such as 
MNPs. The latter can be subdivided into either magnetothermal activation, magnetomechanical 
activation and magnetoelectric activation. All will be discussed in detail.
3.5. transcranial magnetic stimulation (tMs)
TMS is a technique used for neuromodulation in which an electric current generated in a copper 
wire coil induces a non-invasive magnetic field able to penetrate thought the skull into brain 
regions directly below the coil. This magnetic field subsequently induces another electric current 
in the underlying brain capable of inducing neuromodulation. Since the magnetic field strongly 
decays with distance, TMS is mainly limited to cortical stimulation. Depending on the given 
stimulation protocol, TMS can induce immediate effects through stimulation and disruption and 
after-effects through neuroplastic changes when multiple consecutive magnetic pulses are given 
called ‘repetitive TMS’ (rTMS). A general belief is that low frequency rTMS causes long-term 
depression (LTD) in the underlying brain region while high-frequency rTMS causes long-term 
potentiation (LTP) (Klomjai, Katz et al. 2015). Nowadays, rTMS for major depression disorder if 
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FDA approved and other disorder such as stroke and OCD are investigated in research context 
(Demitrack and Thase 2009, Avenanti, Coccia et al. 2012, Elbeh, Elserogy et al. 2016).
One problem with rTMS is its variability between individuals generating a bimodal pattern of 
response with responders and non-responders to a certain given TMS protocol (Fitzgerald, Hoy 
et al. 2016). In some patients low-frequency rTMS has an inhibitory effect while in other patients 
it has an excitatory effect and vice versa. As a consequence, the responds to rTMS therapy is very 
patient-specific and applying multiple rTMS protocols might be necessary (Eldaief, Halko et al. 
2011).
To be less stressful and time consuming for the patient, shortening the time of a TMS pro-
tocol is desired. For this reason, theta-burst (iTBS) and accelerated rTMS protocols have been 
established. rTMS protocols last 30 to 45 minutes, while iTBS paradigms require 1 to 3 minutes. 
In iTBS, short trains of stimuli at a high frequency are repeated in intervals of 200 ms. In the 
THREE-D study, 3 minutes iTBS has shown to have equal effects to 37,5 minutes of high fre-
quency rTMS (Han, Chen et al. 2018). In accelerated rTMs protocols, multiple rTMS session 
are given within one day. Research has shown that accelerated rTMS given for depression can 
shorten the days of treatment in ‘fast responding’ patients, however other patients still need the 
extra days of treatment to show the same decline in BDI-II Scores (Holtzheimer, McDonald et 
al. 2010).
One recent advantage in TMS is the introduction of deep TMS (dTMS). DTMS uses so called 
‘H’ coils providing a magnetic field which penetrates deeper into the brain but automatically also 
generates a bigger field spread making the signal less specific. For this reason different ‘H’ coils 
are designed for different disorders. For Alzheimer disease, findings suggest some improvements 
in the Alzheimer’s disease assessment scale-cognitive subscale when treated with dTMS (Coppi 
2016). A possible refinement of this technique could be the combination of dTMS with MNPs to 
enhance or transduce the signal. Combining these two approaches might lead to the stimulation 
of more defined brain regions deeper in the brain.
3.6. Magnetic stimulation using transducers
Combining magnetic neuromodulation with transducers converting or enhancing the magnetic 
signal has indeed been done before. Magnetothermal activation uses AMFs to induce MNP heat-
ing through hysteresis and triggers heat-sensitive cation channels from the Transient Receptor 
Potential Vanilloid (TRPV) family causing depolarization and action potential firing (Huang, 
Delikanli et al. 2010, Stanley, Gagner et al. 2012, Chen, Romero et al. 2015, Munshi, Qadri et 
al. 2017). Magnetomechanical activation uses the force exerted by iron-containing particles or 
proteins tethered to the cell membrane in the presence of magnetic fields to trigger pressure 
sensitive receptors that convert this signal into neural modulation (Stanley, Sauer et al. 2015). 
Magnetoelectric activation uses magnetoelectric NPs composed of magnetostrictive core and 
a piezoelectric shell to generate local electric fields when exposed to an external magnetic field 
(Guduru, Liang et al. 2015, X. Chen and E. Siringil 2016). In contrast to standard DBS and TMS, 
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adding these transducers allows to operate on a nanoscale increasing its precision and region or 
cellular specific targeting.
The first study to establish remote neuronal control of cell function leveraged RF AMFs and 
MNP heating to activate the capsaicin receptor TRPV1, which resulted in the calcium influx 
into human embryonic kidney (HEK) 293 cells. The authors also showed that the MNP heating 
triggered behavioral responses in C. elegans (Huang, Delikanli et al. 2010). Other researchers 
investigating magnetic cellular activation demonstrated that modified TRPV1 receptors with 
extracellular antibody-coated iron oxide NPs could regulate protein production in vivo when 
exposed to a magnetic field. This work also indicated that a fusion of an iron-binding protein 
ferritin to TRPV enables control of calcium influx in vitro when exposed to a magnetic field 
(Stanley, Gagner et al. 2012). Based on these findings, several groups went on to investigate 
TRPV-ferritin fusion constructs in the context of magnetic manipulation of cellular function in 
behaving rodents (Stanley, Sauer et al. 2015, Stanley, Kelly et al. 2016, Wheeler, Smith et al. 2016). 
The mechanisms of neural modulation in these studies, however, remain poorly understood since 
ferritin is weakly paramagnetic and thereby the physical ability of this protein to activate TRPV 
by either thermal or mechanical stimuli appears unlikely (Meister 2016). Although a number of 
biophysical studies are currently underway (Duret 2017), several questions remain, including 
which mechanism is causing this neuronal activation, what is the extent of excitation, and which 
cell types are affected.
Magnetothermal activation in the mammalian brain was recently demonstrated by AMF 
induced bulk heating of MNP solution injected into the VTA of anaesthetized mice express-
ing TRPV1 following viral delivery (Chen, Romero et al. 2015). Hysteretic heating of MNPs 
in the presence of AMF activates TRPV1, which causes calcium ion influx into heat-sensitized 
cells and yields membrane depolarization and neural excitation. The latter suggests that such an 
approach could be a possible candidate for neuromodulation. As such, the first application of 
magnetothermal activation to control behavior of awake freely moving mice has been recently 
demonstrated (Munshi, Qadri et al. 2017). This work showed that magnetothermal stimulation 
of motor cortex evoked locomotor activity and stimulation of different parts of the striatum 
induced rotation or freezing-of-gate. The same research group recently showed MNP induced 
neuronal silencing. Hippocampal neurons were transfected with the chloride channel Anocta-
min 1 (TMEM16A) and spontaneous firing was suppressed using MNP induced heating opening 
this inhibitory channel (Munshi, Qadri et al. 2018).
The studies discussed above employed genetic tools to achieve TRPV1 expression in the given 
brain areas in mice. This ion channel is endogenously expressed in neurons in the mammalian 
central nervous system (CNS), which suggests that it can be a promising target for future inves-
tigations for delivery of magnetic neuronal control (Marinelli, Pascucci et al. 2005, Starowicz, 
Cristino et al. 2008, Sun, Guo et al. 2013, Terzian, dos Reis et al. 2014, Nam, Park et al. 2015).
To develop magnetic neuronal control for biomedical applications, leveraging endogenously 
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heating and TRPV1 may offer a route to clinical applications with a clear mechanism of stimu-
lation and without genetically engineered TRPV-ferritin fusion constructs (Fig. 2: Schematic 
view of magnetothermal DBS in human). Similarly, the use of magnetoelectric particles has the 
potential to improve upon resolution and cell-type specificity of traditional electrical DBS.
MNPs have already shown promising results in a variety of biomedical applications, ranging 
from cancer hyperthermia to magnetic resonance imaging, and wireless neuromodulation may 
be another intriguing possibility.
4. Magnetic nanoparticles
4.1. Biomedical applications
MNPs can be used in a wide range of biomedical application since they have several beneficial 
characteristics. Firstly, MNPs contain paramagnetic properties making them good candidates as 
contrast agents in imaging. For MRI, the MNPs can alter the relaxation mechanism of protons 
resulting in sharper images (Lee, Yoo et al. 2015). For fluorescence imaging quantum dot nano-
crystals are used as fluorophores emitting light when excited by long wavelengths as thoroughly 
reviewed elsewhere (Utkin 2018). Secondly, MNPs can be targeted toward specific tissue by the 
appliance of an external magnetic field or by coating the NPs with targeting moieties (Steichen, 
Caldorera-Moore et al. 2013). Thirdly, MNPs can be coated with therapeutic agents enhancing 
drug bioavailability while keeping the drug dose low (Latorre, Couleaud et al. 2014). Fourthly, 
MNPs can serve as transducers producing and or converting incoming stimuli. Hyperthermia 
is one of these examples being used in cancer therapy and to transiently increase BBB perme-
ability (Wankhede, Bouras et al. 2012, Wegscheid, Morshed et al. 2014, Tabatabaei, Girouard et 
al. 2015, Wang and Guo 2016). Furthermore, magnetomechanical destruction and heat transfer 
beneficial in cryosurgery can be accomplished by MNPs (Yu, Yi et al. 2014, Wang and Guo 2016). 
Combining multiple characteristics within the same particle to enable both imaging, diagnostic 
and therapy purposes is desired, and this concept is reviewed in more detail elsewhere (Gobbo, 
Sjaastad et al. 2015).
Several decades of research in nanomaterials have delivered a diversity of particles with dif-
ferent composition, structure, properties, and functions (Kateb, Chiu et al. 2011, Chen, Roy et 
al. 2016). MNPs constitute a class of NPs composed of magnetic materials. Some MNPs can 
undergo hysteretic power loss in externally applied AMF resulting in heat dissipation. Depend-
ing on the thermal dosage released by the MNPs, this remote-controlled heating can be used 
for tumor therapy that induces apoptosis of malignant cells or for neural activation as discussed 
above (Maier-Hauff, Ulrich et al. 2011, Chen, Romero et al. 2015). Combined with their utility 
for imaging and drug delivery, MNPs constitute a promising platform for nanotheranostics. With 
the new concept of magnetic neuronal control using MNPs, MNP heating for the purpose of 




MNPs are crystal structures with their linear dimensions in the order of 100th of nm or less 
(Mody, Siwale et al. 2010). For the purpose of MNP-heating in AMFs, their inorganic core needs 
to be composed of a magnetic material and their chemistry needs to be optimized to maximize 
heat dissipation under specific AMF conditions (Chen, Christiansen et al. 2016). The commonly 
used MNPs consist of magnetite phase (Fe3O4) of iron-oxide (Silva, Oliveira et al. 2011). The 
common methods of MNP synthesis are chemical coprecipitation, thermal decomposition, and 
microemulsion. In chemical coprecipitation, a mixture of Fe2+ and Fe3+ ions are submitted to 
hydrolysis forming magnetite precipitates. The particle-size depends on the ratio of different ions 
and the temperature during hydrolysis (Petcharoena K. 2012, Verma, Lal et al. 2014). Thermal 
decomposition is a process in which organometallic iron precursors are decomposed under 
high temperatures of up to 473 K. The advantages of this method compared to coprecipitation 
include superior control over chemical composition, size, and shape of the MNPs. The solvent 
in which the MNPs are synthesized greatly influences the consistency of magnetic properties of 
the particles, and optimizing the solvent’s redox activity is important for appropriate magnetic 
phases with desirable magnetic properties (Chen, Christiansen et al. 2016). Another approach of 
producing uniform size-controlled NPs is microemulsion. In this method Fe2+ salts are oxidized 
in a microemulsion in which the controlled temperature and added surfactant concentration 
determines the particle size. However, large amounts of solvent are necessary to synthesize 
substantial amounts of MNPs, which makes this process challenging to scale (Lee Y. 2005, Lu, 
Salabas et al. 2007, Laurent, Forge et al. 2008, Verma, Lal et al. 2014, Wegscheid, Morshed et al. 
2014).
4.3. particle coating
Besides an iron-oxide core, MNPs need a surface coating of a biocompatible material to ensure 
their solubility in aqueous physiological solutions, to minimize potential cytotoxicity, and to 
enhance their biocompatibility. Iron oxide can give iron-mediated radical formation and oxida-
tive stress in the brain if not coated, so adding coating is a must (Petters, Irrsack et al. 2014). 
However, it must be noted that coating can also limit characteristics of the particles such as 
heating, therefore choosing the right surface coating is critical. Various in vitro and in vivo stud-
ies have applied a variety of coatings including dextran, carboxydextran, glycosaminoglycan, 
N-(a-trimethyl ammonioacetyl)-didodecyl-D-glutamate chloride, and polyethylene glycol 
(PEG) (Laurent, Forge et al. 2008, Silva, Oliveira et al. 2011). For human studies, however, only 
aminosilane-coated MNPs have been used to date (Maier-Hauff, Rothe et al. 2007, Maier-Hauff, 
Ulrich et al. 2011). It is also important to consider possible coating effects on the particle’s phar-
macokinetics and biodistribution. Table 1 summarizes different types of MNP coating material 
for studies using magnetic hyperthermia. To induce target delivery of MNPs to specific cells, 
MNPs can be decorated with targeting moieties such as short peptides, binding proteins, and 
antibodies (Wankhede, Bouras et al. 2012, Shah, Pasquale et al. 2014, Wegscheid, Morshed et 
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al. 2014, Yin, Shah et al. 2014, Munshi, Qadri et al. 2017). These target moieties will recognize 
the cells of interest and only stimulate the neuronal cells in close vicinity due to a small span of 
signal transduction. While the majority of targeting strategies have been explored in the context 
of tumor therapies, similar approaches may permit targeting of specific neurons deep in the brain 
for neuromodulation (Gobbo, Sjaastad et al. 2015).
5. Mnps in the central nerVous systeM
5.1. delivery
In order to reach specific neurons in the brain, MNPs either need to cross the BBB or should 
be delivered directly into the brain via invasive means. Crossing the BBB remains a challenge 
for systemic delivery of MNPs and other substances due to its selective nature. For this reason, 
either direct intratumoral delivery or convection-enhanced delivery (CED) has been used in 
clinical applications of MNPs (Hadjipanayis, Machaidze et al. 2010, Maier-Hauff, Ulrich et al. 
2011). Although these methods allow for the delivery of high concentrations of MNPs or other 
therapeutic substances into the brain, they are invasive and carry a potential risk of hemorrhage 
and infection. Many ways to cross the BBB has been researched including intra-carotid arte-
rial infusion of hyperosmotic solutions, CNS vaccines, the lipidization of small molecules and 
receptor mediated transport all being inappropriate for nanoparticle transport (Pardridge 2007). 
Photodynamic therapy has also been investigated to increase BBB resulting into several studies 
showing a high accumulation of a photosensitizer into glial tumors (Stummer, Novotny et al. 
2000), but only scarcely detectable amounts in intact BBB of the rat (Madsen, Angell-Petersen 
et al. 2006). Notable, it was recently shown that MNP heating in brain capillaries can transiently 
increase BBB permeability without causing inflammation or neurovascular damage (Tabatabaei, 
Girouard et al. 2015). It seems that this technique offers promise as an approach to deliver MNPs 
or other substances directly into the brain with minimal invasiveness. Focused ultrasound in the 
presence of microbubbles provides another way to transiently increase BBB permeability (Chu, 
Chai et al. 2016). However, in the context of magnetic hyperthermia tumor therapy or magneto-
thermal neuromodulation, increasing the BBB permeability may not be sufficient and magnetic 
field gradients may be necessary to aid transport of MNPs across the disrupted BBB (Liu, Hua et 
al. 2010). Another way to transiently open the BBB has been demonstrated in patients suffering 
from malignant glia tumors. In this study, dTMS was able to increase the BBB permeability for 
contrast agents in 10 out of 15 patients. Increased BBB permeability was found not only directly 
in the tumor region but also peritumoral, in the ipsilateral and contralateral hemisphere (Vazana, 
Veksler et al. 2016). This method could be combined with the administration of NPs and might 
be a promising application for the future.
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5.2. Biodistribution, uptake and clearing
What happens with MNPs once they are in the CNS? A rodent study showed that intratumoral 
instillation of aminosilane-coated MNPs led to the formation of stable deposits, which allowed 
for repeated magnetic field treatments (Jordan, Scholz et al. 2006). For the purpose of neuro-
modulation, it has been shown that in mice NPs are distributed in extracellular spaces close to 
cell membranes and synaptic clefts, with a small fraction taken up by microglia and neuronal 
axons (Chen, Weitemier et al. 2018). In multiple mice studies NPs seem to minimally disperse 
within one month after injection (Chen, Romero et al. 2015, Chen, Weitemier et al. 2018). 
Several other research groups have demonstrated that activated microglia in vitro can display 
macrophagic properties and internalize MNPs primarily into vesicles, albeit the fate of MNPs 
following macrophagic internalization remains to be investigated (Rogers and Basu 2005, Ribot, 
Bouzier-Sore et al. 2007). Furthermore, research showed that coating MNPs with PEG prevents 
non-specific cellular MNP uptake when incubated in human plasma (Schottler, Becker et al. 
2016). A group investigating magnetoelectric NPs in human astrocyte cells and peripheral blood 
mononuclear cells showed that there is no significant toxicity of these particles when analyzed 
with a Cell Proliferation Assay Kit (XTT) (Guduru, Liang et al. 2015). Post mortem analysis 
of patients treated with magnetic hyperthermia for glioblastoma multiforme (GBM), the most 
aggressive malignant form of brain cancer, revealed that the majority of MNPs were aggregated 
in areas of necrosis within the tumor and largely distributed around the site of instillation. The 
survival of patients after MNP-injection ranged from two weeks to 7.9 months. The MNPs at 
the border of the aggregates were internalized mainly by macrophages (95%) and only a few by 
tumor cells (5%) (van Landeghem, Maier-Hauff et al. 2009). The larger clinical trials investigat-
ing MNP heating for GBM did not explicitly report the location of the MNPs after a certain 
exposure time (Maier-Hauff, Ulrich et al. 2011). Further research is warranted to investigate the 
long-term effects and clearance of MNPs.
6. Mnp heating and its applications in the BioMedicine 
and neuroscience
6.1. Thermal dosage
MNPs dissipate heat when exposed to an AMF (Maier-Hauff, Rothe et al. 2007, Nair, Nagaoka et 
al. 2010, Maier-Hauff, Ulrich et al. 2011, Silva, Oliveira et al. 2011, Wankhede, Bouras et al. 2012, 
Lee Titsworth, Murad et al. 2014, Rivet, Yuan et al. 2014, Schaub, Rende et al. 2014, Verma, Lal et 
al. 2014, Wegscheid, Morshed et al. 2014, Dan, Bae et al. 2015, Tabatabaei, Girouard et al. 2015). 
Prolonged local rise in temperature above the normal body temperature is applied in cancer 
therapy to induce apoptosis in malignant cells. When applied in conjunction with standard 
treatments, MHT using MNPs enhances the overall survival rate of patients following diagnosis 
of first tumor recurrence of GBM (Maier-Hauff, Ulrich et al. 2011). Applied AMF parameters 
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can be adjusted in order to decrease the thermal dosage delivered by MNPs, thereby making the 
heating signal suitable for neuromodulation without inducing cell damage. Importantly, when a 
MNP solution was employed for magnetothermal neural excitation in the ventral tegmental area, 
only the neurons within a 200 µm border experienced local heating and no significant damage 
was observed following repeated cycles of AMF exposure (Chen, Romero et al. 2015).
MNP heating originates from hysteresis when the particles are exposed to an AMF with a 
given field frequency and amplitude. The amount of heat released by a MNP during one cycle 
of an AMF equals to the area of its hysteresis loop. The amount of heat produced by MNPs 
in a given AMF depends on their properties, such as the magnetic anisotropy, the saturation 
magnetization, its volume, and the magnetic interactions between the particles. The MNP heat-
ing efficiency can be quantified either by the specific loss power (SLP), which refers to the power 
achievable per gram of iron in the MNPs at a given AMF, or by the specific absorption rate (SAR), 
which refers to the amount of energy converted into heat per time and mass. Both metrics are 
expressed in watts per gram. Table 1 summarizes studies that used MNP heating for either GBM 
therapy, cellular or neuronal modulation, showing SLP and SAR for particular MNPs and AMF 
parameters used.
This table shows different articles investigating MNP heating in either GBM therapy, cellular 
or neuronal modulation. It states the composition of the MNPs, the AMF parameters used and 
the amount of energy produced by their MNPs in their experiments.
6.2. treatment of brain cancer
In clinical trials for the treatment of recurrent GBM, an aqueous MNPs dispersion is instilled 
within the tumor using neuronavigation. Postoperatively, the patient is placed in an alternating 
magnetic field applicator MFH 300F causing an AMF and subsequent MNP heating within the 
tumor. Results from Maier-Hauff et al show that the intratumoral median temperature following 
AMF varied between 39-51.2°C with a maximum intratumoral temperature of 82°C (Maier-
Hauff, Rothe et al. 2007, Maier-Hauff, Ulrich et al. 2011). The maximal duration of hyperthermia 
lasted for 60 minutes per session, which was enough to produce a cytotoxic effect in the tumor 
cells. Hyperthermia treatment consisted of six semi-weekly treatment sessions, combined with 
stereotactic radiotherapy. In a rat model of GBM, 40 minutes of AMF was already sufficient to 
cause this cytotoxic effect (Jordan, Scholz et al. 2006). Comparisons between treatment para-
digms are summarized in table 1.
6.3. The path towards neuromodulation
The application of MNP heating for cellular activation and neuromodulation requires a lower 
thermal dosage and median increase in temperature, as compared to hyperthermia used for GBM 
treatment (Table 1). As a consequence, optimization strategies for MNP properties and AMF 
parameters differ between the two applications. In the study by Chen et al. 2015, the combination 
of high MNP SLPs and short 10 second AMF stimulation pulses enabled a rapid raise in median 
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table 1. Materials chemistry of MNPs used for hyperthermia in either GBM therapy, cellular of neuronal mod-
ulation and the AMF parameters used.
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temperature up to 43°C with a maximum increase to 45°C. During the 50 seconds rest epochs, 
the tissue cooled back down to 37°C. This short intermittent exposure to AMF induced neural 
activation and prevented the harmful heating of cells by prolonged AMF exposure, thereby avoid-
ing cytotoxicity (Table 1). In the study of Munshi et al. 2017, the combination of high MNP SLPs 
and three to four one-minute stimulation epochs during a 10-15 minutes experiment enabled 
control of motor behavior in mice while avoiding brain tissue damage. Their results show that 
magnetothermal stimulation of the motor cortex elicited running. Magnetothermal stimulation 
of the striatum caused rotation around the body axis, while stimulation of the ridge between 
dorsal and ventral striatum caused freezing of gait. Furthermore, their findings demonstrate 
short latencies between starting or terminating the AMF stimulation and the observed behavior 
(Munshi, Qadri et al. 2017). These reports show that a short intermittent AMF stimulation 
induces well dosed and temporarily precise MNP heating, which is the key to safe and effective 
magnetic neuromodulation.
table 1. Materials chemistry of MNPs used for hyperthermia in either GBM therapy, cellular of neuronal mod-
ulation and the AMF parameters used. (continued)
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7. adVerse effects of Mnp heating
Adverse effects of MNP heating are subject of vigorous investigation. Clinical research for MHT 
in GBM treatment indicated that adverse effects, such as swelling of the brain and rise of intra-
cranial pressure, could be avoided by very slow injection of the magnetic fluid (Maier-Hauff, 
Rothe et al. 2007). In these studies, moderate adverse effects included sweating (50%), a general 
sensation of warmth in the treated area (47.0%), headaches during hyperthermia (13,8%), focal 
convulsions (22.7%), motor disturbances (21.2%), and perifocal edema (9%). Focal convulsions 
stemmed primarily from a pre-existing hemiparesis. Only 2% of the patients who experienced 
motor disturbances or focal convulsions had developed these side effects during MHT. Despite 
worsening of pre-existing hemiparesis, none of the side effects persisted in the long term, and 
their physiological origins remain unclear (Maier-Hauff, Ulrich et al. 2011).
Another adverse effect of increased temperature could be the aggregation of the MNPs. A 
study investigating citrate-coated-iron- oxide MNPs, observed accelerated aggregation of the 
particles following hyperthermia in vitro. This clustering of MNPs can change their magnetic 
properties and cause occlusion when administered into a blood vessel (Wegscheid, Morshed et 
al. 2014). This could have great disadvantageous clinical consequences, therefore preventing this 
is utterly important. Surface chemistry plays a significant role in avoiding MNP aggregation so a 
carefully designed surface passivation is essential for clinical efficacy of MNPs.
table 1. Materials chemistry of MNPs used for hyperthermia in either GBM therapy, cellular of neuronal mod-
ulation and the AMF parameters used. (continued)
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The effects of magnetic hyperthermia on the viability of healthy neurons greatly differ among 
different MNP studies. For MHT on healthy rat astrocytes, it has been found that stimulating 
for 2 consecutive hours led to decreased astrocyte viability, even at physiological temperatures 
(Schaub, Rende et al. 2014). Another study found that 2 hours exposure of healthy chick em-
bryonic cortical neurons to hyperthermia did not yield any negative effects (Rivet, Yuan et al. 
2014). Intermittent magnetothermal stimulation of healthy neurons in the VTA of mice showed 
no difference in neuronal or glial density between stimulated and non-stimulated groups (Chen, 
Romero et al. 2015). Therefore, the effects of magnetic hyperthermia on neuronal viability de-
pend for a large part on MNPs composition, magnetic field stimulation paradigms, the interval 
of increased temperature, the maximum increased temperature reached, and the type of tissue 
stimulated. On top of that, such results highlight the importance of conducting studies that 
directly compare neuronal viability outcomes using the same magnetic stimulation paradigms.
Another area lacking experimental investigation is the long-term effect of MNP-heating on 
microvasculature. It is plausible that the nearby microvasculature adapts to repetitive exposure 
of heat and, therefore, should be taken into consideration.
Due to the dearth of studies and lack of consistency between MNP chemistries, AMF param-
eters, as well as exposure paradigms, toxicological data concerning hyperthermia with MNPs 
remain inconclusive (Table 1) (Nano, Lascialfari et al. 2012, Wankhede, Bouras et al. 2012). 
Some evidence point in the direction of astrocytic mitochondrial stress and attachment defects 
after nanoparticle administration in vitro (Au, Mutkus et al. 2007). In patients treated with MNP 
heating for GBM, key parameters for iron metabolism were determined before and after the 
administration of MNPs, showing no indication of iron release from intratumoral deposits or 
iron being metabolized (Maier-Hauff, Ulrich et al. 2011). Nonetheless, the long-term toxicologi-
cal effects of NPs located in the CNS and their clearance require further investigation, in which 
different magnetic stimulation parameters should be taken into account as well.
8. future challenges for Mnp induced 
neuroModulation
Magnetic coils suitable for cancer hyperthermia and magnetothermal neuromodulation in 
rodents can be engineered to efficiently generate appropriate AMF conditions over small experi-
mental volumes (Attaluri, Kandala et al. 2015, Kossatz, Grandke et al. 2015, Christiansen, Howe 
et al. 2017, Munshi, Qadri et al. 2017). Scaling AMF coils to volumes necessary for neuromodula-
tion or tumor therapy in deep brain regions of human patients present a formidable challenge, as 
the power requirements to achieve comparable AMF conditions increase substantially. Despite 
these challenges, recent engineering efforts build upon techniques in the field of power electron-
ics to pave the way toward development of scaling approaches for AMF coils (Lacroix, Carrey et 
al. 2008, Christiansen, Howe et al. 2017). The next step for this neuromodulation approach could 
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be the implementation of magnetic neuronal control into different animal models mimicking 
human diseases such as PD and upscaling the size to non-human primates. For instance, MNPs 
injected into the STN expressing TRPV1 of 6-OHDA rats, a rat model of PD, could possible 
revert Parkinson’s-like behavior such as circling motor abnormalities upon stimulation. Another 
robust experiment could be the injection of MNPs into the VTA expressing TRPV1 to modulate 
both rewarding and aversive drug-dependent behavior.
A different approach for MNP induced neuromodulation could be by the usage of dTMS. 
dTMS is able to penetrate slightly deeper in the brain than TMS, however deep brain regions 
such as the STN can still not be reached. One possibility could be to combine dTMS with the 
usage of MNPs. The magnetic field might not be strong enough to modulate the tissue on its 
own but added MNPs might be able to detect the magnetic signal, transducing it into a signal 
for neuromodulation. The challenge here remains making MNPs that respond to low frequencies 
or a TMS device working at frequencies in the kHz range. So far, the MNPs discussed above are 
activated by frequencies in the kHz range while dTMS for MDD works at a frequency of 18 Hz 
(Tendler, Barnea Ygael et al. 2016).
Other forms of neuromodulation such as optogenetics and DREADD can incorporate the 
usage of MNPs for a more wireless approach and to incorporate genes virus free making it more 
clinically applicable.
To get MNPs and or drugs into a desired brain region, FUS or dTMS seem to be a promising 
candidates. Both are capable of transiently increasing BBB permeability and future research 
combining these techniques with targeting neuromodulation using moieties need to prove its 
feasibility.
9. conclusion
Current techniques of neuromodulation are limited as they require permanent implants, are 
invasive, lack cell-type specificity, have limited penetration depth into different brain regions, 
or rely on slow pharmacokinetics. Refinements are needed and are slowly making their entrance 
into the field. DBS is a neuromodulation technique already widely used in the clinics but inter-
feres with both pathological and physiological neural activity due to its lack in cell-specificity 
causing unwanted side-effects in some patients. At the moment mostly continuous stimulation 
is given, but promising improvements like aDBS and CR DBS are now being investigated. For 
optogenetics, the limitation is the need of visible light through an invasive probe to drive neu-
rons. Nonetheless, refinements are on the way using other actuators like NPs to convert the light 
signal and overcome invasive light probes. Also, small, fully implantable, optoelectronic devices 
converting RF radiation into visible light are now being researched. Chemogenetics, still requires 
DREADD introduction via viral components or genetic engineering and is mostly limited in 
temporal precision due to slow pharmacokinetics of the administered drug. Since the actuator 
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of DREADD is now assumed to be Clozapine instead of CNO, previous study results need to be 
interpreted with caution. Nanoparticle-based gene delivery could circumvent the need of viruses 
in DREADD, making it more convenient for clinical applications. Ultrasonic neuromodulation 
seems a promising technique not needing permanent implants and being less invasive than the 
aforementioned techniques. These sound pressure waves can penetrate the skull and interact 
with deep brain structures without losing its signal, making it an interesting candidate for clini-
cal neuromodulation purposes. Furthermore, it can disrupt the BBB, making it an interesting 
candidate to deliver NPs and or NP encapsulated drugs into the brain. Magnetic neuronal control 
is another promising technique since it also does not require the implantation of invasive elec-
trodes or optical devices. With this method, stimulation of deep brain regions is possible because 
of the negligible magnetic susceptibility and low conductivity of biological tissue. In addition, 
this technique has a faster response rate than that achieved with drug delivery.
Subsequently, we discussed the application of MNPs for nanomaterial-mediated neuromodula-
tion in more detail and compared this application method to the current use of these particles in 
treating recurrent GBM. The application of MNPs as transducers of magnetic field into thermal, 
electrical, mechanical or chemical stimuli offers a possibility to remotely and wirelessly modulate 
specific groups of cells in arbitrarily deep regions of the brain. Magnetothermal stimulation ap-
plication of AMF pulses only causes a short and modest temperature increase, which modulates 
cells whilst avoiding cytotoxicity due to prolonged exposure. Further research should implement 
this new technique in various animal models of signs and symptoms as expressed in mental, neu-
ropsychiatric, neurosensory and neurodegenerative disorders in order to restore physiological 
brain functions and to define the therapeutic value of magnetothermal DBS in these disorders.
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7 Endogenous TRPV1 expression in the human cingulate- and medial frontal gyrus
Milaine Roet, Anne Jansen, Govert Hoogland, Yasin Temel and Ali 
Jahanshahi




Background: The transient receptor potential vanilloid subtype-1 (TRPV1) channel is a calcium 
selective ion channel that responds to various stimuli such as heat, low pH, and capsaicin. Re-
cently this channel was studied as an actuator for wireless neuromodulation in rodents, e.g., heat-
induced activation of TRPV1 resulted in neuronal excitation. From a translational perspective, 
we addressed if TRPV1 is endogenously expressed in the human medial frontal gyrus (MFG) 
and cingulate gyrus (CG) in depressed and control subjects and if it can be used as a means for 
neuromodulation in mood and also other neuropsychiatric disorders.
Methods: We assessed TRPV1 expression levels by Western blotting and evaluated its tissue 
and cellular distribution by means of immunohistochemistry.
results: TRPV1 was observed in all tissue samples, i.e., depressed and control, MFG and CG, 
yet the expression level as assessed by Western blotting varied between individuals. No intra-
individual differences were seen between the MFG and CG. Immunohistochemistry showed that 
TRPV1 was expressed by glial-like cells but also in neurites, endothelial cells, and to a lesser 
extent in neuronal cell bodies. Fluorescent co-labeling of TRPV1 and glial fibrillary acidic pro-
tein (GFAP) identified most glial cells expressing TRPV1 to be astrocytes.
conclusion: These findings indicate that TRPV1 is endogenously expressed in the human CG 
and MFG. As TRPV1 is predominantly expressed by glial cells, this may suggest an opportunity 
for non-neuronal network modulation.
131
Endogenous TRPV1 expression in the human cingulate- and medial frontal gyrus
7
1. introduction
The transient receptor potential vanilloid subtype-1 (TRPV1) is a subfamily of the transient 
receptor potential cation channels and functions as a molecular integrator for multiple types 
of sensory input. It is selective for calcium ions and responds to capsaicin, noxious heat, low 
extracellular pH, divalent cations, and particular toxins [1]. TRPV1 has been described in the 
peripheral pain pathway where the receptor can initiate nociceptive signaling by generating a 
receptor potential [2]. In addition to peripheral expression, various reports state that TRPV1 
can be found in the brain [3]. Recently TRPV1 was used as an actuator for neuromodulation in 
mouse brain [4]. However, due to low endogenous expression of TRPV1 in the central nervous 
system of rodents, the TRPV1 channel was introduced with lentiviral delivery. This method of 
neuromodulation seems to be a promising approach for future clinical application, although 
lentiviral delivery of TRPV1 might be undesirable.
To explore the possible clinical use of TRPV1 for neuromodulation we investigated if TRPV1 
is endogenously expressed in the human brain. A sufficient expression of TRPV1 in neurons 
is necessary for this technique to work properly. We focused on subjects with depression since 
TRPV1 channels have been implicated in depression and anxiety [5-9].
We investigated the medial frontal gyrus (MFG) and cingulate gyrus (CG) of subjects whom 
experienced depression in their medical histories and compared them to non-demented control 
subjects. The MFG, which is part of the dorsolateral prefrontal cortex, is hypoactive in MDD 
while the CG is hyperactive in MDD [10, 11]. Therefore, these brain regions are potential targets 
for neuromodulation. In this paper we aim to examine whether TRPV1 is sufficiently expressed 
in these brain regions to be considered as a target for neuromodulation.
abbreviations: DBS; deep brain stimulation, CG; cingulate gyrus, GFAP; glial fibrillary acidic 
protein, MDD; major depressive disorder, MFG; medial frontal gyrus, PD; Parkinson’s disease, 
SN; substantia nigra, TRPV1; transient receptor potential vanilloid subtype 1.
2. Materials and Methods
2.1. subjects
Fresh-frozen and paraffin embedded brain tissue of depressed and control subjects containing 
the CG and MFG were provided by the Netherlands Brain Bank (NBB) (Table 1). As a posi-
tive control, we used temporal neocortical tissue of an epileptic patient provided by Maastricht 
UMC+ (MUMC+) for an abundant expression of TRPV1 in patients with mesial temporal lobe 
epilepsy has been reported earlier [12]. All experiments have been carried out in accordance with 





Western blot analysis was performed to investigate and compare TRPV1 expression in the CG 
and MFG of depressed and control subjects. Fresh frozen brain tissue was cut on a cryostat 
and lysed in homogenization buffer (1 g/ 9 mL) containing 10% protease inhibitor (cat. no. 
11697498001; Roche). Total tissue lysates were centrifuged at 12,000 rpm for 10 min at 4°C. Pro-
tein concentrations in the supernatants were estimated using the Lowry protein assay (Bio-Rad). 
Odyssey protein molecular weight marker and samples (100 μg/lane) were loaded onto a 4% 
stacking gel (acrylamide/Bis 29:1, 1M Tris-HCl pH 6.8, 20% SDS, 10% APS, TEMED) / 8% run-
ning gel (acrylamide/Bis 29:1, 3M Tris-HCl pH 8.8, 20% SDS, 10% APS, TEMED). The resolved 
proteins were transferred onto a PVDF membrane using a mini-protein transfer system (Bio-
Rad) at 100 V for 2 h in transfer buffer (1.4% glycine, 0.3% trizma base, 20% methanol). Next, 
membranes were blocked for 1 h at room temperature (RT) with Odyssey blocking buffer (cat. 
no. 927-40003; LI-COR) and then incubated overnight at 4°C with primary antibodies (mouse 
anti-glycerylaldehyde-3-phosphate-dehydrogenase (GAPDH) (1:1,000,000, cat. no. 10R-G109a; 
Fitzgerald) and rabbit anti-TRPV1 (1:1,000; cat. no. PA1-748; Thermo Fisher Scientific) diluted 
in Odyssey blocking buffer. The following day, the membranes were washed and subsequently 
incubated with secondary antibody (goat anti-rabbit IR Dye 800 CW, Alexa 488 (1:10,000, 925-
32211; LI-COR) and donkey anti-mouse IR Dye 680, Alexa 700 (1:10,000, 925-68072; LI-COR) 
for 1 h at RT in the dark. After washing, the membranes were dried between filter paper and 
analyzed using an Odyssey scanner.
To validate TRPV1 specificity and to visualize TRPV1 degradation products, one membrane 
was stained with anti-TRPV1 (1:1,000; cat. no. PEP-202; Thermo Fisher Scientific) that was 
preabsorbed with TRPV1 synthetic peptide (1:1).
Optical densities (OD) of TRPV1 for each sample were calculated relative to the GAPDH 
protein band in that same sample with the use of the program ImageJ. To plot TRPV1 degrada-
tion against post-mortem delay, we calculated the ratio of the relative OD of TRPV1 degradation 
products and TRPV1 degradation products together with intact TRPV1.
table 1. Clinical characteristics of the subjects in the NBB samples.
subject
no.
diagnosis gender age (years) resected tissue amyloid Braak post-mortem delay
P1 Depression F 84 MFG O 2 08:45
P2 Depression M 89 CG O 1 04:35
MFG
P3 Depression F 66 CG O 1 07:55
MFG
P4 Non-demented control F 84 MFG A 2 05:36
P5 Non-demented control M 89 CG O 2 06:50
MFG
P6 Non-demented control F 82 CG A 1 07:45
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2.3. immunohistochemistry
Paraffin-embedded tissue was cut into 5 μm thick sections using a microtome.
All sections were deparaffinized followed by antigen retrieval in boiled citrate buffer (10 
mmol) for 10 min and allowed to cool down a consecutive 20 min. Sections were blocked for en-
dogenous peroxidase activity using a 0.3% H2O2 in TBS solution for 30 minutes. After washing, 
primary antibody was added overnight at 4°C (TRPV1; 1:100 or 1:200; cat. no. PA1-748; Thermo 
Fisher Scientific). The following day, all sections were incubated with secondary antibody for 1 h 
at RT (biotinylated donkey anti-rabbit; 1:200; cat. no. 711-065-152; Jackson ImmunoResearch). 
All sections were then washed and stained with an ABC kit (1:400; cat. no: PK-6100; Vector 
Labs) followed by an incubation in DAB-NiCl (1 DAB : 1 Tris-HCl, 0.5 % NiCL); cat. no: d5637-
10g; Sigma-Aldrich) for 10 min. After washing, the sections were dehydrated in ethanol and 
coverslipped with Pertex. Photomicrographs were taking using an AX-70 microscope (Olympus 
Provis) and Cell^P software.
2.4. immunofluorescence double-labeling
For immunofluorescence all sections underwent deparaffinization and antigen retrieval as 
described above. The primary antibodies were added overnight at 4°C (TRPV1; 1:50; cat. no. 
PA1-748; Thermo Fisher Scientific and anti-GFAP, 1:50, G3893; Sigma-Aldrich). The next day 
secondary antibodies were added for 1 h at RT (for TRPV1; donkey anti-rabbit Alexa 647 (1:100, 
cat. no. A-31573, Invitrogen), for GFAP; donkey anti-mouse Alexa 488 (1:100, cat. no. A-21202, 
Invitrogen)). All sections were washed and stained with Hoechst (1:500). A final step of 10 min 
incubation with Sudan black (0.5% in 100% ethanol) at RT in the dark was done to prevent 
autofluorescence from lipofuscin. All sections were coverslipped with glycerol. Microscopy was 




Results showed an immunoreactive band of 95 kDa in control tissue and the MFG and CG in 
both depressed and control subjects (Fig. 1 and supplementary Fig. 1).
Pre-absorption of the anti-TRPV1 antibody with synthetic peptide resulted in a loss of the 95 
kDa immunoreactive band. In addition, this condition also resulted in the loss of several lower 
immunoreactive bands (supplementary Figs. 2 and 3). Analysis of the OD showed a high inter-
individual variability of the 95 kDa immunoreactive band and thus TRPV1 expression (Fig. 2).
Relative OD values were compared between the CG and MFG regions of all subjects. For the 
CG, both samples from the depression group showed a higher relative OD as compared to the 
controls. However, a univariate ANOVA showed no significant difference in the interaction effect 
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between regions and the subjects state (depression vs control; p=0.442). No diff erences were 
found for the MFG region (Fig. 3).
In subjects of whom we were able to investigate both the CG and MFG, no signifi cant diff er-
ence in relative OD values of TRPV1 expression was found (n=3; Student’s paired t-test p=0.083; 
Fig. 4). For the other subjects either the CG or MFG was not available for research.
We found a moderate negative correlation between the post-mortem time and the expression 
level of TRPV1 (Spearman correlation coeffi  cient rs=-.456). A short post-mortem time of 4.5 h 
resulted in 91.48% degradation of TRPV1 95 kDa into 50-75 kDa bands compared to 99.34% 
with a post-mortem time of 7 h (Fig. 5).
figure 1. Western blot trpV1 expression. Western blot of TRPV1 expression per subject and brain region. 
CG: cingulate gyrus, MFG: medial frontal gyrus, Con: Control, Dep: depressed, P#: subject number.
figure 2. individual trpV1 expression levels. Th e individual TRPV1 relative OD values per subject and 
brain region represented by bar charts. CG: cingulate gyrus, MFG: medial frontal gyrus, Con: Control, Dep: 
depressed, P#: subject number.
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3.2. immunohistochemistry and double immunofl uorescence labelling
To investigate in which cell types TRPV1 is expressed we executed immunohistochemistry and 
double immunofl uorescence labelling on paraffi  n-embedded tissue of the CG and MFG of the sub-
ject that showed the highest TRPV1 expression in the western blots. We observed a high TRPV1 
expression in glial-like cells in both the CG and MFG (Figs. 6 and 7), endothelial cells in the 
CG and MFG, neurite structures in the CG, and to a lesser extend in the MFG and neuronal cell 
bodies in the CG and MFG. Neuronal cell bodies were found scarcely and stained less intensely 
than the others mentioned structures (Figs. 6 and 7).
Fluorescent double labelling revealed TRPV1 co-expression with GFAP containing cells both 
in the CG and MFG (Fig. 8).
figure 3. diff erences in trpV1 expression levels between depression and control within one brain region. 
Relative OD values measured in a) the depression (n=2) and control group (n=2) in the CG. b) the depression 
(n=3) and control group (n=2) in the MFG. Each dot represents one individual value and the average is repre-
sented with a horizontal line. CG: cingulate gyrus, MFG: medial frontal gyrus.
figure 4. relative od values of the cg and Mfg in the same subjects. Th e relative OD values of TRPV1 




figure 5. trpV1 degradation and post-mortem delay. Th e amount of degraded TRPV1 and post-mortem 
delay per subject and brain region represented by bar charts. Degraded TRPV1 is represented as a percentage 
by calculating the ratio of the relative OD of 50-75 kDa : (the relative ODs of 50-75 kDa + 95 kDa).
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sections containing the CG from subject #2. Note the expression of TRPV1 (1:200) in cells with a morphological 
like appearance of a) glial cells, b) dendritic structures in white matter, c) endothelial cells, and d) neuronal cells. 
Th e images were acquired using a 40x objective. Th e scale bar of 50 μm is applicable to a, b, c, and d. Insets in the 
upper right corner: photomicrograph of cells indicated by the arrow at 100x magnifi cation.
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figure 7. cellular distribution of trpV1 in the Mfg. Representative photomicrographs of anti-TRPV1 
stained sections containing the MFG from subject #2. Note the expression of TRPV1 (1:200) in cells with a mor-
phological like appearance of a) glial cells, b) dendritic structures in white matter, c) endothelial cells, and d) 
neuronal cells. Th e images were acquired using a 40x objective. Th e scale bar of 50 μm is applicable to a, b, c, and 
d. Insets in the upper right corner: photomicrograph of cells indicated by the red arrow at 100x magnifi cation.
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In the present study we showed that the TRPV1 channel was expressed in both the CG and MFG 
of subjects with a history of depression as well as controls. No differences in TRPV1 expression 
levels were found between the depression and control groups. However, strong inter-individual 
differences in TRPV1 expression level were detected. Immunohistochemistry revealed TRPV1 
expression in morphologically glial-like cells, endothelial cells, neurites, and neurons. In addi-
tion, fluorescent double labeling showed abundant co-expression of TRPV1 with GFAP indicat-
ing its expression in astrocytes.
The TRPV1 channel has been implicated in depression and anxiety in rodents before [8]. How-
ever, TRPV1 expression in the human brain has only been reported scarcely [12]. In rodents, 
the function of TRPV1 in depression has shown some contradictory results. Reports have stated 
both antidepressant-like and depressant-like effects when activating TRPV1 channels [7-9]. In 
this study, TRPV1 did not seem to significantly differ between the depressed and control groups, 
indicating that TRPV1 expression is neither up- nor downregulated in depression. Nevertheless, 
it should be noted that as we studied post-mortem tissue a potential in vivo difference may have 
been missed. Furthermore, within subjects no differences were found in TRPV1 expression be-
tween the CG and MFG, although only three subjects were examined due to scarcity of available 
tissue.
In this study, in addition to observing the presence of TRPV1 in our western blots, pre-
absorption with anti-TRPV1 resulted in the absence of not only the 95 kDa but also several lower 
immunoreactive bands. This illustrates that the 95 kDa band is TRPV1 specific and that the few 
bands below the 95 kDa are most likely degradation products of TRPV1. Additionally, we found 
a moderate negative correlation between the post-mortem time and TRPV1 expression indicat-
ing that TRPV1 is an unstable protein sensitive to degradation. We therefore conclude that the 
interpretation of post-mortem TRPV1 expression levels needs to be done with precaution.
Immunohistochemistry showed that TRPV1 is expressed in presumably glial cells, neurites, 
endothelial cells, and neuronal cell bodies. Neuronal expression of TRPV1, however, was rather 
scares. More abundant TRPV1 expression was seen in astrocytes, shown by the co-labeling of 
TRPV1 and GFAP. Expression of TRPV1 in microglia was also considered, but given the fact that 
microglia cells are much more mobile than astrocytes, we did not consider them stable enough 
to fulfill the purpose of neuromodulation. For this reason TRPV1 expression in microglia cells 
was not studied. TRPV1 expression in astrocytes in rats and humans has been shown before [13]. 
Research stated that TRPV1 in astrocytes can mediate the production of ciliary neurotrophic fac-
tor inhibiting the degeneration of nigral dopaminergic neurons in rodent models of Parkinson’s 
disease (PD). Furthermore, PD individuals express more TRPV1 and GFAP in their substantia 
nigra compared to healthy subjects [13]. Given these results, astrocytic TRPV1 might play a 
more crucial role than previously expected.
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DBS outcomes have thus far mainly been attributed to a direct effect on neural elements. How-
ever, there is a growing insight into the role of astrocytes in neuronal communication and DBS 
[14, 15]. Astrocytes communicate with neurons via so called ‘tripartite synapses’ and potentially 
participate in synaptic transmission through Ca2+ and gliotransmitter signaling such as ATP [14, 
16]. One human astrocyte interacts with approximately two million synapses making it a feasible 
candidate for the modulation of a neural network [17]. Astrocytes can be triggered directly by 
electrical stimulation, releasing the neuromodulators ATP and glutamate [18, 19]. This makes 
it plausible that DBS-induced modulation of network activity is partially due to astrocytic glio-
transmission. Modulation of astrocytes, and thereby network activity, could potentially be done 
using the TRPV1 channel.
Given our results, using endogenous TRPV1 as a mean for neuromodulation can be a less 
effective approach. TRPV1 expression shows a great inter-individual variability, so using TRPV1 
for this purpose requires the assessment of TRPV1 expression in each individual which does not 
seem to be feasible at this time. Furthermore, TRPV1 appears to be scarcely expressed in neu-
rons, thereby restricting direct neuronal neuromodulation. Nevertheless, abundant expression 
of TRPV1 was shown in astrocytes making neuronal modulation through these cells a potential 
approach in future research.
5. conclusion
This study showed that TRPV1 is present in the human CG and MFG in both depressed and 
control subjects. TRPV1 expression levels differ between subjects and do not seem to be depen-
dent on depression in one’s medical history. TRPV1 expression was extensively co-localized with 
GFAP indicating its abundant expression in astrocytes. Since endogenously neuronal TRPV1 
expression is scarce, the potential use of endogenously TRPV1 for neuromodulation seems 
restricted. Interestingly, endogenous glial expression of TRPV1 may indicate an alternative 
approach for neuromodulation.
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supplementary fi gure 1. Western blot trpV1 expression, raw data. Western blot of TRPV1 expression per 
subject and brain region. a) Colored channel green: TRPV1, red: GAPDH b) Black on white green channel: 
TRPV1. CG: cingulate gyrus, MFG: medial frontal gyrus, Con: Control, Dep: depression, P#: subject number.
145
Endogenous TRPV1 expression in the human cingulate- and medial frontal gyrus
7
supplementary fi gure 2. Western blot trpV1 expression, raw data, without peptide incubation. Western 
blot of TRPV1 expression per subject and brain region. a) Colored channel green: TRPV1, red: GAPDH b) 
Black on white green channel: TRPV1. CG: cingulate gyrus, MFG: medial frontal gyrus, Con: Control, Dep: 
depression, P#: subject number.
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supplementary fi gure 3. Western blot trpV1 expression, raw data, with peptide incubation. Western blot 
of TRPV1 expression when incubated with anti-TRPV1 peptide per subject and brain region. a) Colored chan-
nel green: TRPV1, red: GAPDH b) Black on white green channel: TRPV1. CG: cingulate gyrus, MFG: medial 
frontal gyrus, Con: Control, Dep: depression, P#: subject number.
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This general discussion and conclusion will start with the research questions formulated in the 
introduction. Following these research questions, I will address the limitations of my studies, 
future perspectives, and will end with a conclusion.
research question 1
- How can we further improve deep brain stimulation outcomes for treatment-resistant de-
pression?
Open-label trials and randomized controlled trials (RCTs) have shown inconsistent results for 
deep brain stimulation (DBS) in patients suffering from treatment-resistant depression (TRD). 
While open-label trials show promising effects, not all RCTs can replicate these findings [1-4]. 
Discussions arise concerning the criteria for patient selection, the choice of stimulation target, 
the optimal stimulation parameters, the correct interpretation of trial results and if subtypes of 
depression exist, which is in favor of a more personalized approach for DBS. Challenges remain 
to find the correct patient-specific target for stimulation and to discover the disrupted neural 
circuits in depression. In my animal research, I tried to enhance the knowledge of microcircuits 
in the prefrontal cortex responsible for different depressive domains in an animal model of 
depression. This enhanced my understanding of different microcircuits causing different depres-
sive traits in animals, which might be extrapolated to the human state of depression, showing 
different inter-individual depressive traits.
From literature I have concluded that a personalized treatment approach holds the potential to 
increase the overall efficacy of DBS for TRD. A precise evaluation of patient specific symptoms, 
biomarkers, and resting-state connectivity patterns are essential to discriminate clinical subtypes 
of TRD [5-8]. Furthermore, this data might provide more insights into the working mechanism 
of DBS and help in selecting patient specific optimal DBS targets for TRD.
research question 2
- Can we disentangle depression into multiple microcircuits responsible for different modali-
ties seen is this disorder using an animal model of depression?
In my research, I have used the ‘chronic unpredictable stress’ (CUS) model, which is a well-
validated and widely used animal model of depression [9]. In this model, rats are sequentially 
exposed to a variety of severe stressors in a random order over a period of four weeks. This model 
mimics the natural induction of depression, in which a chronic depressive-like state develops 
gradually over time in response to stress and unfortunate events. After the stress induction, I 
stimulated three different subregions of the ventromedial prefrontal cortex (vmPFC) with DBS 
and tested depressive-like behavior in different modalities of depression, such as anhedonia, 
anxiety and behavioral despair. In this thesis, I showed that prelimbic (PreL)-DBS decreased 
anhedonia, as is shown with an enhanced sucrose preference in the sucrose preference test (SPT), 
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and decreased helplessness, as is showed by a decrease in immobility time in the forced swim test 
(FST). These depressive symptoms were not alleviated when stimulating the infralimbic (IL)-
cortex. These findings indicate the existence of different microcircuits in the vmPFC, responsible 
for different domains of ‘depressive-like’ behavior in rats. This might indicate that also in the 
human subgenual cingulate gyrus (SCG), the human analog of the rodents vmPFC [10], micro-
circuits are present which might partially explain the inconsistent outcomes of SCG DBS trials in 
TRD. This emphasizes that DBS needs to be more individualized.
When stimulating the dorsal peduncular (DP)-cortex, I found a high incidence in seizure 
induction. The same stimulation paradigm did not induce seizures in the PreL- and IL-cortex. 
This finding showed that investigating mood-related behavior in the DP-cortex with DBS is not 
practicable and that serious side-effects of DBS can occur when stimulating particular brain 
regions. It emphasis that the region for stimulation should be chosen carefully and that acciden-
tally activated nearby brain structures can give rise to adverse side-effects, making the correct 
placement of electrodes utterly important.
research question 3
- Can the current method of deep brain stimulation be improved with the usage of nanopar-
ticles, so that deep brain stimulation could potentially stimulate microcircuits and work 
wirelessly?
The field of neuromodulation is developing rapidly. However, current techniques of modulation 
are still limited as they depend on implants [11], require invasive procedures, are not cell-type 
specific [12], involve slow pharmacokinetics [13] or have a restricted penetration depth [14, 
15] complicating stimulation of deep brain regions. Magnetic nanoparticles (MNP) can work 
as transducers in neuromodulation, which can improve existing methods of neuromodulation 
[16-18]. For DBS, replacing the stimulation electrodes for MNPs could advance its technique, 
making it potentially remote and wirelessly, and possibly more region specific by stimulating 
microcircuits [19].
research question 4
- Does magnetothermal deep brain stimulation, which operates with nanoparticles, work in 
animal models?
The current technique of DBS requires the implantation of electrodes through invasive neurosur-
gery, powered by a chronically implanted battery. These electrodes work through a nonspecific 
electrical signal which is unable to selectively target specific neural subregions. To overcome some 
of these limitations we, in collaboration with the Massachusetts Institute of Technology (MIT) 
(Boston, USA) investigated a wireless alternative to DBS, called magnetothermal DBS (mDBS), 
which uses MNPs to induce neural excitation [19]. Our results showed that unilateral mDBS of 
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the subthalamic nucleus (STN) in wild-type mice resulted in more contralateral rotations around 
the body axis compared to sham animals. This finding indicates that unilateral mDBS of the STN 
can wirelessly control contralateral rotational behavior in wild-type mice through MNPs.
research question 5
- Is it possible to apply magnetothermal deep brain stimulation in humans?
In this thesis, we have demonstrated that unilateral mDBS of the STN can induce contralateral 
rotational behavior in awake, freely moving and naïve mice. For mDBS in mice, lentiviral deliv-
ery of the transient receptor potential vanilloid subtype-1 (TRPV1) protein was needed, since 
endogenous expression of TRPV1 in mice is very low. I investigated if in the human medial 
frontal gyrus (MFG) and cingulate gyrus (CG), TRPV1 is expressed endogenously which might 
make mDBS without lentiviral introduction of TRPV1 possible. Results showed that TRPV1 is 
endogenously expressed in the human CG and MFG in both depressed and control subjects. 
The expression level of TRPV, however, did not seem to be dependent on depression, but rather 
showed strong inter-individual expression level differences. Furthermore, TRPV1 extensively 
co-localized with glial fibrillary acidic protein (GFAP), suggesting its profuse expression in as-
trocytes. Neuronal TRPV1 expression was limited, restricting its potential in neuromodulation. 
However, glial modulation through TRPV1 might be an interesting approach as the role of 
astrocytes in mediating neuromodulation is more and more investigated.
Limitations of our studies
The studies presented in this thesis show promising results, but like any research, are also bound 
to limitations. The biggest limitation is the exploration of depression in an animal model, in 
which a lot of the etiology of the disorder is lost. This makes behavioral and cellular outcomes 
of animal research hard to translate back to humans. However, fundamental research is needed 
to gain insights into the various disturbed microcircuits in TRD and the effect of DBS. In my 
thesis, I used the ‘chronic unpredictable stress’ (CUS) animal model, which to my knowledge, 
is one of the best animal models to simulate and investigate ‘depression’ with great validity and 
translational potential [9, 20], however its success can be user dependent [21]. With my research, 
I gained more insight into possible microcircuits in depressive-like behavior in the vmPFC in 
rats and possibly in the SCG of humans, partially explaining the inconsistent results in SCG DBS 
trials.
Another limitation of my studies is the sole use of male rats in my research. Since the prevalence 
of depression is higher in women, researching both male and female rats would have had the 
preference. However, I only used male rats since previous research has shown that the estrogen 
cycle of female rodents interfere with behavior and the release of neurotransmitters, causing a 
larger spread in behavioral outcomes [22, 23]. This would have interfered with my behavioral 
readouts and with the comparison to previously done research in our lab, in which also only used 
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male rats were used [24]. For these reasons, I only investigated male rats. However, following the 
results of my research in which DBS of the PreL-cortex and not IL-cortex resulted in alleviation 
of anhedonia and helplessness, it would be interesting to research this finding in female rats.
Another issue to address is the restricted amount of available human brain tissue for depression 
research. Due to the scarcity of brain tissue of depressed patients, I was only able to investigate a 
small number of subjects for my TRPV1 project. Due to this limitation, I was only able to make 
assumptions regarding TRPV1 expression in the CG and MFG of depressed subjects but no hard 
conclusion could be drawn.
future perspectiVes
My research suggest that circuits emerging from distinct subregions in the prefrontal cortex are 
responsible for different depressive modalities in rats, such as anhedonia and behavioral despair. 
Future research is needed to disentangle other microcircuits in depression, investigating other 
brain regions possibly responsible for different modalities seen in depression. Furthermore, we 
need to discover the working mechanism of DBS within these microcircuits by analyzing neu-
rotransmitter changes using microdialysis and cellular changes by the usage of electrophysiology.
Finally, in this thesis, we have shown that mDBS of the unilateral STN in wild-type mice 
caused contralateral rotational behavior. The next step would be to incorporate mDBS into dif-
ferent animal disease models to investigate if mDBS could alleviate or recover various disease 
states. Also for mDBS, it is needed to know what cellular changes it induces using microdialysis 
and electrophysiology and what side-effects could occur.
conclusion
In conclusion, major depressive disorder (MDD) is a circuitopathy that involves a wide range of 
brain structures and exhibits diverse clinical manifestations. A precise evaluation of symptoms, 
biomarkers, and resting-state connectivity patterns are essential to distinguish clinical subtypes 
of TRD, might provide insight into the working mechanisms of DBS, and help in selecting opti-
mal DBS targets in patients.
In ‘depressed’ rats, microcircuits in the vmPFC are responsible for different modalities of de-
pression shown with different ‘depressive-like behavior’. These data suggest that also in humans, 
microcircuits are present which might partially explain the inconsistent outcomes of SCG DBS 
trials in TRD. This also indicates that a more personalized approach in DBS holds the potential 
to increase the overall efficacy of DBS for TRD.
Furthermore, advancing the method of current DBS with the insertion of MNPs could over-
come the limitation of electrode and device implantation, making its application wirelessly. We 
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have shown that unilateral mDBS of the STN is able to induce contralateral rotational behavior, 
which paves the way to its induction in various animal disease models and potentially might 
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Major depressive disorder (MDD) is globally the leading cause of disability with a worldwide 
prevalence of 4.4 %, affecting 322 million people in 2015. For the diagnosis of MDD, according 
to the Diagnostic and Statistical Manual of Mental Disorders number 5 (DMS-5), five of the 
following symptoms need to be present: a depressed mood, anhedonia, insomnia or hyper-
somnia, psychomotor retardation or agitation, loss of energy or fatigue, worthlessness or guilt, 
change in weight or appetite, impaired concentration or indecisiveness, and thoughts of death or 
suicidal ideation or an attempt. The treatment of MDD include antidepressant medication and 
psychological therapies. However, approximately one-third of treated patients do not respond 
adequately to these treatments. These patients suffer from treatment-resistant depression (TRD) 
which is associated with more hospitalizations and past suicide attempts. For TRD, different 
therapies modalities can be given such as electroconvulsive therapy (ECT), vagal nerve stimu-
lation (VNS), transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS). In 
this thesis we have focused on deep brain stimulation in TRD, if we can disentangle TRD into 
different microcircuits, how we can improve clinical DBS outcomes and if we can refine DBS 
with a non-invasive technique called magnetothermal DBS introducing nanomaterial-mediated 
neuromodulation.
chapter 1 is a general introduction into the theme and aims of this thesis. It gives information 
about major depressive disorder, treatment-resistant depression, current treatment options such 
as DBS and our view of possible microcircuits responsible of different traits in TRD. It provides 
our research questions and outline of this thesis.
chapter 2 provides a narrative review of recent studies investigating the effectiveness of DBS 
in TRD. We especially focus on the relationship between the targeted brain structures and clini-
cal outcomes. It discusses the importance of clinical subtypes of TRD. We concluded that precise 
evaluations of symptoms, biomarkers, and resting-state connectivity patterns are essential when 
distinguishing clinical subtypes of TRD. Subtyping TRD may provide more insight into the 
working mechanisms of DBS and help in selecting optimal targets in patients allowing for more 
personalized symptom-based treatment approaches.
chapter 3 aimed to investigate different microcircuits within the prefrontal cortex of rats in 
an model of depression. We hypothesized that different microcircuits cause different behavioral 
traits in depressive-like behavior, and therefore, the treatment of depression and depressive traits 
lies in the modulation of different neural microcircuits. In this study, we found that High fre-
quency (HF) DBS in the prelimbic (PreL) cortex but not the infralimbic (IL) cortex alleviated 
anhedonia and behavioral despair revealed by the sucrose preference and forced swim tests, 
respectively. These results suggest that modulation of specific sub-regions with its own micro-
circuits in the prefrontal cortex might be a potential approach towards providing tailored DBS 
therapy for different subtypes of depression.
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chapter 4 presents the adverse side-effects when stimulating a different subregion in the 
prefrontal cortex named the dorsal peduncular (DP) cortex. Stimulation in this DP subregion 
caused acute induction of seizures in ~40% of stimulated animals. Clinically relevant stimulation 
parameters were applied. We therefore conclude that the DP subregion of the vmPFC is not a 
suitable target to conduct DBS in mood disorders. It emphasis that the region for stimulation 
should be chosen carefully and that nearby brain structures can give rise to adverse side-effects.
chapter 5 provides a review in which we describe and evaluate advanced techniques of neu-
romodulation of the brain and their latest refinements incorporating the usage of nanoparticles. 
We emphasize on DBS and magnethothermal deep brain stimulation (mDBS) using magnetic 
nanoparticles (MNPs) for nanomaterial-mediated neuromodulation. We conclude the applica-
tion of MNPs as transducers of magnetic field into thermal, electrical, mechanical or chemical 
stimuli offers a possibility to remotely and wirelessly modulate specific groups of cells in arbi-
trarily deep regions of the brain.
chapter 6 presents a study of mDBS in awake, freely moving mice done in collaboration with 
the research group of prof. dr. P. Anikeeva at the research laboratory of electronics (rle) at the 
Massachusetts Institute of Technology (MIT) (Boston, USA). We found that unilateral subtha-
lamic nucleus (STN) mDBS in mice injected with MNPs results in more contralateral rotations 
around the body axis when compared to mice injected with non-MNPs. This results showed 
that mDBS in mice works and offers opportunities to further explore this techniques in various 
animal models of neuropsychiatric, neurosensory and neurodegenerative disorders.
chapter 7 describes endogenously transient receptor potential vanilloid subtype-1 (TRPV1) 
expression in the human cingulate gyrus (CG) and medial frontal gyrus (MFG). Thus far, TRPV1 
is needed for mDBS and has shown to be present in the CG and MFG of humans, albeit more 
in glial cells than in neurons. The potential use of endogenously TRPV1 for neuromodulation 
seems restricted. However, endogenously glial expression of TRPV1 may indicate an alternative 
approach for neuromodulation.
chapter 8 summarizes the main findings in this thesis and provides answers to our research 








This Valorization Addendum describes how the knowledge obtained from our research in this 
thesis can be of value for both clinical and societal use.
societal relevance
Major depressive disorder (MDD) is a medical condition affecting around 322 million people 
worldwide in 2015. This disorder includes a wide range of neuropsychiatric symptoms that 
vary greatly between patients. Approximately one third of treated patients do not responds to 
standard therapy including deep brain stimulation (DBS) and suffer from treatment resistant 
depression (TRD). For these people, treatment remains a challenge and research is needed to 
explore underlying neural mechanisms in depression.
Implementing clinical subtypes of TRD into future studies investigating DBS for TRD could 
increase its overall efficacy. Looking at homogenous subtypes of depressed patients and investigat-
ing which DBS target works the best for each particular subtype may lead to a more personalized 
DBS approach. This would be superior to looking at primary outcomes across all participants. 
With this approach we hopefully find correct patient-specific targets for stimulation.
We believe in the existence of microcircuits in depression and TRD and have showed that these 
exist in the prefrontal cortex in rats. This might be extrapolated to the human state of depres-
sion showing different inter-individual depressive traits. These findings are relevant for science 
and society so that further research into microcircuits in TRD can lead to more patient-specific 
targeting based on their depressive traits.
A lesson learned from our side-effect study is that adjacent brain regions can cause severe 
side-effects upon stimulation. This implicates the importance of correct electrode placement and 
indicates that caution is vital when exploring new brain regions for stimulation.
With our literature study into nanoparticle-mediated neuromodulation we have shown that 
magnetic nanoparticles (MNPs) can acts as transducers of a magnetic field into thermal, electri-
cal, mechanical or chemical stimuli. This offers a possibility to remotely and wirelessly modulate 
specific groups of cells in arbitrarily deep regions of the brain. We hope to stimulate research 
groups to implement these advanced neuromodulation techniques, advancing the field of neuro-
science and improving the specificity of these techniques.
We thoroughly described a new method called ‘magnetothermal deep brain stimulation’ 
(mDBS) in this thesis and in collaboration with the Massachusetts Institute of Technology (MIT) 
in Boston (MA, USA) are one of the first researcher groups to research mDBS in freely moving 
mice. Further research should implement this new technique in various animal models of signs 
and symptoms as expressed in mental, neuropsychiatric, neurosensory and neurodegenerative 
disorders in order to restore physiological brain functions and to define its therapeutic value. For 
clinicians such as neurosurgeons, mDBS could overcome invasive surgery for neuromodulation.
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Our TRPV1 study (chapter 7) shows that the use of endogenously TRPV1 for neuromodula-
tion seems restricted, but glial expression of TRPV1 may indicate an alternative approach for 
neuromodulation. This is mainly interesting for researchers trying to overcome the viral induc-
tion of TRPV1 for mDBS, or researchers interested in the function and modulation of glial cells 
in neuromodulation. Thus far, most studies only research the direct effect of modulation on 
neurons, various new insight could be obtained when investigating the role of glial cells in this 
process.
target audience
Findings from our literature study (chapter 2) are relevant for patients, clinicians and research-
ers, since they can incorporate the precise evaluation of symptoms, biomarkers, and resting-state 
connectivity patterns to distinguishing clinical subtypes of TRD.
The findings from our DBS study (chapter 3) acknowledging the existence of microcircuits are 
relevant for both patients, clinicians as well as researchers since these insight pave a way to more 
patient-specific targeting based on depressive traits.
Our findings from the side-effect study (chapter 4) are relevant for clinicians and research-
ers showing that correct electrode placement is of the utmost importance and that simulating 
adjacent brain regions with the same clinically relevant parameters can cause severe side-effects 
which needs to be considered when researching new brain regions.
Implementing nanoparticles into neuromodulation (chapter 5 and 6) is relevant for both 
researchers and clinicians. For researchers, nanoparticles can refine current methods of neuro-
modulation. For clinicians such as neurosurgeons, these refinements could overcome invasive 
surgery for neuromodulation in the future.
Finally, results from our TRPV1 study (chapter 7) are mainly interesting for researchers since 
it showed that the use of endogenously TRPV1 for neuromodulation seems restricted, but glial 
expression of TRPV1 may indicate an alternative approach for neuromodulation.
products/innovation
The studies of this thesis can be considered innovative in several ways. Firstly, this work included 
a novel concept of clinical subtypes of TRD comprising of different microcircuits. This theory 
was implemented into an animal model of depression showing the existence of different mi-
crocircuits responsible for different behavioral traits within the prefrontal cortex of rats. This is 
crucial for future research into patient-specific neuromodulation targeting in depression.
Another innovative approach in this thesis is the review of the implementation of nanoparticles 
into different forms of neuromodulation with an emphasis on DBS. We describe a the method 
mDBS and in collaboration with colleagues from MIT, are one of the first researchers to research 
magnetothermal DBS in freely moving mice.
Furthermore, we were the first to describe the existence of TRPV1 in the human cingulate- and 





The knowledge and novel insights obtained from the studies in this thesis will be shared with 
health care professionals, patient organizations and scientific societies.
Future studies investigating TRD will hopefully implement clinical subtypes of TRD and 
explore the underlying microcircuits of different behavioral traits. We will encourage this by 
presenting our results at different neuroscientific congresses as we have presented them at the So-
ciety of Neuroscience in San Diego (CA, USA) in 2018. Health care professionals can contribute 
to these studies by incorporating precise evaluation of symptoms, biomarkers, and resting-state 
connectivity patterns for TRD in patient care. For patient organizations its valuable information 
and reassuring to see that advances in the treatment of TRD are still being made.
To advance current methods of neuromodulation, we hope that various research groups will 
implement nanoparticle-mediated neuromodulation. In particular we would like to encourage 
the usage of mDBS in different animal models in order to restore physiological brain functions 
and to define its therapeutic value. We will engage with different groups conducting nanoparticle-
mediated neuromodulation experiments. For clinicians, such as neurosurgeons, it is good to 
know that non-invasive remote neuromodulation through nanoparticles holds potential in the 
future. Since at the school for Mental Health and Neuroscience (MHeNS), the department of 







Daar is het dan, mijn proefschrift! Na flink aantal jaren keihard werken van ‘s ochtends vroeg 
tot ‘s avonds laat in het Maastricht’s laboratorium. Na een jaar bij onze Amerikaanse buren op 
de Massachusetts Institute of Technology (MIT) nieuwe technieken te leren. Na het combineren 
van het afronden van dit mooie boekje met een baan als arts. Na dat alles mag ik dan toch nu 
echt zeggen, it’s done!
Ik kijk terug op mooie, leerzame, soms ook vermoeide en stressvolle jaren vol met herin-
neringen die mij voor altijd bij zullen blijven. Ik wil iedereen bedanken die me heeft bijgestaan 
in deze geweldige tijd en neem graag dit moment om enkele mensen in het bijzonder in de 
schijnwerper te zetten.
Allereerst wil ik mijn promotieteam bedanken, bestaande uit prof. dr. y. temel en 
dr. a. Jahanshahi.
Beste yasin, heel erg bedankt voor het vertrouwen dat je in mij had vanaf het moment dat wij 
elkaar in Rotterdam tijdens jouw presentatie hebben leren kennen. Jij hebt mij de kans gegeven 
een geweldig promotietraject tegemoet te gaan als jong en net afgestuurd arts. Je liet mij zelfs 
richting Boston afreizen om nieuwe kennis op te doen voor de groep. Jij gaf mij en de groep de 
vrijheid om ons tot goede onderzoekers te ontwikkelen. Ik waardeer jouw altijd positieve insteek 
op alle uitdagingen die een PhD (en het leven zelf) met zich mee brengen.
Dear ali, thank you for all the faith you had in me when experiments took a lot of effort and 
sometimes got on my nerves. I admire the fact that you always knew how to get the most out of 
my experiments and always had some great new ideas. Besides that, I could always talk with you 
about everything, share stories about wild foxes in your garden, ideas of starting a potato farm or 
just enjoy glow in the dark midget golf at which I wasn’t the best and mostly missed.
Dear prof. p. anikeeva, dear polina, thank you for welcoming me into your research group at 
the Massachusetts Institute of Technology (MIT). You are an inspiration for everyone who want 
to life there dream. Thank you for your hospitality, staying at your apartment made me want to 
live the American dream as well. From long work days to running the marathon to organizing a 
cookie bake contest for us at Christmas, you are a power woman in every way!
leden van de beoordelingscommissie, heel erg bedankt voor het lezen en beoordelen van mijn 
proefschrift. Ik hoop dat deze u is bevallen en nieuwe inzichten heeft geboden.
Aan alle co-auteurs die samen met mij urenlang aan de artikelen in dit proefschrift hebben 
gewerkt, heel erg bedankt! Zonder jullie was mij dit niet gelukt. Jos prickaerts, heel erg bedankt 
voor jouw inzichten in het stressmodel van mijn ratten en soms ook van de impact van dit 
Chapter 8
168
stressmodel op mijzelf. Jouw inzicht heeft enorm geholpen mijn experimenten en analyses te 
optimaliseren en de artikelen de draai te geven die ze nodig hadden om tot een mooie conclusie 
te komen. hellen steinbusch, ontzettend bedankt voor jouw hulp bij het opzetten van mijn 
immunologische experimenten. Door jou eindigde veel histologische kleur experimenten met 
een glimlach op mijn gezicht. We hebben veel kunnen sparren over nieuwe ideeen, wat vaak ook 
nog eens goed uitpakte. denise hermes, ook aan jou heel veel dank voor ongekende inzet voor 
mijn gedragsexperimenten. Jij stond altijd voor iedereen klaar als de dingen toch net wat anders 
liepen dan gepland. Wist ik even geen oplossing dan wist jij dit zeker! Marjan peeters, bedankt 
voor je geweldige hulp met mijn western blots, dit vak apart is altijd beter met goede hulp. Aan 
alle dierenverzorgen, paul, ingeborg, Mandy, richard, rick, bedankt voor de gezellige tijd in de 
kelder. Zonder jullie was dit alles niet mogelijk.
Lieve collega’s van de afdeling neurochirurgie en MHeNS, wat een eer dat ik bij jullie in Maastricht 
heb mogen werken. Bedankt voor het warme onthaal en de gezelligheid en leerzame momenten 
tijdens mijn promotieonderzoek. De maandag ochtend meetings met de trein vanuit Rotterdam 
waren altijd een goed begin van de week. Als hechte club heb ik zeker een paar vrienden voor het 
leven gemaakt en hoop jullie nog vaker te mogen zien in Limburg danwel in de Randstad. Ik wil 
graag een paar van jullie persoonlijk bedanken.
Lieve gusta, me gusta jou als leuke, lieve sportieve collega en vriendin. Al vonden jouw ratten 
mij in het begin een beetje eng en is het litteken op mijn ringvinger permanent, jij brak gelijk het 
ijs als collegas met je vrolijke buien waar geen ontkomen aan was gezien je rechtstreeks tegenover 
mij zat. Ik heb genoten van onze congrestripjes, de SFN in San Diego waar we ons brein flink 
hebben geprikkeld met alle top notch research en weer hebben kunnen dempen de grens over in 
Tijuana. Dank je wel voor alle leuke momenten samen!
freddie (Mercury), jij bent een van de eerste gezichten die ik zag bij de start van onze promotie. 
Jij als slimme AKO’er bruist van de innovatieve ideeen en je bent nog super hilarisch en gezel-
lig ook! Alleen jij kon mij in een deuk laten liggen en lekker op mijn zenuwen werken als ik 
gefrustreerd een proefopstelling in elkaar probeer te hameren op kantoor. Met de helium gevulde 
ballon zijn we ook het derde stadium van de PhD doorgekomen. Ik wens je al het geluk toe in 
Boston en weet zeker dat jij er wel komt!
anne, Annie, mamma van de groep. Wat moesten wij zonder jou als stabiele factor in de groep. Jij 
organiseerde altijd de momenten die we nodig hadden om als groep samen leuke herrineringen 
te maken. Ik heb van je genoten als jij, Gusta en Fred weer eens de tent afbraken terwijl ik nors in 
een hoekje probeerde te werken. Jij fleurt de dag en ruimte (lees kerstversiering) altijd op! Voor 




Dear Bethany, what a lovely crazy personality stepped into our room from Amsterdam/England. 
I love how we always had the most surprisingly conversations, your great sense of humor and the 
way you always seem to find new ways to pronounce my name. I really hope you enjoyed your 
time with us, as much as we enjoyed your company. Thank you for the smiles you put on my face.
sarah thank you for our experience together in Boston and in Maastricht. We managed to keep 
faith in our experiments, enjoyed some wonderful moments at MIT such as its 100th anniversary, 
in Boston such as American football and brought back new ideas for the field of neuroscience.
Dear Majed, I admire your positivity in life, always smiling and always bringing in birthdays 
cakes or any cakes/treats for that matter. The dinners at your house were amazing, bringing the 
whole group together. I really wish you the best in the next adventures for you to come!
sylvana, ook al zit je niet meer in Maastricht, bedankt voor alle gezelligheid in de tijd dat wij er 
samen waren. In jou vond ik een ook trouwe fan van het MacDonald’s ontbijt. Een bouwmarkt 
expert voor het klussen tijdens onze experimenten. Een collega waarmee ik goede discussies kon 
voeren voor het verbeteren van ons onderzoek en resultaten. Jeroen, bedankt voor jou gezellig-
heid in het team. Mede door jouw inzet hebben we in een steeds groter geworden groep weer wat 
samenhorigheid gevonden. Jij zorgde ervoor dat iedereen zich welkom voelde met menig eten-
tjes. Margot, ook jij zorgde weer voor een leuke spontante nieuwe twist in onze groep. paul, wat 
een eer dat de Randstad jouw heeft mogen verwelkom als chirurg in opleiding. Melinda, thank 
you for always being there, I enjoyed our dinners and movies together. roman, Jana, Jackson, 
christian, faris, Mohammed, amee, stijn, faisal, raghu, sol, Koen, glenny, aryo, sandra 
and Birgit and other old colleagues, thank you for everything. You have made Maastricht a 
wonderful experience.
govert, bedankt dat je altijd tijd had kritisch naar onderzoeks ideeen en resultaten te kijken. 
Ik heb tesamen met jou en Anne Jansen veel geleerd over het goed uitvoeren van een nieuw 
onderzoeksplan. En zelfs naast al de serieuzere zaken was niets je te gek voor het maken van een 
goed promotie filmpje. Mark, heel erg bedankt voor weer wat nieuwe dynamiek in onze groep.
Dear colleagues at the MIT. Thank you for giving me the chance to work with you and to broaden 
my research and life knowledge.
Dear danijela, you’re such an amazing person. Thank you for opening up your home to me 
throughout this big adventure. No matter which day of the week you could always brighten the 
day with good ideas as going out for burgers and beer, Halloween decoration shopping or just 
staying in for a lazy Sunday. Thank you for always being the nanoparticle master we all needed 
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so much. Seeing you evolve from the party animal into a beloved mother to be, I realized you are 
truly amazing.
Dear Micheal, I love the way you always kept calm explaining the physical properties of the 
magnet and letting us build and use this magnet with you. You are one of the smartest people I 
know and have a great sense of humor! Thank you for letting me see that even as an American 
you can appreciate some sarcasm. It was an honor to show you our hometown and I hope we will 
meet again someday.
Dear liz, thank you for letting me get to know you. Your heart is in the right place! Celebrating 
your birthday and introducing us into your family and friends was an honor. Dear Dekel, working 
with you was a delight. Rats getting on your nerves did not stop you from doing some amazing 
research. You were always there when things needed to be fixed. Dear Alex, thank you for the 
good discussion we always had. I wish you all the best. Dear Pohan, Mehmet, Siyuan, Seongjun 
and other colleagues thank you for this great experience!
Lieve diva’s bedankt dat jullie er altijd voor mij en elkaar zijn en dat jullie naar Maastricht zijn 
afgereisd om het mooie carnaval mee te maken. Ik weet dat er nog veel van dit soort momenten 
volgen, waar in de wereld dan ook!
Lieve Jc strike, en met name lieve esther, dankjewel voor de steun tijdens mijn promotieonder-
zoek. Esther, met een ontspannen theetje en een goed gesprek waren de zorgen over de vertraging 
van mijn PhD ineens veel minder erg. We hebben veel kunnen sparren over de artikelen die in 
andersmans ogen toch nog net niet zijn wat het moet zijn en over de pieken en dalen die een 
promotietraject kent. Hopelijk geeft dit goede moed dat met doorzettingkracht de thesis hoe dan 
ook goedkomt! Ik waardeer je enorm als altijd lief en bezorgde vriendin/club-/dispuut genoot, 
je bent een kanjer!
Lieve IMC’ers, nadia, Marjolein, lisa en djazz. Dankjewel voor al die jaren vriendschap en er 
altijd voor de ander zijn!
Lieve mam Jeanette en pap erik, lieve zus charessa, bedankt dat jullie mij steunen in alle keuzes 
die ik maak. Mij komen opzoeken in Maastricht en samen de Limburge grotten trostseren ookal 
wordt het wat claustrofobisch. Zelfs mij in Boston paketten pindakaas, chocola en drop sturen als 
de nood hoog is. Ik voel me gezegend met familie als jullie en zonder jullie was dit nooit gelukt!
Lieve sara, lieve lux, ookal hebben jullie nog geen idee wat promotieonderzoek is, met de zin 





Lieve familie, dankjewel voor alle steun. Oma Mary, levensgenieter, ik hoop dat ik net als u de 
wereld mag ontdekken met vele verre reizen. didi, de kunstzinnige van de familie, wat een gaaf 
design van mijn kaft! Bedankt. 
Lieve schoonfamilie, wat heb ik het met jullie getroffen. hélène en Johan, bedankt voor alle 
ontspanning en steun in het verre noorden. 
Lieve, lieve Thomas, wat ben ik blij met jou als mijn man! Na een halfjaar samen te hebben 
gewoond op zo’n 10 vierkante meter in mijn studentenhuis gingen wij samenwonen op de Pieter 
de Hoochstraat in Rotterdam. Tenminste dat dachten we, want eigenlijk al gelijk kreeg ik dit 
promotieonderzoek in Maastricht aangeboden en vertrok ik doordeweeks (en jij in het weekend) 
richting het zuiden. Ik ben alleen nog maar gekker op je geworden omdat niets je te ver was 
voor onze relatie. Ook bijna een jaar Amerika schrikte je niet af. In tegendeel, een geweldige 
reis Boston, New York samen tijdens kerst en oud en nieuw stond voor ons op de planning. Bij 
jou kon ik terrecht tijdens al mijn goede en strevolle momenten tijdens deze PhD periode. Een 
avondje eten bij Gauchos op het vrijthof werd ons ritueel. Nu aan het einde van mijn promotie 
wonen we dan eindelijk samen in ons eigen grote mensenhuis in Sweet Lake City. Dankjewel dat 
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